Sample,PatientId,consensus_sex,inferred_sex,inferred_ethnicity,centerID,CEBPA_Biallelic,ageAtDiagnosis,isRelapse,isDenovo,isTransformed,finalFusion,specificDxAtAcquisition_MDSMPN,nonAML_MDSMPN_specificDxAtAcquisition,priorMalignancyNonMyeloid,priorMalignancyType,cumulativeChemo,priorMalignancyRadiationTx,priorMDS,priorMDSMoreThanTwoMths,priorMDSMPN,priorMDSMPNMoreThanTwoMths,priorMPN,priorMPNMoreThanTwoMths,Classification,dxAtInclusion,specificDxAtInclusion,ELN2017,ELN2008,dxAtSpecimenAcquisition,specificDxAtAcquisition,ageAtSpecimenAcquisition,timeOfSampleCollectionRelativeToInclusion,specimenGroups,specimenType,rnaSeq,exomeSeq,totalDrug,rnaSeqAnalysis,analysisExomeSeq,analysisDrug,cumulativeTreatmentTypeCount,cumulativeTreatmentTypes,cumulativeTreatmentRegimenCount,cumulativeTreatmentRegimens,cumulativeTreatmentStageCount,cumulativeTreatmentStages,responseToInductionTx,typeInductionTx,responseDurationToInductionTx,mostRecentTreatmentType,currentRegimen,currentStage,mostRecentTreatmentDuration,vitalStatus,overallSurvival,causeOfDeath,any_different_labs,any_different_labs_also_beataml,different_lab_ids,different_id_karyotype_interval,%.Basophils.in.PB,%.Blasts.in.BM,%.Blasts.in.PB,%.Eosinophils.in.PB,%.Immature.Granulocytes.in.PB,%.Lymphocytes.in.PB,%.Monocytes.in.PB,%.Neutrophils.in.PB,%.Nucleated.RBCs.in.PB,ALT,AST,Albumin,Creatinine,FAB/Blast.Morphology,Hematocrit,Hemoglobin,Karyotype,LDH,MCV,Other.Cytogenetics,Platelet.Count,Surface.Antigens.(Immunohistochemical.Stains),Total.Protein,WBC.Count,any_different_cgs,any_different_cgs_also_beataml,different_cgs_lab_ids,FLT3-ITD,NPM1,ABL1,ASXL1,ASXL2,ATM,BCOR,BCORL1,BRAF,BRCA2,CALR,CBL,CCND2,CCND3,CD36,CEBPA,CHEK2,CIITA,CREBBP,CSF3R,CTCF,CUX1,DNMT3A,EP300,ETV6,EZH2,FBXW7,FLT3,GATA1,GATA2,IDH1,IDH2,IKZF1,JAK1,JAK2,JAK3,KDM6A,KIT,KMT2A,KMT2D,KRAS,MEN1,MPL,MUTYH,MYD88,NF1,NOTCH1,NRAS,PAX5,PDGFRB,PHF6,POT1,PRDM1,PTPN11,RAD21,ROS1,RUNX1,SETBP1,SF3B1,SMC1A,SOCS1,SRSF2,STAG2,STAT3,SUZ12,TCL1A,TET2,TP53,TYK2,U2AF1,WT1,ZRSR2,LSC17_Score,LSC17_Category
12-00023,550,Female,Female,White,1,n,71.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,71.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",4,Allogeneic - Sibling|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,7.0,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Sibling,-1.0,Dead,397.0,Dead-Disease,False,False,,0,0.0,68,,1.0,,30.0,49.0,3.0,,14,18.0,3.0,0.85,M5,21.9,7.6,"46,XX[20]",313.0,102.9,Normal,125.0,"Blast Immunphenotype: CD13, CD33, CD34, CD38, dim CD45, CD117, CD123, and HLA-DR positive; Promonocyte Immunophenotype: CD11b, CD13, CD14, CD33, CD64, and HLA-DR",5.5,14.9,False,False,,negative,negative,,,,,,,G596R,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,2400/10000 copies,,-0.2320235193982843,Low
12-00051,635,Female,Female,White,1,n,55.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,55.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,7.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1.0,Dead,707.0,Dead-Disease,False,False,,0,0.0,88,93,0.0,,6.0,0.0,1.0,,19,26.0,3.4,0.88,,28.2,9.6,"46,XX[20]",678.0,99.9,Normal,19.0,"partial CD7, CD13, CD25, CD33, partial CD34, dim CD45, CD117, CD123, and partial HLA-DR positive",6.8,17.9,False,False,,positive,positive,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,8000/10000 copies (High),,0.5082224212328931,High
12-00066,559,Male,Male,White,1,n,70.0,False,False,True,None,False,False,n,,y,n,n,n,y,y,n,n,,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,70.0,34,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"Dasatinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine",4,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,153.0,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,4.0,Dead,311.0,Dead-Disease,True,False,12-00032,0,5.0,36,9,5.0,,21.0,38.0,22.0,,19,22.0,3.6,1.18,M4,28.7,9.7,"46,XY[20]",231.0,99.6,Normal,47.0,"CD11b, CD13, CD14, CD15, variable CD16, dim CD33, CD58, bright CD64, HLA-DR positive",7.1,21.0,True,False,12-00262,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,-0.6268456247719207,Low
12-00150,722,Male,Male,AdmixedBlack,7,n,,False,False,False,Unknown,False,True,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,unknown,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,unknown,18.0,0,Unknown,Peripheral Blood,y,n,y,y,n,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,,False,False,,0,,,,,,,,,,,,,,,,,,,,,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.05600131004512701,Low
12-00211,764,Female,Female,White,1,n,50.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,50.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|HiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,27.0,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Sibling,-1.0,Alive,1396.0,Alive,False,False,,0,0.0,90,82,0.0,,1.0,0.0,2.0,,19,30.0,2.8,0.86,,26.4,9.1,"46,XX,t(11;17)(q13;q21)[20]",1165.0,97.7,"While the chromosome 17 breakpoint is clearly within band 17q21 by metaphase chromosome analysis, these results suggest that it is not within the RARA gene",8.0,"dim CD4, CD13, dim CD15, dim CD33, CD38, CD58,CD64, CD117, CD123, dim HLA-DR, and cMPO",5.3,84.1,False,False,,negative,positive,,,,,,,,,,,,,,negative,,,,,,,,,,,,A680V;negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,"5000/10,000 copies",,-0.4165622768016459,Low
12-00258,799,Female,Female,White,1,n,81.0,False,False,True,None,False,False,y,Anal carcinoma|Breast Cancer|Breast Cancer,y,y,n,n,y,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,81.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,n,y,y,n,y,1,Supportive/Palliative Care,1,Azacitidine,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Azacitidine,Supportive/Palliative Care,42.0,Dead,147.0,Dead-Disease,False,False,,-112,0.0,,,0.0,,12.0,33.0,7.0,,60,64.0,3.2,1.08,M5,26.6,8.8,"46,XX,t(8;16)(p11.2;p13.3)[8]/46,XX,del(7)(q11.2q22),del(20)(q13.1q13.3)[cp3]/46,XX[12]",2700.0,92.4,,46.0,,6.3,37.1,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-2.087646527077196,Low
12-00294,825,Male,Male,White,1,n,72.0,False,True,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72.0,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,n,y,y,n,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,3.0,Dead-Other,False,False,,0,0.0,95,96,0.0,,3.0,0.0,1.0,,47,58.0,2.7,0.96,M4,16.5,5.6,"46,XY[20]",697.0,114.0,Normal,51.0,"Blasts: partial CD13, CD34, CD38, CD58, dim CD123, cTdT, HLA-DR, and partial/dim cMPO positive; Promonocyte/monoblast: CD11b, CD14, dim CD33, CD38, CD58, CD64, HLA-DR and dim cMPO positive",4.9,97.0,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,negative,,,,negative,,,negative,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,-0.44820363851507167,Low
12-00372,555,Male,Male,Asian,1,n,56.0,True,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60.0,309,Relapse|Post-Chemotherapy,Peripheral Blood,y,n,y,y,n,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),8,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Sorafenib|Clofarabine|Clofarabine, Cytarabine",5,Consolidation|Salvage|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,Cytarabine,Consolidation,64.0,Dead,1735.0,Dead-Disease,True,True,12-00371;12-00224,-121,0.0,77.5,75,1.0,,16.0,1.0,4.0,,,,,,NOS,26.3,9.3,"46,XY[4]",,87.8,Normal,9.0,"CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive",,7.9,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.2814924749936964,Low
12-00423,923,Male,Male,White,1,n,61.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,61.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Induction,Refractory,Standard Chemotherapy,7.0,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,7.0,Unknown,,,False,False,,0,0.0,46,66,1.0,,24.0,5.0,4.0,,18,34.0,3.2,1.05,M2,26.4,8.8,"46,XY[20]",551.0,89.1,Normal,72.0,"CD13, CD33, CD34, CD117, dim CD123, HLA-DR,partial MPO (+)",7.0,16.5,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,D835,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.25454188031755953,High
12-00426,50,Male,Male,White,1,n,11.0,True,False,False,DEK-NUP214,False,False,n,,y,n,n,n,n,n,n,n,DEK-NUP214,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,14.0,950,Relapse|Post-Transplant|Post-Chemotherapy,Bone Marrow Aspirate,y,n,y,y,n,y,5,DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)|Intrathecal,13,"Cyclophosphamide, TBI|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Cytarabine, Mitoxantrone, Sorafenib|ADE (Cytarabine, Daunorubicin & Etoposide)|Donor Lymphocyte Infusion|Cytarabine|Sorafenib|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)|Methotrexate|Etoposide, Cytarabine",8,Allogeneic - Sibling|Consolidation|Unknown|Induction|Experimental|Intensification|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,9.0,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,187.0,Dead,1655.0,Dead-Disease,True,False,12-00403,0,0.0,80,0,3.0,,78.0,3.0,16.0,,42,38.0,4.3,0.66,M2,41.6,14.3,"48,X,-Y,+4,t(6;9)(p22;q34),+8,+10,del(15)(q11.2q15)[20]",,102.9,"DEK/NUP probe set; 70/100 (70%) interphasecells scored had a 1 red/ 1 green/ 2 yellow fusion signal pattern,consistent with DEK/NUP fusion and the 6;9 translocation observed in themetaphase karyotype.",50.0,"CD13, CD33, CD34, CD38, CD117,  CD123, dim HLA-DR, partial MPO",7.6,2.2,False,False,,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.1917400992531682,High
13-00007,29,Male,Male,White,1,n,34.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,36.0,574,Post-Chemotherapy|Residual Relapse,Bone Marrow Aspirate,y,n,y,y,n,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Consolidation|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,43.0,Dead,595.0,Dead-Unknown,True,False,12-00161,0,1.0,90,30,0.0,,46.0,30.0,8.0,,43,11.0,2.8,0.92,,25.5,9.1,"46,XY,add(17)(p13)[19]/46,XY[1]",123.0,85.0,Normal,14.0,"partial CD7, CD13, CD33, CD38, dim CD45, dimCD58, CD117, CD123, and HLA-DR",5.8,0.6,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5494935754826364,High
13-00028,953,Male,Male,White,1,n,24.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,24.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,3,DLI|Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Busulfan, Cyclophosphamide",5,Consolidation|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,DLI,Donor Lymphocyte Infusion,Unknown,0.0,Alive,1207.0,Alive,False,False,,0,0.0,88,94,0.0,,3.0,40.0,3.0,,13,14.0,2.8,0.62,M4,31.7,10.9,"47,XY,+10[18]/46,XY[2]",419.0,86.3,Normal,89.0,"CD11b, dim CD13, dim CD14, CD33, CD34, dim CD38, partialCD56, CD58, partial CD64, CD117, CD123, dim HLA-DR, and MPO",5.8,21.7,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,,,,,negative,,,negative,,,negative,,,,,,p.V1578delV; MAF 50%,negative,,,,,,,,,,,,,,,,,,,,,,,,,1.328210764424839,High
13-00034,958,Female,Female,White,2,n,61.0,False,False,False,Unknown,False,False,y,Follicular lymphoma,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,61.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,16.0,Dead-Disease,False,False,,0,1.0,50,89,1.0,,0.0,0.0,0.0,,61,,2.5,0.84,,25.3,8.4,,,102.8,,24.0,"CD2(-), CD4(dim +), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +), CD15(variably and slightly bright +), CD16 (-), CD33(variably bright +), CD34(-), CD36(partial +), CD38(variably +), CD45(variably +), CD56(+), CD64(partial +), CD117(-), HLA-DR(partial dim +), MPO(+), TdT(-).",4.5,53.0,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.8222965354610157,Low
13-00098,1011,Female,Female,Black,2,n,64.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,64.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,7.0,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Induction,5.0,Unknown,,,False,False,,0,1.4,76,0,0.1,,94.3,1.5,2.7,,22,20.0,3.6,0.48,,32.6,10.9,"46,XX[14]",184.0,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],",32.0,"CD4(few +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(partial +), CD16(-), CD34(-), CD36(-), CD38(+), CD45(+), CD56(few +), CD64(-), CD117(partial +), HLA-DR(-), MPO(+) and TdT (+)",7.5,1.5,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.527235704129453,Low
13-00118,685,Male,Male,White,1,n,54.0,True,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,57.0,349,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,7,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",5,Consolidation|Salvage|Induction|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,7.0,Standard Chemotherapy,Decitabine,Re-induction,160.0,Dead,1378.0,Dead-Disease,True,False,12-00109,-349,3.0,71,83,2.0,,5.0,10.0,4.0,,35,31.0,3.9,0.81,M4,33.7,11.7,"47,XY,+21[15]/46,XY[5]",438.0,100.6,Trisomy 21,119.0,"CD13, CD33, CD38, CD58, dim CD64, CD117, and CD123",7.1,33.8,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.5750856011878461,Low
13-00123,1027,Male,Male,White,1,n,83.0,False,False,False,None,False,False,y,Colon Cancer,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,83.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,9.0,Dead-Disease,False,False,,-1,0.0,,>90,0.0,,9.0,7.0,4.0,,242,341.0,1.9,2.48,M5,17.6,6.2,"47,XY,+8[6]/46,XY[13]",2037.0,94.5,trisomy 8,14.0,"Immunophenotype:  CD11b, CD13, dimCD14, CD15, dim CD16, CD33,     CD56,     CD58, CD64, CD123, and HLA-DR positive",3.6,85.9,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,D835,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.3484794417938577,Low
13-00145,1045,Male,Male,White,2,n,70.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,n,y,y,n,y,2,Standard Chemotherapy|Supportive/Palliative Care,2,"7+3 (Cytarabine, Idarubicin)|Azacitidine",2,Hypomethylating/Low Dose Cytarabine|Induction,Refractory,Standard Chemotherapy,-1.0,Supportive/Palliative Care,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,194.0,Dead-Disease,False,False,,-22,,,78,,,12.0,5.0,3.0,,,,,1.12,,24.7,8.2,"46,XY,del(7)(q22q36)[7]/47,idem,+22[cp12]/46,XY[1]",,89.2,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[187/200], (D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",18.0,,,24.4,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.1863322221910622,High
13-00146,1046,Female,Female,White,1,n,7.0,False,True,False,RUNX1-RUNX1T1,False,False,n,,y,n,n,n,n,n,n,n,RUNX1-RUNX1T1,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,7.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,1,Standard Chemotherapy,1,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,9.0,Standard Chemotherapy,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",Re-induction,-1.0,Dead,158.0,Dead-Other,False,False,,0,0.0,85,30,0.0,,42.0,0.0,27.0,,18,19.0,3.9,0.41,,27.7,9.4,"46,XX,t(8;21)(q22;q22)[19]/46,XX[1]",747.0,90.5,"AML/ETO fusion, t(8;21)",71.0,"CD13, CD33, CD34, CD56, CD71, CD117, HLA-DR, MPO-positive",7.3,4.8,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,,,,negative,,,D816V; MAF 50%,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-2.0946831769683305,Low
13-00147,819,Female,Female,AdmixedAsian,3,n,57.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,58.0,215,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Unknown,Standard Chemotherapy,-1.0,Standard Chemotherapy,HiDAC,Consolidation,-1.0,Dead,257.0,Dead-Disease,True,False,12-00288,-14,,,,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,,,,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.8567445469764686,High
13-00149,1049,Male,Female,White,1,n,78.0,False,False,False,None,False,False,y,Bladder Cancer,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,79.0,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,Decitabine,Induction,-1.0,Dead,267.0,Dead-Disease,False,False,,0,0.0,87,72,1.0,,17.0,4.0,1.0,,19,41.0,3.4,0.75,,32.3,10.6,"45,X,-Y[19]/46,XY[1]",460.0,103.6,Normal,15.0,"CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +",6.2,8.5,False,False,,negative,negative,,,,,,,,,,,,,,1031?1032 ins AAC; MAF 50%,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,p.R369R; MAF 50%,,-1.4931506996166368,Low
13-00150,1051,Male,Male,White,1,n,52.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",Adverse,Adverse,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",53.0,234,Post-Transplant|Post-Chemotherapy|Residual Disease,Peripheral Blood,y,n,y,y,n,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide",5,Salvage|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,Decitabine,Salvage,80.0,Dead,404.0,Dead-Disease,False,False,,-2,0.0,,59,0.0,,9.0,2.0,29.0,,32,34.0,3.7,0.68,,34.0,11.1,"45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3]",167.0,102.8,Deleted 5q,152.0,,6.7,14.0,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.9204074707064154,High
13-00157,1054,Female,Female,White,1,n,60.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,MiDAC,Consolidation,104.0,Alive,1379.0,Alive,False,False,,0,0.0,80,32,0.0,,11.0,13.0,23.0,,32,50.0,2.9,0.64,,41.1,13.4,"46,XX[20]",660.0,86.1,normal,228.0,"partial CD7, partial CD11b, CD13, CD33, dim CD45, CD58,     partial CD64, partial CD117, CD123, dimHLA-DR,  MPO positive",7.4,53.9,False,False,,negative,positive,,,,,,,,,,,,,,negative,,,,,,,p.Q696fs*9; MAF 40% ,,,,,negative,,,p.R132H; MAF 40%,,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,p.G503A; MAF 40%,,,negative,,,,,,,,,,,negative,,,negative,,-0.3008783907617519,Low
13-00160,967,Male,Male,White,1,n,70.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,73.0,93,Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|Azacitidine",2,Induction|Maintenance,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,Azacitidine,Maintenance,-1.0,Dead,1165.0,Dead-Unknown,True,False,13-00049,-93,,,,,,,,,,,,,,,,,"46,XY[19]",,,Normal,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.06913450932584135,High
13-00163,1058,Male,Male,HispNative,1,n,24.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,24.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine, Methotrexate|Busulfan, Cyclophosphamide",4,Allogeneic - Sibling|Consolidation|Unknown|Induction,Complete Response,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1.0,Alive,400.0,Alive,False,False,,0,0.0,50,6,0.0,,19.0,52.0,16.0,,,,,,M4,26.3,9.2,"47,XY,inv(16)(p13q22),+22[20]",,91.5,inv(16),53.0,"- 14% Myeloid blasts: CD13, CD34, CD38, CD58, partial CD64,     CD117, CD123,          HLA-DR, and MPO positive     - 30% Monoblasts/promonocytes: CD11b, CD13, CD14, CD38, CD58, bright CD64,     HLA-DR, and MPO",,13.8,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,p.D816H; MAF ~50%,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,rs16754; MAF ~50%,,-1.7693836165502195,Low
13-00165,1060,Female,Female,White,3,n,33.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,33.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)",4,Allogeneic - Sibling|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1.0,Dead,439.0,Dead-Treatment,False,False,,-2,,,,,,,,,,,,,,,,,"46,XX[7]",,,,,,,,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.8440072636657778,High
13-00166,1061,Male,Male,White,1,n,65.0,False,False,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,67.0,0,Post-Chemotherapy|Residual Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,8,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cladribine",6,Hypomethylating/Low Dose Cytarabine|Salvage|Consolidation|Unknown|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,Cladribine,Unknown,5.0,Dead,1020.0,Dead-Unknown,False,False,,0,0.0,,77,0.0,,15.0,1.0,3.0,,18,10.0,3.6,1.01,M2,28.1,9.3,,132.0,93.5,,22.0,,6.3,19.5,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.5799572784214173,High
13-00186,1072,Male,Male,White,1,n,74.0,False,False,True,None,False,False,n,,n,n,n,n,y,y,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,126.0,Dead-Unknown,False,False,,0,0.0,60,29,1.0,,26.0,18.0,24.0,,250,160.0,3.2,0.59,,22.0,7.1,"46,XY[20]",399.0,87.4,,107.0,"partial CD7, CD13, CD33, CD34, CD38, CD58, CD117, CD123, TdT, and HLA-DR positive",7.0,11.8,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,p.A142Gfs*4; MAF 30% ,,,,,p.P95L; MAF 48%,,,,,,negative,,,negative,,0.40635628536179375,High
13-00195,1078,Male,Male,White,1,n,66.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,66.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,MiDAC,Consolidation,74.0,Alive,972.0,Alive,False,False,,0,0.0,90,24,0.0,,14.0,61.0,1.0,,19,14.0,2.4,1.13,M5,23.9,7.9,"46,XY[20]",387.0,103.6,normal,122.0,"CD11b, dim/partial CD13, CD14, CD33, CD38, CD58, CD64,     partial CD117, dim/partial CD123, and HLA-DR positive",6.3,28.0,False,False,,negative,positive,,,,,,,,,,,,,,negative,,,p.Q2208H; MAF 50%,,,,p.R882H; MAF 50%,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,rs16754; MAF 50%,,-1.7089216771832167,Low
13-00202,1086,Male,Male,White,3,n,53.0,False,True,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,53.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,752.0,Dead-Other,False,False,,-1,,73,32,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,"atypical monocytic cells expressing weaker than   normal CD13 and CD33, with increased promonocytes/monoblasts representing approximately 44% of the leukocytes,",,22.79,False,False,,negative,positive,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.7963764113097821,Low
13-00204,1088,Female,Female,White,1,n,65.0,False,True,False,PML-RARA,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,65.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin)",1,Induction,Unknown,Standard Chemotherapy,5.0,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,3.0,Dead,7.0,Dead-Other,False,False,,0,0.0,72,57,0.0,,36.0,1.0,8.0,,24,33.0,2.9,0.6,M3,20.7,6.8,"46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3]",398.0,90.2,"Unusual t(15;17), with the fusion signal on the derivative chromosome 15",10.0,"partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive",5.6,9.8,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,negative,,p.K66N; MAF 40%,,,,,,,,,negative,,,rs16754; MAF 50%,,0.29333526665157345,High
13-00226,928,Female,Female,White,1,n,83.0,False,False,True,PML-RARA,False,False,n,,y,n,n,n,n,n,y,y,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,83.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"ATRA, Arsenic Trioxide|Idarubicin",2,Induction|Symptom Control,Complete Response,Standard Chemotherapy,253.0,Standard Chemotherapy,Idarubicin,Symptom Control,0.0,Alive,1429.0,Alive,False,False,,0,0.0,75,2.1,0.0,,17.0,2.0,23.0,,14,9.0,3.7,0.7,M3,23.4,8.1,"46,XX,t(15;17)(q24;q21)[12]/46,XX,idem,del(16)(q12.1q24)[3]/46,XX[5]",367.0,86.2,16q deletion,,"CD13, CD33, partial CD34, CD64, CD117, CD123, and MPO-positive",6.8,6.0,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,D835H; MAF Unlisted,,,negative,,,,p.V617F; MAF 90%,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,,,-0.8580985050852353,Low
13-00232,1101,Female,Female,White,1,n,22.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,22.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Matched Unrelated Donor,-1.0,Alive,1001.0,Alive,False,False,,0,0.0,55,29,2.0,,7.0,33.0,24.0,,67,16.0,2.2,0.64,M4,24.0,8.0,"46,XX[24]",373.0,95.2,normal,34.0,"CD7, CD13, CD33, CD34, CD38, CD56, partial CD64,     CD117,        dim CD123, HLA-DR and MPO+",6.5,29.4,False,False,,negative,negative,,,,,,,,,,,,,,p.D107fs*; MAF ~50%,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,rs16754; MAF ~50%,,-1.2100252966275833,Low
13-00245,1108,Male,Male,Asian,1,n,8.0,False,True,False,RUNX1-RUNX1T1,False,False,n,,y,n,n,n,n,n,n,n,RUNX1-RUNX1T1,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,8.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",2,Induction|Intensification,Complete Response,Standard Chemotherapy,11.0,Standard Chemotherapy,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",Intensification,62.0,Alive,857.0,Alive,False,False,,0,0.0,30,17,0.0,,33.0,17.0,20.0,,,,,0.53,M2,29.3,10.3,"46,XY,t(8;21)(q22;q22)[5]/46,idem,der(7)t(7;8)(q22;q11.2)[13]/46,XY[2]",,93.5,t(8;21),109.0,"dim CD7, CD13, CD33, CD34, CD38, partial CD56,CD58, CD117, CD123, dim HLA-DR, and MPO",,19.5,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.854347302794079,Low
13-00250,1111,Male,Male,White,1,n,78.0,False,False,True,Unknown,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,78.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,2,Azacitidine|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Induction,Unknown,Standard Chemotherapy,-1.0,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,356.0,Dead-Disease,False,False,,0,,,,,,,,,,,,,,,,,,,,,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0257542120413337,High
13-00253,1113,Female,Female,White,1,n,42.0,False,True,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,42.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,4.0,Dead,273.0,Dead-Disease,False,False,,0,0.0,70,9,0.0,,43.0,6.0,38.0,,36,28.0,3.5,0.81,M7,34.8,12.0,,762.0,85.2,"Extra signals were observed for BCR (22q11.2), PML (15q22), MLL (11q23),     RUNX1T1 (8q21.3) and RUNX1 (21q22) in roughly 45-60% of interphase cells.     These results suggest the presence of a hyperdiploid clone.",13.0,"CD7, CD13, CD33, CD58, partial CD61, CD71, and Factor 8 positive",6.8,7.9,False,False,,negative,negative,,,,,,,,,,,,,,p.V119?M120insV; MAF 30% ,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,1.6858875332101,High
13-00255,1104,Male,Male,White,1,n,72.0,False,False,True,None,False,False,n,,y,n,n,n,y,y,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72.0,8,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,6.0,Dead,176.0,Dead-Unknown,True,True,13-00237,-8,0.0,,5,1.0,,3.0,77.0,8.0,,57,27.0,3.5,0.61,M4,26.3,8.7,"46,XY,del(12)(p11.2p13)[15]/46,XY[5]",324.0,92.8,12p deletion,19.0,,7.2,56.5,False,False,,negative,negative,,p.A619fs*14; MAF 50%,,,,,,,,,,,,negative,,,,,,,negative,,,p.R583*; MAF 95%,,D835,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,p.D61H; MAF 15%,,, p.P345?S356del; MAF 25%,,,,,,,,,,p.Y867H; MAF 50%,negative,,,negative,,0.8544413371351425,High
13-00260,1117,Male,Male,White,1,n,14.0,False,True,False,RUNX1-RUNX1T1,False,False,n,,y,n,n,n,n,n,n,n,RUNX1-RUNX1T1,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,14.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,1,"COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)",1,Induction,Complete Response,Standard Chemotherapy,133.0,Standard Chemotherapy,"COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)",Induction,133.0,Alive,1011.0,Alive,False,False,,0,0.0,62,64,0.0,,28.0,1.0,7.0,,15,9.0,4.1,0.58,M2,18.5,6.3,"45,X,-Y,t(8;21)(q22;q22)[4]/45,idem,del(9)(q12q22)[13]/46,XY[3]",486.0,105.8,"RUNX1T1/ RUNX1 fusion and t(8;21),",63.0,"CD13, CD33, CD34, dim CD45, partial CD56, CD58, dim CD117, HLA-DR, MPO, and partial TdT-positive",7.9,13.3,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,p.S366A; MAF 50% ,,,,,-2.2851820376247143,Low
13-00262,1118,Female,Female,White,2,n,64.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5,"Crenolanib|MEC, plexifor, GCSF|Sorafenib|7+3 (Cytarabine, Idarubicin) plus LBH|Clofarabine, Cytarabine",4,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,21.0,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,124.0,Dead,455.0,Dead-Disease,False,False,,-1,,81,94,,,6.0,,,,87,47.0,2.8,0.53,,27.2,9.7,"46,XX,t(3;11)(q21;p11.2),t(15;15)(q15;q22)[19]/46,XX,t(2;14)(q21;q11.2)[2]",743.0,,"nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",11.0,"CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +).",5.2,26.0,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0066761212058413,High
13-00266,1119,Male,Male,White,1,n,77.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,7.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,7.0,Dead,129.0,Dead-Disease,False,False,,1,,,47,,,,,,,,,,,,,,"46,XY,-7,+13,i(17)(q10)[20]",,,Monosomy 7,,"CD13, CD33, CD34, CD117, dim CD123, and HLA-DR-positive",,25.3,False,False,,negative,negative,,p.W583*; MAF 50%,,,,,,,,,,,,negative,,,,,,,negative,,p.N384*; MAF 40%,,p.T196A; MAF 50%,negative,,,negative,,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,p.P95H; MAF 70%,,,,,,negative,,,,,1.1908463984867552,High
13-00270,1123,Female,Female,White,1,n,18.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,18.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",Re-induction,-1.0,Alive,151.0,Alive,False,False,,0,0.0,50,22,0.0,,24.0,49.0,20.0,,13,15.0,3.6,0.77,M4,21.0,7.4,"46,XX,inv(16)p13.1q22)[4]/47,idem,+22[15]/46,XX[1]",415.0,97.8,CBFB rearrangement and inv(16),23.0,"Blast phenotype:  CD13, CD33, CD34, CD38, CD58, dim CD123,     HLA-DR-positive               - Monocytic phenotype:  CD11b, CD13, CD14, CD33, CD58, CD64, HLA-DR-positive",7.6,8.8,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,Negative FLT3-D835 was observed in GeneTrails;negative,,,negative,,,,negative,,,negative,,,p.G13D; MAF 10%,,,,,,,p.G13D; MAF 30%,,,,,,,,,,,,,,,,,,,,negative,,,,,-1.6897355128328384,Low
13-00281,1131,Female,Female,White,4,n,79.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,79.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Azacitidine, Lenalidomide",1,Salvage,,,,Standard Chemotherapy,"Azacitidine, Lenalidomide",Salvage,137.0,Dead,189.0,Dead-Disease,False,False,,0,,73,56,,,,1.0,,,,,,,,,,"46,XX,del(16)(p11.2)[3]/46,XX[2]",,,,,"CD34, CD4(dim), CD7, CD11c(dim), CD13, CD33(dim),CD38, CD117, and HLA-DR",,8.7,False,False,,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,R140Q,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.6252645789691598,High
13-00331,1153,Female,Female,White,4,n,35.0,True,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,37.0,1,Post-Chemotherapy|Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI",5,Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Re-induction,53.0,Dead,761.0,Dead-Treatment,False,False,,0,,92,97,,,,,,,,,,,M5,,,"46,XX[5]",,,,,"CD45, DIM CD64, DIM CD13, DIM CD33, CD15, CD38, MPO, CD11C, DIM CD4, DIM PARTIAL CD19, CD117, AND HLA-DR",,140.0,False,False,,negative,positive,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,D835,,,positive,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.35740944199128255,High
13-00338,1157,Female,Female,White,4,n,53.0,True,False,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,60.0,0,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,5,"7+3 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Azacitidine, Gemtuzumab|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Cytarabine",2,Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,"Azacitidine, Gemtuzumab",Re-induction,-1.0,Alive,2522.0,Alive,True,False,13-00337,0,,82,25,,,,19.0,,,,,,,M4eo,,,"47,XX,t(16;16)(p13;q22),+22[20]",,,Positive,,,,4.3,True,False,13-00337,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,D835,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.29218713962303144,Low
13-00342,1159,Male,Male,Asian,4,y,31.0,True,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,32.0,0,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,4,DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,7,"7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI ",6,Allogeneic - Sibling|Consolidation|Salvage|Unknown|Induction|Re-induction,Complete Response,Standard Chemotherapy,8.0,Supportive/Palliative Care,Decitabine,Salvage,-1.0,Alive,902.0,Alive,False,False,,0,,28,23,,,,6.0,,,,,,,,,,"46,XY[20]",,,,,"CD34, CD117, CD38, MPO, CD11c (dim),CD13, CD33, CD15, and HLA-DR,CD7 and CD56 (partial)",,4.0,False,False,,negative,negative,,,,,,,negative,,,,,,,Double mutation,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-1.449161752064132,Low
13-00353,1161,Female,Female,Asian,1,n,30.0,False,False,False,MLLT3-KMT2A,False,False,y,Not specified,y,n,n,n,n,n,n,n,MLL-MLLT3,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,30.0,0,Post-Chemotherapy|Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,6.0,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,31.0,Dead,270.0,Dead-Disease,False,False,,0,0.0,64,65,0.0,,28.9,25.4,19.3,1.7,48,33.0,3.6,0.64,,21.8,7.5,"46,XX,t(9;11)(p11;q34)[19]/46,XX[1]",,111.8,Disruption of MLL signal and t(9;11),29.0,"CD11b, CD13, CD14,  CD33, CD64, CD56, CD123 and HLA-DR positive",6.1,29.25,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,p.T910S; MAF 40%,,,,negative,,,,,p.D835; MAF 35%,,,negative,,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,negative,,-0.4472797177777672,Low
13-00354,1163,Male,Male,Asian,4,n,73.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,73.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Decitabine|Stanford Protocol 9153 (TLI, ATG)",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Stanford Protocol 9153 (TLI, ATG)",Allogeneic - Mismatched Unrelated Donor,-1.0,Dead,330.0,Dead-Other,False,False,,0,,84,71,,,,6.0,,,,,,,,,,"46,XY[20]",,,,,""" CD4(subset), CD11c(partial), CD13(partial), CD14(partial), CD15(partial), CD33(subset), CD34(subset), CD38, CD64(subset), CD117(subset), HLA-DR and MPO""",,16.2,False,False,,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.3675924747297302,Low
13-00365,1171,Female,Female,White,4,n,72.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Azacitidine, Lenalidomide|Temozolomide, Vorinostat",2,Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,"Temozolomide, Vorinostat",Re-induction,-1.0,Dead,420.0,Dead-Unknown,True,False,13-00366,-13,,,,,,,,,,,,,,,,,"46,XX,del(5)(q31q35),inv(7)(p15q32),del(12)(q?15)[2]/45~46,idem,add(3)(q27),-9,-del(12)(q?15),+add(12)(q13),-16,-17,+mar1,+mar2x2[cp16]/46,XX[2]",,,,,,,,True,False,13-00366,positive,positive,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,positive,,,,,-0.013099903164762412,Low
13-00384,1181,Female,Female,White,4,n,71.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,3,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,3,"Cytarabine|Azacitidine|Stanford Protocol 9153 (TLI, ATG)",3,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,,,,Standard Chemotherapy,Cytarabine,Supportive/Palliative Care,9.0,Dead,719.0,Dead-Disease,True,True,13-00383,0,,34,8,,,,15.0,,,,,,,,,,"46,XX,t(8;19)(q24;q13),del(11)?(q14q23)[19]/46,XX[1]",,,,,"CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7",,4.2,True,True,13-00383,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.6663501031343044,Low
13-00393,1184,Male,Male,HispNative,2,n,52.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,52.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG",5,Consolidation|Salvage|Induction|Experimental|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,15.0,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Allogeneic - Matched Unrelated Donor,-1.0,Dead,1237.0,Dead-Disease,False,False,,0,,21,5,,,68.0,4.0,23.0,,17,23.0,3.6,0.89,,28.3,8.5,"89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]",183.0,,"nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]",22.0,"partialCD4, partialCD15, dimCD33, CD34, CD38, dimCD45, CD117, HLA-DR, TdT, MPO",7.5,3.42,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.1011180145349314,Low
13-00396,1187,Male,Male,White,1,n,63.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,Decitabine,Consolidation,-1.0,Dead,228.0,Dead-Treatment,False,False,,-2,1.8,51,3.5,0.9,,41.2,37.7,11.4,0.0,20,20.0,3.2,1.37,M4,33.7,11.0,"42~45,XY,del(4)(q31q35),del(5)(q13q35),add(9)(q21),add(13)(p11.2),-16,-21[cp15]/40~46,sl,+9,-add(9)(q21),-15,+der(16)t(15;16)(q11.1;p13.3),-18,+mar[cp5]",,92.6,Extra MLL signal,24.0,"CD13, CD33, CD34, CD56, CD58, dim CD64, CD117 and partial HLA-DR.",7.1,5.23,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,negative,,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,,,,,,,,,,,,p.R273S; MAF 40%,,,negative,,0.2938158765802503,High
13-00406,1190,Male,Male,White,1,n,62.0,False,True,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,62.0,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,2.0,Dead-Disease,False,False,,0,0.0,95,66.3,0.0,,9.5,1.9,4.8,0.2,93,104.0,3.2,1.85,M5,26.2,8.5,"46,XY[20]",2941.0,104.8,Normal,92.0,"CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38,      partial CD56, CD58, CD64, CD123, and HLA-DR positive",6.5,250.23,True,True,13-00409,positive,negative,,,,,,,,,,,,,,negative,,,,,,,p. R882C; MAF 50%,,,,,negative,,,negative,,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,"Intron 5, 3' splice site mutation; MAF 50%",,,,,,,,,,,negative,,,,,-0.33736350368471113,Low
13-00409,1190,Male,Male,White,1,n,62.0,False,True,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,IntermediateOrAdverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,62.0,1,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,2.0,Dead-Disease,True,True,13-00406,0,0.0,95,95,0.0,,9.5,1.9,4.8,0.2,93,104.0,3.2,1.85,M5,26.2,8.5,"46,XY[20]",2941.0,104.8,Normal,92.0,"CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38, partial CD56, CD58, CD64, CD123, and HLA-DR positive",6.5,250.23,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,p.R882C; MAF 50%,,,,,negative,,,negative,,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,"Intron 5, 3' splice site mutation; MAF 50%",,,,,,,,,,,negative,,,,,-0.30302991342365976,Low
13-00420,1194,Male,Male,White,2,n,75.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",75.0,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",4,Consolidation|Induction|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,Azacitidine,Maintenance,34.0,Dead,383.0,Dead-Disease,False,False,,-98,,,,,,,,,,,,,,,,,"47,XY,+8,inv(9)(p11q12)c[1]/48,idem,+3[5]/49,idem,+3,+15[1]/50,idem,+3,+8,+mar(8]/46,XY,inv(9}(p11q12)c[5]",,,"nuc ish (D8Z2x3~4)[134/200],(D15Z4x3)[114/200]",,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.17448836081792832,Low
13-00425,1197,Female,Female,White,2,n,40.0,False,True,False,MLLT3-KMT2A,False,False,n,,y,n,n,n,n,n,n,n,MLL-MLLT3,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,40.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,HiDAC,Consolidation,5.0,Alive,486.0,Alive,False,False,,-1,,84,29,,,63.0,3.0,5.0,,21,23.0,3.7,0.65,,35.0,12.0,"46,XX,t(9;11)(p22;q23)[20]",613.0,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1) [179/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",34.0,"brightCD4, partialCD11b, brightCD15, brightCD33, partialCD36, partialCD38, CD45, brightCD64, partialCD117, HLA-DR",6.5,9.1,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.8209401481522279,Low
13-00450,1224,Female,Female,White,2,n,79.0,True,False,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,79.0,0,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,"7+3 (Cytarabine, Idarubicin)|Crenolanib",2,Induction|Experimental,Complete Response,Standard Chemotherapy,4.0,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,14.0,Dead,124.0,Dead-Disease,False,False,,0,,,,,,,,,,,,,,,,,,,,,,,,,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.7611005428567502,High
13-00454,1226,Female,Female,HispNative,2,n,31.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,31.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response i,Standard Chemotherapy,5.0,Standard Chemotherapy,HiDAC,Consolidation,95.0,Unknown,,,False,False,,0,,,45,3.0,,25.0,20.0,7.0,,,,,1.04,,22.0,7.4,"46,XX,inv(16)(p13.1q22)[11]/47,idem,+22[4]/46,XX[5]",229.0,,"nuc ish(D4Z1,D10Z1)x2[199],(SCFD2,LNX,PDGFRA/KIT)x2[200],(5'PDGFRB,3'PDGFRB)x2(5'PDGFRB con 3'PDGFRBx2)[200],(5'FGFR1,3'FGFR1)x2([200],(RUNX1T1,RUNX1)x2[200](ABL1x2,BCRx3)[63/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(ETV6,RUNX1)x2[198],(PML,RARA)x2[200],(CBFBx2)(5’CBFB sep 3’CBFBx1)[147/200]",30.0,"CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial+), CD16(-), CD22(few +), CD33(dim + to -), CD34(+), CD36(-), CD38(variably +), CD41(-), CD45(variably +), CD56(-), CD61(-), CD64(-), CD117(variably +), HLA-DR(partial +), Gly-A(-), MPO(+), TdT(partial +)",,13.63,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.17510840149389795,Low
13-00466,1566,Male,Male,White,2,n,71.0,False,True,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Other,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|BL-8040",4,Consolidation|Salvage|Induction|Experimental,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,Cytarabine,Salvage,-1.0,Dead,973.0,Dead-Disease,False,False,,0,0.5,,0,2.5,,56.8,2.6,37.6,,21,27.0,3.9,0.93,,33.4,11.2,,195.0,,,89.0,,6.9,2.0,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.20368741205702479,Low
13-00468,1233,Male,Male,White,1,n,61.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,61.0,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,Decitabine,Salvage,126.0,Dead,370.0,Dead-Disease,False,False,,0,,17,10,,,27.7,,39.2,,47,22.0,3.8,0.5,,25.8,8.5,"47~49,XY,-21,+1~4mar[cp21]/46,XY[2]",,86.6,Monosomy 21,40.0,"CD13, CD33, CD34. CD45, subset CD64, CD79a, CD117,HLA-DR, and subset TdT positive).",7.6,5.5,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,p.T618I; MAF 50%,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,benign SNP rs16754 (R369R: no amino acid change); MAF 50%,,-1.3670073858893377,Low
13-00487,1243,Female,Female,White,1,n,35.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,35.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,HiDAC,Consolidation,94.0,Alive,358.0,Alive,False,False,,0,0.0,49.4,28.6,1.8,,19.6,37.5,7.1,0.0,20,17.0,3.1,0.88,M4,14.3,4.8,"46,XX,t(16;16)(p13.1;q22)[16]/47,idem,+22[4]",505.0,100.7,Trisomy 22,36.0,"Myeloid blasts (21%): CD13, CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive. Promonocytic/monocytic cells (55%): CD11b, CD13, CD14, CD33, dim/partial CD34, CD38, CD58, CD64, variable CD123, HLA-DR, and MPO-positive.",7.8,49.4,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,P552S; MAF 50%,,,,,,,,,negative,,,negative,negative,,,negative,,K395N; MAF 50%,D816V; MAF 1%,,,negative,,negative,,,,,G13D; MAF 6%,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-1.4508260406910969,Low
13-00493,1246,Male,Male,White,2,n,62.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,63.0,0,Post-Chemotherapy|Residual Relapse,Peripheral Blood,y,y,y,y,y,n,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide",5,Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,24.0,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,141.0,Dead,568.0,Dead-Unknown,True,False,13-00494,0,0.0,81,59,0.0,,0.0,0.0,10.0,,34,15.0,4.0,,,30.2,10.7,"46,XY",,,,17.0,"CD2(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(variably +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD45(moderately +), CD56(-), CD64 (partial +), CD117(variably +), HLA-DR(-), MPO(+), TdT(-).",6.0,1.8,True,False,13-00494,positive,positive,,,,,,,,,,,,"Foundation, P203S; MAF 8%",,,Foundation; T367fs*15; MAF 9%,,,,,,"Foundation, R882H; MAF 9%",,,,,"Foundation, Y591_V592INSVDFREYEYDLKWEFPRENLEFD; MAF 13%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.3133615792853355,High
13-00496,1247,Female,Female,White,2,n,33.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,33.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,HiDAC,Consolidation,103.0,Alive,1480.0,Alive,True,True,13-00497,0,0.0,72,18,0.0,,38.0,26.0,3.0,,85,30.0,3.4,,,25.9,9.0,"47,XX,inv(16)(p13.1q22),+22",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5’CBFB sep 3’CBFBx1)[140/200]",18.0,"CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+)",6.1,26.3,True,True,13-00497,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.9363764812290385,Low
13-00500,1248,Male,Male,White,2,n,71.0,False,False,False,None,False,False,y,Prostate Cancer,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,55.0,Dead,156.0,Dead-Unknown,False,False,,0,0.0,76,58,2.0,,38.0,6.0,14.0,,27,25.0,3.1,,,25.0,8.5,"46,XY",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",93.0,"CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial +), HLA-DR(+), TdT(partial +), MPO(-)",5.8,7.5,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.17420340832317777,High
13-00513,1255,Male,Male,White,1,n,55.0,False,True,False,MLLT3-KMT2A,False,False,n,,y,n,n,n,n,n,n,n,MLL-MLLT3,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,55.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,4.0,Dead,246.0,Dead-Disease,False,False,,-274,1.4,75,,8.5,,11.4,8.5,34.0,0.2,62,31.0,3.8,1.44,M5,38.1,12.2,"46,XY,t(9;11)(p22;q23)[20]",497.0,87.6,MLL rearrangement and t(9;11),32.0,,7.9,10.21,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.33663771943907705,Low
13-00515,1257,Male,Male,White,2,n,73.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),7,"Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)",6,Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,39.0,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,33.0,Dead,658.0,Dead-Unknown,False,False,,0,1.0,32,67,2.0,,8.0,3.0,14.0,,15,30.0,4.1,,,32.8,11.0,"46,XY,+1,dic(1;15)(q12;p11.2)[2]/46,XY[18]",,,"18].nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",90.0,"CD4(partial dim +), CD7(-), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variably +), CD34(+), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(-), CD79a(-)",5.8,24.2,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.525580309971113,High
13-00522,1261,Female,Female,White,3,n,68.0,False,False,True,None,False,False,y,Not specified,y,n,n,n,n,n,y,y,,MYELOPROLIFERATIVE NEOPLASMS,Secondary myelofibrosis,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68.0,49,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Cyclophosphamide, Fludarabine, TBI|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine",3,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,339.0,Dead-Other,False,False,,0,,29,40,,,,,,,,,,,,,,"46,XX,der(9)t(9;12)(p13;q13),del(11)(q21q25),der(12)add(12)(p11.2)add(12)(q13),del(13)(q14q22)[9]/46,idem,add(12)(q24.3),+13,-del(13)[9]/46,idem,add(17)(p13)[2]",,,,,,,11.36,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.54368963146398,High
13-00532,1281,Male,Male,HispNative,2,n,21.0,False,False,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",22.0,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),13,"HiDAC|Crenolanib|Etoposide|Topotecan|Decitabine|Clofarabine|Thioguanine|7+3 (Cytarabine, Idarubicin)|Cyclophosphamide|Thiotepa|Sorafenib|Mitoxantrone|Vinorelbine",4,Induction|Experimental|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,5.0,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,15.0,Dead,537.0,Dead-Disease,False,False,,0,0.0,88,92,0.0,,8.0,0.0,0.0,,22,20.0,3.3,0.51,,25.8,9.1,,208.0,,,,,6.4,3.2,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.4312647552927853,High
13-00544,1285,Male,Male,White,2,n,68.0,False,False,True,Unknown,False,False,n,,y,n,n,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",68.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,5.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,5.0,Dead,29.0,Dead-Disease,False,False,,0,,,41,,,,,,,,,,,,,,,,,,,,,9.5,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5347375917365728,High
13-00545,1286,Male,Male,White,4,n,71.0,False,False,False,GATA2-MECOM,False,False,y,Prostate Cancer,y,n,n,n,n,n,n,n,EVI1_F,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,72.0,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",4,Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,555.0,Dead-Disease,True,True,13-00546,2,,,,,,,,,,,,,,,,,"45,XY,-7,t(3;3)[20]",,,,,,,,True,True,13-00546,positive,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,D835,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,1.7969563250345713,High
13-00546,1286,Male,Male,White,4,n,71.0,False,False,False,GATA2-MECOM,False,False,y,Prostate Cancer,y,n,n,n,n,n,n,n,EVI1_F,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,72.0,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,n,y,y,n,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",4,Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,555.0,Dead-Disease,False,False,,2,,,,,,,,,,,,,,,,,"45,XY,-7,t(3;3)[20]",,,,,,,,False,False,,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,D835,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,1.8210515540744816,High
13-00551,1314,Male,Male,Black,2,n,51.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",51.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1.0,Alive,1487.0,Alive,False,False,,-3,,,1,,,17.0,35.0,23.0,,16,14.0,3.7,0.8,,25.0,8.7,"46,XY[20]",,83.8,,16.0,,6.8,3.2,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.233503600103824,High
13-00552,1315,Male,Male,White,3,n,74.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,75.0,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Etoposide, Mitoxantrone",3,Hypomethylating/Low Dose Cytarabine|Salvage|Induction,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,-1.0,Dead,415.0,Dead-Disease,False,False,,-7,,,,,,,,,,,,,,,,,"46,XY,add(1)(p34),del(7)(q22),del(20)(q11.2)[20]",,,"normal, no evidence of RUNX1T1/RUNX1 transloc or 11q23 or 16q22",,,,,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.2454887211673746,High
13-00557,1233,Male,Male,White,1,n,61.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62.0,43,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,Decitabine,Salvage,126.0,Dead,370.0,Dead-Disease,False,False,,0,,17,2,,,32.2,,34.2,,34,15.0,3.7,0.3,,32.4,10.4,"46~49,XY,-21,+1~4mar[cp20]",,87.2,Monosomy 21,21.0,"CD11b, CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, HLA-DR and partial TdT positive; aberrant monocytic population: CD11b, CD13, CD14, bright CD33, dim CD56, CD64, and HLA-DR positive.",7.0,7.2,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.08924989079797029,High
13-00558,1341,Male,Male,White,1,n,61.0,False,False,True,None,False,False,n,,y,n,n,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,61.0,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide",5,Allogeneic - Sibling|Salvage|Induction|Re-induction|Symptom Control,Refractory,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1.0,Dead,213.0,Dead-Treatment,False,False,,0,0.0,25,20,13.0,,6.0,12.0,55.0,0.9,45,34.0,3.1,0.8,,31.1,9.8,"42~44,XY,t(1;10)(q12;q21),-5,-7,-11,add(13)(p11.1),der(18)t(11;18)(q14;q21.1),add(20)(q12),+1~3mar[cp4]/41~44,sl,add(4)(q23)[cp9]/41~44,sl,del(4)(q21q?27)[cp5]/41~42,",,88.9,Monosomy 5,243.0,"CD13, CD33, CD34, CD117, and MPO+.",6.4,96.64,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5388415538893025,High
13-00563,1343,Female,Female,White,4,n,64.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Fludarabine, BCNU, Melphalan|Decitabine, Midostaurin",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,249.0,Bone Marrow Transplant,"Fludarabine, BCNU, Melphalan",Allogeneic - Sibling,-1.0,Alive,1021.0,Alive,True,False,13-00562,-2,,,,,,,,,,,,,,,,,"46,XX,t(2;3)(p13;q25~26)[2]/46,idem,i(14)(q10)[18]",,,,,,,,True,False,13-00562,positive,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,1.361574305538154,High
13-00572,1348,Male,Male,HispNative,3,n,39.0,False,False,False,None,False,False,y,Not specified,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,39.0,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,7,"Nelarabine|POMP (Prednisone, Methotrexate, 6-MP, Vincristine)|3+7 (Cytarabine, Daunorubicin)|HyperCVAD|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)",5,Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance|Re-induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Re-induction,-1.0,Dead,169.0,Dead-Disease,False,False,,0,,59.3,28,,,,,,,,,,,,,,"46,XY,t(10;11)(p13;q14)[11]/45,sl,-Y[7]/46,sdl1,t(1;8)(q12;p21)[2]",,,Normal,,"Increased atypical myeloblasts (partial CD34+, weak CD7+, partial CD61+), representing approximately 91% of the leukocytes, consistent with persistent acute myeloid leukemia.",,1.7,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.4943854647131065,High
13-00573,1349,Male,Male,White,1,n,85.0,False,False,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,86.0,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,169.0,Dead,333.0,Dead-Disease,False,False,,0,0.0,,,0.0,,17.0,44.0,39.0,0.0,15,9.0,3.5,0.9,,25.7,8.2,,175.0,88.0,,18.0,,6.9,13.22,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.4220762773370418,Low
13-00578,1353,Female,Female,White,2,n,30.0,False,False,False,DEK-NUP214,False,False,n,,y,n,n,n,n,n,n,n,DEK-NUP214,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,31.0,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib",3,Salvage|Induction|Experimental,Refractory,Standard Chemotherapy,-1.0,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,52.0,Dead,568.0,Dead-Disease,True,True,13-00581,3,,,47,,,,,,,49,31.0,4.2,0.85,,,,"47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]",329.0,,,10.0,,6.3,20.2,True,True,13-00581,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,D835,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.2646643799539208,High
13-00581,1353,Female,Female,White,2,n,30.0,False,False,False,DEK-NUP214,False,False,n,,y,n,n,n,n,n,n,n,DEK-NUP214,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,31.0,3,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,n,y,y,n,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib",3,Salvage|Induction|Experimental,Refractory,Standard Chemotherapy,-1.0,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,52.0,Dead,568.0,Dead-Disease,False,False,,0,,65,52,0.0,,10.0,0.0,28.0,,,26.0,3.9,0.87,,22.4,7.9,"47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]",,90.9,,20.0,"CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myeloid and lymphoid antigens(-).",,43.3,False,False,,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,D835,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.7186573893343452,High
13-00593,1257,Male,Male,White,2,n,73.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74.0,37,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),7,"Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)",6,Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,39.0,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,33.0,Dead,658.0,Dead-Unknown,False,False,,0,6.0,66,40,2.0,,19.0,20.0,8.0,,22,36.0,4.3,,,34.7,11.6,"46,XY",,,"nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]",67.0,"CD2(-), CD4(-), CD7(-), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variable and bright +), CD34(variably +)",6.2,13.9,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.6772958244438188,High
13-00601,1369,Male,Male,White,2,n,,False,False,False,None,True,False,n,,y,n,y,n,n,n,n,n,,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,Intermediate,,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,,4,Unknown,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Unknown,Standard Chemotherapy,60.0,Standard Chemotherapy,Decitabine,Induction,60.0,Dead,116.0,Dead-Unknown,False,False,,-3,,,,,,,,,,,,,,,,,"46,XY[20]",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,-0.6642355745498852,Low
13-00602,1370,Male,Male,White,2,y,63.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1.0,Alive,1433.0,Alive,False,False,,-2,,,85,0.0,,9.0,3.0,3.0,,16,27.0,2.9,0.75,,,,"46,XY,del(11)(q14q23)[13]/46,XY[7].ishdel(11)(5'MLL-,3'MLL+)[2].",682.0,,"nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(5'MLLx1,3'MLLx2)(5'MLL con 3'MLLx1)[118/200]",,,6.6,33.0,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.1177929814136227,Low
13-00615,1375,Female,Male,HispNative,4,n,62.0,False,True,False,RUNX1-RUNX1T1,False,False,n,,y,n,n,n,n,n,n,n,RUNX1-RUNX1T1,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,62.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Induction,-1.0,Alive,239.0,Alive,False,False,,0,,52,57,,,,6.0,,,,,,,,,,"46,XY,t(8;21)(q22;q22)[14]",,,,,"CD34, PARTIAL CD38, CD33, CD13, CD64, PARTIAL CD11C, PARTIAL CD19, HLA-DR, PARTIAL CD15, CD117, AND MPO",,12.9,False,False,,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,,,,negative,,,,,,,positive,,,,,,,,,,,,,,,,,,,,negative,,,,,-1.5375116895188867,Low
13-00619,1373,Female,Female,White,2,n,47.0,False,False,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47.0,2,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,"Crenolanib|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Salvage|Experimental,,,,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,4.0,Dead,934.0,Dead-Unknown,True,False,13-00612,0,0.0,,72,0.0,,28.0,0.0,0.0,,10,17.0,2.8,0.56,,14.5,5.3,,291.0,,,10.0,,5.1,1.2,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.1191555308046048,High
13-00625,1378,Male,Male,White,4,n,21.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,21.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,2,"SWOG S1203 (7+3 +/- Vorinostat)|Fludarabine, Cyclophosphamide, TBI ",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,177.0,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Allogeneic - Sibling,-1.0,Alive,605.0,Alive,False,False,,0,,66,1,,,,17.0,,,,,,,M1,,,"45,XY,-7[6]/47,XY,+13[cp5]/46,XY[12]",,,,,"CD34, CD4, CD13, CD15, partial CD33, CD38, partial CD117, partial CD11c, HLA-DR, MPO and TdT",,2.1,False,False,,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,positive,,,,,,,,,,,,,,,,,,,,negative,,,,,0.7171322437236767,High
13-00650,2737,Male,Male,White,7,n,,False,False,False,Unknown,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,20.0,2,Unknown,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,,False,False,,0,,,,,,,,,,,,,,,,,,,,,,,,,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.39209438172113437,Low
13-00655,1394,Male,Male,White,3,n,62.0,False,False,False,MLLT3-KMT2A,False,False,y,Prostate Cancer,y,n,n,n,n,n,n,n,MLL-MLLT3,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,62.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin) ",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Fludarabine, TBI",Allogeneic - Matched Unrelated Donor,-1.0,Dead,979.0,Dead-Disease,True,True,13-00654,-1,,93,58,,,,,,,,,,,M5a,,,"47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]",,,8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present,,"Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.",,14.66,True,True,13-00654,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.292994625787357,Low
13-00658,1396,Male,Male,White,1,n,60.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,MiDAC,Consolidation,114.0,Alive,201.0,Alive,False,False,,0,0.8,30,42.4,4.5,,19.7,8.3,15.9,0.3,49,23.0,3.5,1.22,,30.6,10.6,"46,XY[21]",536.0,95.6,Normal,141.0,"CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive",7.2,11.93,False,False,,negative,positive,,,,,,,,,,,,,,p. Q83fs*27 (c.245?246insTGTTCCA); MAF 50%,,,,,,,negative,,,,,p.I836delI; MAF 25%,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-0.3271458064218361,Low
13-00659,1397,Male,Male,White,1,n,55.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,55.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide",4,Allogeneic - Sibling|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,5.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1.0,Dead,386.0,Dead-Unknown,False,False,,0,0.0,54,54,0.0,,14.0,59.6,5.3,0.0,463,477.0,2.7,1.14,M4,19.3,6.6,"47,XY,+8[16]/46,XY[4]",,93.7,Trisomy 8,47.0,"partial CD13, CD15,  CD33, CD56, CD38, CD58, CD64, dimCD123, HLA-DR and MPO positive",5.7,16.66,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,"p.G12R, MAF 50%",,,,,,,,,,,,,,,,,,,,negative,,,negative,,-1.153401396542646,Low
13-00660,1398,Male,Male,Black,1,n,72.0,False,False,True,None,False,False,n,,y,n,n,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,Decitabine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1.0,Alive,60.0,Alive,False,False,,0,2.6,41,,0.0,,15.3,9.3,28.8,0.6,36,31.0,3.8,1.66,,23.3,7.2,"46,XY,-7,+mar.ishder(7)del(7)(p11.2)del(7)(q11.2)(D7Z1+)[20]/45,XY,-7[2]/46,XY[3]",398.0,82.0,"Two of twenty-five metaphase cells examined were monosomy 7, shown by  fluorescent in situ hybridization (FISH) in  a companion study  (GLC-13-06587) to be a true clone.  Twenty cells appeared to be missing a  chromosome 7 with an additional small marker.",42.0,"CD13, dimCD19, partial CD33, partial CD34, CD38, CD58, dim cCD79a, CD117, and TdT positive.",6.6,12.44,False,False,,negative,negative,,,,,,,,,,p.L370del; MAF 63%,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,p.V617F; MAF 43%,,,negative,,,negative,,,,,,,negative,,,,,,,,,p.R166G; MAF 22%,,,,,,,,,,,negative,,p.Q157R; MAF 40%,,,0.7857661234165998,High
14-00001,1400,Male,Male,HispNative,1,n,56.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,56.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,n,y,n,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,HiDAC,Consolidation,111.0,Alive,217.0,Alive,False,False,,0,0.8,95,95,0.0,,25.6,0.0,0.0,0.7,27,16.0,3.4,0.97,,11.1,3.7,"46,XY[20]",314.0,95.7,Normal,20.0,"CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive",7.1,13.26,True,True,14-00004,positive,positive,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,p.R140Q; MAF 50%,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-1.2575486299282883,Low
14-00012,1406,Male,Male,White,4,n,72.0,False,True,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Supportive/Palliative Care,1,Hydroxyurea,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1.0,Dead,33.0,Dead-Disease,True,False,14-00013,0,,94,71,,,,0.0,,,,,,,M5,,,"48,XYY,+8[21]",,,,,"CD38, CD56, CD13(dim), CD64, CD11c, CD4, CD56, HLA-DR, and CD15",,24.2,True,False,14-00013,negative,positive,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,D835,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.9327222111640211,Low
14-00015,1161,Female,Female,Asian,1,n,30.0,True,False,False,MLLT3-KMT2A,False,False,y,Not specified,y,n,n,n,n,n,n,n,MLL-MLLT3,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,31.0,147,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,6.0,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,31.0,Dead,270.0,Dead-Disease,False,False,,0,0.0,75,35,0.0,,9.9,9.9,37.2,0.8,37,39.0,3.1,0.56,,22.1,7.7,"46,XX,t(9;11)(p22;q23)[20]/46,XX[1]",,89.8,MLL disruption and t(9;11),39.0,"dim/partial CD13, CD33, CD38, CD56, CD58, CD64, partialCD117, CD123 and HLA-DR positive",6.0,43.72,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,MAF 70%,,,,,,,negative,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.08428062890947167,Low
14-00021,1408,Male,Male,White,4,n,74.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,4,"Hydroxyurea|Decitabine|Temozolomide, Vorinostat|Azacitidine, MLN4924",4,Salvage|Induction|Re-induction|Symptom Control,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,Decitabine,Salvage,-1.0,Dead,357.0,Dead-Disease,True,False,14-00022,-49,,,,,,,,,,,,,,,,,"46,XY",,,,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.886296695415091,High
14-00023,1409,Female,Female,White,1,n,74.0,False,True,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,74.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,6.0,Alive,28.0,Alive,False,False,,0,0.9,,,0.0,,11.4,44.7,35.1,7.1,17,28.0,2.6,0.79,,28.1,9.4,,645.0,98.3,,71.0,,6.2,35.91,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.E76Q; MAF 40%,,,,,,,,,,,,,,,,,,,-0.9001671595905585,Low
14-00026,1410,Male,Male,HispNative,2,n,38.0,False,False,True,Unknown,False,False,n,,y,n,y,y,n,n,n,n,EVI1_F,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Intermediate,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,39.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Supportive/Palliative Care,4,"7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Salvage|Unknown|Induction|Maintenance,Refractory,Standard Chemotherapy,5.0,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Unknown,6.0,Unknown,,,False,False,,0,,,16,,,20.0,10.0,54.0,,152,49.0,4.3,0.77,,30.5,10.6,,340.0,,,215.0,,7.0,4.01,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.4408758487453004,High
14-00034,1431,Male,Male,White,1,y,55.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,55.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Busulfan, Cyclophosphamide",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1.0,Alive,906.0,Alive,False,False,,0,0.0,50,25,0.0,,45.3,19.6,9.3,6.0,27,20.0,3.7,1.01,,30.6,10.1,"46,XY[20]",,98.4,Normal,15.0,"CD7, CD13, CD33, CD34, CD38, CD64, CD123, HLA-DR, and MPO",6.3,3.85,False,False,,negative,negative,,,,,,,,,,,,,,c.242?243insCTTGGTT (7bp out-of-frame insertion); MAF 50%,,,,,,,,,,,,negative,,,negative,negative,,,negative,,,negative,,,,,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,negative,,-1.1542253538382619,Low
14-00041,1434,Female,Female,White,4,n,71.0,False,True,False,GATA2-MECOM,False,False,n,,y,n,n,n,n,n,n,n,EVI1_F,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,71.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,AG-221,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,AG-221,Hypomethylating/Low Dose Cytarabine,-1.0,Alive,952.0,Alive,True,False,14-00042,0,,22,8,,,,10.0,,,,,,,M4,,,"46,XX,inv(3)?(q21q25)[21]",,,,,"CD34, CD117, CD38, CD56 (minor subset), partial CD13, partial CD33, CD11c, and HLA-DR",,2.6,True,False,14-00042,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,positive,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.8657386331215075,High
14-00044,1153,Female,Female,White,4,n,35.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,37.0,160,Residual Relapse|Post-Chemotherapy|Post-Transplant,Peripheral Blood,y,n,y,y,n,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI",5,Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Re-induction,53.0,Dead,761.0,Dead-Treatment,True,True,13-00331,-159,,,,,,,,,,,,,,,,,"46,XX[5]",,,,,,,,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5191706409780995,High
14-00045,1435,Female,Female,HispNative,2,n,47.0,True,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,48.0,0,Post-Chemotherapy|Post-Transplant|Relapse,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide",4,Allogeneic - Sibling|Consolidation|Salvage|Induction,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,-1.0,Dead,582.0,Dead-Unknown,False,False,,0,0.0,62,66,0.0,,7.0,0.0,13.0,,24,40.0,3.4,,,35.5,12.1,"46,XX",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",29.0,"CD2(-), CD4(partial +), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(variably +), CD56(partial +), CD64(-), CD117(partial +), HLA-DR(partial dim +)",5.8,58.5,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.8150149108205287,High
14-00053,1438,Male,Male,White,4,n,71.0,False,True,False,GATA2-MECOM,False,False,n,,y,n,n,n,n,n,n,n,EVI1_F,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,71.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,n,y,n,n,1,Standard Chemotherapy,3,"CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,23.0,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,4.0,Dead,262.0,Dead-Unknown,True,True,14-00052,-14,,,,,,,,,,,,,,,,,"45,XY,inv(3)(q21q26),-7[20]",,,,,,,,True,True,14-00052,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,1.2774376630464435,High
14-00060,1441,Male,Male,White,1,n,68.0,False,False,False,None,True,False,n,,y,n,y,n,n,n,n,n,,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",Adverse,,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",68.0,0,Unknown,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,Azacitidine,1,Induction,Unknown,Standard Chemotherapy,6.0,Standard Chemotherapy,Azacitidine,Induction,6.0,Dead,299.0,Dead-Unknown,False,False,,-13,0.0,,15,1.7,,38.7,3.4,30.3,0.0,27,23.0,3.0,1.18,,21.0,7.0,"45~48,XY,del(5)(q22q35),+8,del(13)(q12q14),- 20,der(21)t(20;21)(p11.2;p11.1),+der(22)t(?;22)(?;q11.2)[cp15]/46,XY[4]",1138.0,88.6,,26.0,"CD13, CD33, CD34, CD38, CD58, CD117, CD123 and HLA-DR positive",5.7,2.42,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.1913453554463325,High
14-00061,202,Male,Male,White,1,n,68.0,True,False,False,None,False,False,y,Lung Cancer|Lung Cancer|Lung Cancer|Lung Cancer|Lung Cancer|Lung Cancer,y,y,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,72.0,1207,Relapse,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|MiDAC|Decitabine",3,Consolidation|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,7.0,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,9.0,Dead,1238.0,Dead-Disease,False,False,,-2,0.0,,,0.0,,14.9,0.8,2.5,0.0,,,,,,22.7,7.6,"47,XY,del(9)(q22),+13[18]/48,idem,+mar[2]",556.0,93.8,Missing ABL and ASS signal,32.0,,,47.2,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,p.R162S; MAF 50%,,,,,p.P95R; MAF 44%,,,,,,negative,,,negative,,-0.4388786691736172,Low
14-00063,1443,Female,Female,White,3,n,80.0,False,True,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,80.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Unknown,1,Bevacizumab,1,Unknown,,,,Unknown,Bevacizumab,Unknown,-1.0,Dead,10.0,Dead-Disease,False,False,,-4,,,,,,,,,,,,,,,,,"44-47,XX,del(5)(q13q33),der(14;18)(q10;q10),-20,-21,+1-4mar[cp15]",,,,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.040151842132566,High
14-00064,1444,Male,Male,White,2,n,58.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,59.0,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Other,8,"E7070, Idarubicin, Cytarabine|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|BL-8040|IGN523",4,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,-1.0,Dead,357.0,Dead-Disease,False,False,,0,1.0,10,6,0.0,,32.7,12.6,53.7,,45,19.0,3.7,0.69,,26.8,9.4,"46,XY[20]",88.0,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x1[47/200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",75.0,"CD2 (-), CD4(+), CD7(+), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(bright +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).",5.8,1.6,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.32371590907431397,High
14-00078,1450,Male,Male,White,1,n,17.0,False,True,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",17.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,3,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Clofarabine, Cyclophosphamide, Etoposide|HAM (Cytarabine, Mitoxantrone)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,74.0,Standard Chemotherapy,"Clofarabine, Cyclophosphamide, Etoposide",Re-induction,5.0,Dead,713.0,Dead-Disease,False,False,,0,0.0,,,0.0,,48.5,0.6,1.2,1.6,18,11.0,3.5,0.7,,25.6,9.1,,,87.4,Normal,25.0,,6.9,4.34,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,,,,negative,,,negative,PTD,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,MAF A382fs*6; 40%,,-0.13267923385560215,Low
14-00081,1453,Female,Female,White,1,n,71.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,"Azacitidine, Lenalidomide",Re-induction,28.0,Unknown,,,False,False,,0,0.0,46,49.1,0.0,,20.5,8.0,17.0,0.9,32,39.0,3.3,0.73,M2,20.7,6.4,"42~45,XX,add(5)(q13),der(17)add(17)(p11.2)add(17)(q11.2),-18,-22[cp6]/43~44,sl,add(13)(q32),add(14)(q11.2),+mar[cp12]/43~44,sl,add(14)(q11.2),-21,",685.0,79.0,5q deletion,11.0,"partial CD7, CD13, partial CD33, CD34, partial CD38, CD58, CD117, dim/partial CD123, partial TdT, HLA-DR positive.",6.6,12.87,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,V186D,,,V173M; MAF 80%,,,negative,,0.7611519111089907,High
14-00083,1989,Male,Male,White,4,n,46.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,46.0,0,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,5,"HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine",4,Consolidation|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Salvage,-1.0,Unknown,,,False,False,,-2,,,,,,,,,,,,,,,,,"46,XY[20]",,,,,,,,False,False,,negative,positive,,,,,,,negative,,,,,,,negative,,,,,,,positive,,,,,negative,,,positive,negative,,,,,,negative,,,negative,,,,,,,positive,,,,,,,,,,,,,,,,,,,,negative,,,,,0.19336940372096784,High
14-00092,1461,Female,Female,White,1,n,63.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,63.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1.0,Alive,566.0,Alive,False,False,,0,1.7,13,14,0.8,,9.4,28.2,49.6,1.6,18,26.0,2.8,0.74,M4,21.2,7.3,"46,XX[20]",514.0,101.4,Normal,57.0,"CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive",6.1,63.75,False,False,,negative,positive,,,,,,,,,,,,,,negative,,,p.V319I; MAF 50%,,,,p.T138I; MAF 50%,,,,,,,,negative,negative,,,,,,,,,negative,,,,,,,p.Q61H; MAF 40%,,,,,,,,,,,,,,,,,,,,negative,,,,,-1.300531938966048,Low
14-00096,1464,Male,Male,White,4,n,56.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,56.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Induction|Re-induction,Complete Response,Standard Chemotherapy,27.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1.0,Dead,198.0,Dead-Unknown,True,False,14-00098,0,,72,88,,,,1.0,,,,,,,,,,"40~43,XY,add(1)(p36),-2,-4,-5,-8,-12,-14,-15,-16,-17,?add(17)(p13),der(19)?t(8;19)(q11.2;p13),-20,-22,+7mar[cp18]",,,,,"CD34, CD38 (dim), CD13, CD33 (dim),CD64 (partial), CD11c, CD4 (partial), CD15, CD117, HLA-DR, and MPO(partial).",,12.9,True,False,14-00098,positive,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,1.3292066390781414,High
14-00113,1466,Male,Male,White,3,n,41.0,False,False,False,PML-RARA,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,44.0,0,Post-Chemotherapy|Post-Transplant,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,7,"Busulfan, Fludarabine|Etoposide, TBI|PETHEMA Trial LPA05 (ATRA (Tretinoin), Idarubicin, Mitoxantrone, Cytarabine)|Idarubicin, Mitoxantrone|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate",5,Allogeneic - Sibling|Consolidation|Induction|Maintenance|Re-induction,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Etoposide, TBI",Allogeneic - Sibling,-1.0,Alive,1968.0,Alive,True,False,14-00112,-3,,,,,,,,,,,,,,,,,"46,XY[20]",,,48% PML/RARA translocation,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.4512585838187447,Low
14-00125,1477,Female,Female,White,1,n,10.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,10.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,1,Standard Chemotherapy,1,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",3,Induction|Intensification|Re-induction,Complete Response,Standard Chemotherapy,10.0,Standard Chemotherapy,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",Intensification,29.0,Alive,142.0,Alive,False,False,,-2,0.8,,,0.0,,10.5,21.0,7.3,0.5,,,2.1,0.41,,24.7,8.3,"46,XX,inv(16)(p13q22)[17]/46,XX[3]",702.0,88.5,CBFB rearrangement and inverted 16,31.0,,,55.35,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.774351253579787,Low
14-00126,1451,Male,Male,White,3,n,46.0,False,True,False,Unknown,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",Intermediate,Not Enough Information,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",46.0,14,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Alive,0.0,Alive,False,False,,0,,,,,,,,,,,,,,,,,,,,,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.2816652917838804,Low
14-00127,1481,Male,Male,White,1,n,37.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,38.0,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,2,"7+3 (Cytarabine, Idarubicin)|Azacitidine",2,Induction|Maintenance,Refractory,Standard Chemotherapy,6.0,Supportive/Palliative Care,Azacitidine,Maintenance,-1.0,Dead,207.0,Dead-Disease,False,False,,-1,0.0,,95,0.0,,0.9,0.0,0.0,0.1,17,56.0,1.8,0.6,,23.0,7.9,"48~54,XY,add(2)(p13),+5,add(5)(q13),del(5)(q13),+10,+11,+13,+13,del(13)(q32),+14,-15,-16,del(17)(p12),-20,+21,+21,+22,+mar[cp9]/49~52,sl,-del(17)(p12)[cp8]/51~54,sl",,86.8,Extra chromosome 5,20.0,"CD10, CD13, CD33, CD34, CD56 and HLA-DR positive",5.3,38.47,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,"p.G13D, MAF 46%",,,,,,,,,negative,,,,,,,,,,,"p.R273H, MAF 96%",,,negative,,1.4623700362352792,High
14-00135,1485,Male,Male,White,1,n,72.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,Azacitidine|Decitabine,3,Consolidation|Induction|Maintenance,Unknown,Standard Chemotherapy,38.0,Standard Chemotherapy,Azacitidine,Maintenance,36.0,Dead,252.0,Dead-Disease,False,False,,0,0.0,55,46,0.0,,27.8,27.0,20.6,0.0,32,31.0,2.2,1.37,M4,20.6,6.6,"43~44,X,-Y,t(3;11)(p21.3;p11.2),del(5)(q11.1;q31.1),add(12)(p11.2),-21[cp17]/44~45,idem,-t(3;11),+9[cp4]",435.0,85.8,Previous FISH results were consistent with the deleted 5q and trisomy 9,33.0,"CD13, CD33, CD34, partial CD56,variable CD117, dim CD123, and dim HLA-DR+",5.9,20.82,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,p.H193R; MAF 92%,,,negative,,0.9215636810556973,High
14-00141,1488,Male,Male,Asian,4,n,85.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,85.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Decitabine, Midostaurin",1,Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"Decitabine, Midostaurin",Induction,-1.0,Dead,357.0,Dead-Disease,True,False,14-00142,-15,,,,,,,,,,,,,,,,,"46,XY[14]",,,,,,,,True,False,14-00142,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.8182561733199539,High
14-00152,1495,Male,Male,White,3,n,75.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,75.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,5,"7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,21.0,Standard Chemotherapy,"CLAG (Cladribine, Cytarabine, Filgrastim)",Consolidation,-1.0,Dead,335.0,Dead-Disease,False,False,,-1,,64,7,,,,,,,,,,,M4,,,"46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2]",,,Normal,,"Large population of atypical myelomonocytic cells (CD4+, bright CD64+, MPO positive, partial CD14), representing 85% of the total leukocytes",,4.67,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.785005713666349,Low
14-00175,1508,Male,Male,White,3,n,46.0,False,True,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,46.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,3,DLI|Standard Chemotherapy|Bone Marrow Transplant,8,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Clofarabine|ODSH (2 O, 3-O Desulfated Heparin) ",6,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Post-Transplant Relapse,Complete Response,Standard Chemotherapy,-1.0,DLI,Donor Lymphocyte Infusion,Post-Transplant Relapse,-1.0,Dead,1005.0,Dead-Disease,True,False,14-00176,0,,25.9,0.5,,,,,,,,,,,M5,,,,,,Normal,,"Increased atypical CD56 positive, weak CD117 positive myelomonocytic cells representing approximately 23% of the leukocytes",,3.6,True,False,14-00176,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.10500329232181138,High
14-00184,1513,Male,Male,White,1,n,5.0,False,False,False,None,False,False,y,Not specified,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,5.0,0,Initial Acute Leukemia Diagnosis|Post-Transplant,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"ADE (Cytarabine, Daunorubicin & Etoposide)|Cyclophosphamide, TBI|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Allogeneic - Sibling|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,9.0,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Sibling,-1.0,Alive,690.0,Alive,False,False,,0,0.0,,80,0.0,,33.0,0.0,0.0,0.0,12,32.0,3.0,0.44,M5,17.1,5.7,"46,XY[25]",1072.0,98.8,MLL rearrangement,34.0,"CD4, CD11b, CD15, CD33, bright CD34, CD38, CD58, CD64,CD71, CD117, CD123, HLA-DR and dim/partial MPO positive",7.4,95.2,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.15706259813845866,High
14-00193,1519,Male,Male,White,2,n,56.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,57.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,3.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,3.0,Dead,421.0,Dead-Disease,False,False,,0,0.0,,54,0.0,,38.0,8.0,0.0,,15,23.0,3.0,1.3,,,,"46,XY,del(5)(q15q35),inv(16)(p13.1q22)[20]",409.0,,"nuc ish(D5S721x2,D5S23x2,EGR1x1)[182/200],(D7Z1,D7S522)x2[199], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[192],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB sep 3'CBFBx1)[176/200]",,,6.6,8.2,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Q61H; MAF 5%,,,,,,,,,,,,,,,,,,,,,,,,,-0.49595215240131424,Low
14-00228,1532,Female,Female,White,1,n,46.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,46.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,7.0,Standard Chemotherapy,Azacitidine,Consolidation,339.0,Alive,788.0,Alive,False,False,,0,0.0,80,45,1.6,,9.9,14.9,10.7,0.0,52,28.0,2.5,0.77,M4,25.2,8.4,"46,XX[20]",550.0,88.1,Normal,107.0,"dim CD11b, CD13, CD33, partial CD34, dim CD45, dim CD64, CD117, CD123, and dim HLA-DR+",6.3,57.23,False,False,,negative,positive,,,,,,,,,,,,,,negative,,,,,,,p.R882C; MAF 46%,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,p.E76Q; MAF 40%,,,negative,,,,,,,,,,,negative,,,negative,,0.3045026956639786,High
14-00231,1533,Female,Female,White,2,n,57.0,False,False,False,Complex,False,False,y,Ovarian cancer|Ovarian cancer,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,57.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea",4,Consolidation|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,5.0,Supportive/Palliative Care,"Decitabine, Hydroxyurea",Supportive/Palliative Care,-1.0,Dead,138.0,Dead-Unknown,False,False,,0,0.0,76,79,0.0,,9.0,5.0,4.0,,45,41.0,3.2,,,28.6,9.6,"46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",64.0,"CD2(-), CD4(+), CD5(equivocal), CD7(-), CD11b(+), CD13(-), CD14(partial +), CD15(+), CD16(-), CD33 (bright +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56(+), CD64(+), CD117(partial +), HLA-DR(+)",6.3,19.5,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,MYST3-CREBBP fusion; MAF unlisted,,,,,,,,,negative,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,Y414*; MAF 16%,,,,,,,,,,,,,,,,-1.3559296869689859,Low
14-00259,1546,Female,Female,White,1,n,65.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Fludarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC",4,Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,Fludarabine,Consolidation,4.0,Dead,439.0,Dead-Disease,False,False,,0,0.1,70,,0.1,1.7,8.3,85.2,4.6,0.2,16,13.0,2.7,0.87,M4,30.4,9.6,"46,XX[20]",506.0,101.7,Normal,112.0,"CD11b, partial CD13, partial CD14, dim CD15, partial      CD16, CD33, CD38, CD58, CD64, partial CD123 and HLA-DR positive",7.4,58.86,False,False,,positive,positive,,,,,,,,,,,,,,negative,,,,,,,p.R882H; MAF 50%,,,,,negative;MAF 12%,,,negative,,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,p.F71L; MAF 14%,,,negative,,,,,,,,,,,negative,,,negative,,-0.3169961945250829,Low
14-00279,1558,Female,Female,HispNative,4,n,52.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,52.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,SWOG S1203 (7+3 +/- Vorinostat),1,Induction,Complete Response,Standard Chemotherapy,8.0,Standard Chemotherapy,SWOG S1203 (7+3 +/- Vorinostat),Induction,8.0,Alive,36.0,Alive,False,False,,0,,91,79,,,,0.0,,,,,,,,,,"46,XX,inv(16)(p13.1q22)[cp20]",,,,,"CD34, PARTIAL CD117, CD15, CD38, PARTIAL CD13, CD33, CD64, PARTIAL CD14(SUBSET), PARTIAL CD11c, DIM CD4, HLA-DR AND BRIGHT MPO",,28.1,False,False,,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.8519102437815105,Low
14-00289,1561,Male,Male,White,1,n,23.0,False,False,False,None,False,False,y,mediastinum mass,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,23.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,"Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin) ",3,Consolidation|Induction|Experimental,Complete Response,Standard Chemotherapy,8.0,Targeted Therapy - Kinase Inhibitor(s),Trametinib,Experimental,197.0,Dead,318.0,Dead-Disease,True,False,14-00288,0,3.2,3,20.4,2.1,,25.8,1.1,36.6,43.4,32,131.0,3.0,0.91,,17.9,5.7,"48,XY,add(6)(p22),der(7)t(7;19)(p11.1;p12),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp20]",16499.0,95.2,Low-level tetraploidy or near-tetraploidy,24.0,,5.6,40.76,False,False,,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,p.G12C; MAF 86%,,,,,,,,,,,,,,,,,,,,p.G245S; MAF 87%,,,,,2.017722071909306,High
14-00331,1586,Male,Male,HispNative,2,n,61.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,Standard Chemotherapy,HiDAC,Consolidation,5.0,Unknown,,,True,False,14-00330,0,1.0,81,68,,,5.0,2.0,2.0,,85,52.0,3.1,0.85,,28.8,10.1,"46,XY[20]",1205.0,,"nuc ish(D4Z1,D10Z1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200]",20.0,"CD2(-),CD4(partial dim +), CD7(-), CD11b(few +), CD13(+), CD14(-), CD15(partialCD22(-), CD25(appears partial dim +), CD33(bright +), CD34(few +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(partial +), CD79a(-), CD117(+), CD123(partial +), HLA-DR(partial +), MPO(+), TdT(-).",6.2,152.75,True,False,14-00330,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.6298078031846261,Low
14-00355,1602,Male,Male,White,4,n,78.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,78.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,"Azacitidine|Sorafenib|Decitabine, Midostaurin",3,Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,317.0,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,8.0,Dead,705.0,Dead-Disease,True,False,14-00356,-14,,,,,,,,,,,,,,,,,"46,XY[25]",,,,,,,,True,False,14-00356,positive,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.5446407888717073,High
14-00359,1604,Male,Male,White,3,n,58.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,58.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin) ",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,Standard Chemotherapy,HiDAC,Consolidation,210.0,Alive,761.0,Alive,True,False,14-00360,-2,,,,,,,,,,,,,,,,,"48,XY,+8,inv(16)(p13.1q22),+22[18]/49,sl,+21[2]",,,8q22 (RUNX1T1): gain present  16q22 (CBFB): rearrangement present  21q22 (RUNX1): gain or rearrangement present,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.7314109561284764,Low
14-00376,1614,Male,Male,White,1,n,48.0,False,False,False,None,True,False,n,,y,n,y,n,n,n,n,n,,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,Intermediate,,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,48.0,0,Unknown,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Decitabine|Busulfan, Cyclophosphamide",2,Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,116.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1.0,Alive,714.0,Alive,False,False,,0,0.0,17,5.3,0.0,,67.3,22.1,5.3,0.0,36,20.0,3.5,0.82,,32.5,10.2,"47,XY,+8[18]/46,XY[2]",155.0,83.5,Trisomy 8,105.0,"CD13, CD33, CD34, CD38, CD58, CD117, CD123, MPO+",7.9,0.94,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,p.R882C; MAF 45%,,,,,negative,,,p.R132C; MAF 44%,negative,,,negative,,,negative,,,negative,,negative,,,,,,,,,,,,,,negative,,,,,,,,,,p.P455R; MAF 45%,negative,,,negative,,-0.275290274673995,Low
14-00380,1616,Male,Male,White,3,n,67.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,67.0,0,Post-Chemotherapy|Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,3,Azacitidine|Decitabine|Clofarabine,2,Hypomethylating/Low Dose Cytarabine|Induction,UNKNOWN,Standard Chemotherapy,-1.0,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,30.0,Dead-Treatment,False,False,,-10,,,,,,,,,,,,,,,,,"42,X,add(Y)(p11.1),add(3)(q12),add(4)(q25),del(5)(q12q33),-7,add(8)(p11.2),-11,add(13)(p11.2),del(16)(q22),-17,add(19)(q12.3),-20,add(21)(p11.2),-22,+mar[20]",,,"43% del 5q31, 56% del 7q31, 58% del20q",,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.2730070567795308,High
14-00423,1644,Female,Female,White,4,n,51.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,51.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Stanford Protocol 9022 (BU/CY)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,7.0,Bone Marrow Transplant,Stanford Protocol 9022 (BU/CY),Allogeneic - Matched Unrelated Donor,-1.0,Alive,795.0,Alive,True,False,14-00422,0,,74,61,,,,1.0,,,,,,,M4eo,,,"46,XX,inv(16)(p13q22)[20]",,,,,"CD34+ EXPRESSING CD38, CD13, CD33, PARTIAL DIM CD2, PARTIAL CD64; DIM PARTIAL CD11C, PARTIAL DIM CD4, COEXPRESSION OF CD117 AND CD15, HLA-DR, MPO, AND PARTIAL DIM TDT",,34.4,True,False,14-00422,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.6388494112039106,Low
14-00425,1646,Female,Female,White,1,n,47.0,False,True,False,PML-RARA,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,47.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,"ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,26.0,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Consolidation,31.0,Alive,461.0,Alive,False,False,,0,0.0,,,0.0,,14.8,13.1,13.9,0.9,19,37.0,3.3,0.6,M3,19.5,6.5,"46,XX,t(15;17)(q24;q21)[4]/45,idem,-22[15]/46,XX[1]",819.0,70.8,,9.0,,7.1,25.11,False,False,,positive,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,0.7024468986055897,High
14-00434,1648,Female,Female,White,4,n,69.0,False,True,False,MLLT3-KMT2A,False,False,n,,y,n,n,n,n,n,n,n,MLL-MLLT3,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,69.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Hydroxyurea,1,Induction,Unknown,Standard Chemotherapy,365.0,Standard Chemotherapy,Hydroxyurea,Induction,365.0,Alive,0.0,Alive,False,False,,0,,94,83,,,,0.0,,,,,,,M5a,,,"46,XX[1]",,,,,"CD38, CD56, slightly dim CD4, CD33, dim CD13, CD64, CD11c, CD15 and partial CD117",,137.6,False,False,,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.778557770847528,Low
14-00447,1655,Female,Female,HispNative,1,n,48.0,False,True,False,MLLT3-KMT2A,False,False,n,,y,n,n,n,n,n,n,n,MLL-MLLT3,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,48.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Fludarabine, Melphalan|Idarubicin and Cytarabine",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1.0,Alive,458.0,Alive,False,False,,0,0.0,,,0.0,,9.5,0.0,6.0,0.0,51,152.0,3.1,0.85,M5,30.4,9.7,"47,XX,+8,t(9;11)(p22;q23)[20]",4484.0,80.4,MLL rearrangement,87.0,,6.0,49.29,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,MAF 10%,,,negative,negative,,p.I878V; MAF 50%,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-0.8615972538603383,Low
14-00448,1656,Female,Female,White,4,n,78.0,False,False,False,None,False,False,y,Uterine Sarcoma,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,78.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Azacitidine, MLN4924",1,Induction,Refractory,Standard Chemotherapy,111.0,Standard Chemotherapy,"Azacitidine, MLN4924",Induction,111.0,Dead,161.0,Dead-Disease,True,True,14-00449,0,,78,77,,,,1.0,,,,,,,,,,"46,XX[20]",,,,,"CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR",,5.6,True,True,14-00449,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,,,,,,negative,,,positive,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.6320255410762785,High
14-00454,1665,Male,Male,White,4,n,65.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",66.0,0,Post-Chemotherapy|Residual Relapse,Peripheral Blood,y,y,n,y,y,n,3,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,8,"HiDAC|AG-221|Gilteritinib (ASP2215)|3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|MEC, Lenalidomide|Clofarabine, Cytarabine",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,-1.0,Targeted Therapy - Other,AG-221,Experimental,-1.0,Dead,395.0,Dead-Disease,True,False,14-00455,0,,96,85,,,,5.0,,,,,,,,,,"46,XY,t(4;15)(q31;q22),add(12)(p11~12)[cp7]/46~51,XY,del(7)(q11.2q36),add(12)(p11~12),add(20)(q11.2)[cp5]/46,XY,?inv(8)(p21q22)[cp7]/46,XY[cp2]",,,,,"CD38, CD33; WITH PARTIAL CD34, CD56, CD13, CD11C, CD2 AND CD15/CD117",,0.1,True,False,14-00455,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,,,,,,negative,,,negative,positive,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.25305149274590993,Low
14-00458,1662,Male,Male,White,1,n,51.0,False,False,False,None,True,False,n,,y,n,y,n,n,n,n,n,,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,Intermediate,,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,51.0,0,Unknown,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Fludarabine, Melphalan|Azacitidine, Lenalidomide",2,Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,117.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1.0,Dead,286.0,Dead-Treatment,False,False,,0,0.0,4,6,0.0,,38.9,1.1,56.7,,58,51.0,3.5,0.87,,22.4,7.5,"47,XY,+8[2]/46,XY[18]",438.0,93.7,Trisomy 8,20.0,CD34/CD117 positive myeloid blasts comprise about 4% of total CD45+ cells with possible partial TdT expression,5.9,2.23,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,p.A382fs*4; MAF 44%,,-0.3015740269758723,Low
14-00464,1664,Female,Female,White,4,n,22.0,False,True,False,MLLT3-KMT2A,False,False,n,,y,n,n,n,n,n,n,n,MLL-MLLT3,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,22.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,4,"ATRA (Tretinoin)|Cyclophosphamide, TBI|3+7 (Cytarabine, Daunorubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)",4,Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,7.0,Bone Marrow Transplant,"Cyclophosphamide, TBI",Allogeneic - Matched Unrelated Donor,-1.0,Alive,453.0,Alive,False,False,,0,,65,90,,,,0.1,,,,,,,M1,,,"46,XX,t(9;11)(p22;q23)[22]",,,,,"CD34, CD38 (dim partial), CD13, CD33 (dim partial), CD11c, CD4 (dim partial), HLA-DR, CD117 and MPO",,40.2,False,False,,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,,,,,,D835,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.9288393197608038,High
14-00473,1666,Female,Female,White,1,n,62.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Salvage|Induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,"HAM (Cytarabine, Mitoxantrone)",Salvage,7.0,Dead,167.0,Dead-Other,True,False,14-00468,0,6.1,22,17.4,5.2,16.5,31.3,1.7,21.8,0.2,13,11.0,3.2,0.78,,29.5,9.5,"59~62,XX,+X,+1,+2,del(5)(q13q34),+6,+8,+8,+9,+11,+11,i(11)(q10),+12,+14,+16,+19,+22,+mar[cp19]/46,XX[1]",444.0,101.4,Trisomy 9,34.0,"CD13, CD34, CD58 and CD117",7.0,10.75,True,False,14-00468,negative,negative,negative,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,p.N160S; MAF:40%,,negative,negative,,,negative,,,negative,negative,,negative,,negative,,,,,p.G12D; MAF:11%,,,,,,,,,negative,,,,,,,,,,,p.R280T;  MAF 36%,,,negative,,1.3599674347183726,High
14-00476,1670,Male,Male,HispNative,4,n,47.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,MLL-ELL,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,47.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,3,Standard Chemotherapy|Supportive/Palliative Care|Intrathecal,5,"HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide",5,Consolidation|Induction|CNS|Re-induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,7.0,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,9.0,Dead,228.0,Dead-Disease,False,False,,0,,70,79,,,,2.0,,,,,,,M5,,,"46,XY,t(11;19)(q23;p13.1)[20]",,,,,"CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19",,261.2,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.9607229406630775,Low
14-00488,1675,Female,Female,White,3,n,44.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",44.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction,Unknown,Standard Chemotherapy,-1.0,Targeted Therapy - Kinase Inhibitor(s),Ponatinib,Experimental,-1.0,Dead,342.0,Dead-Unknown,True,True,14-00487,-1,,86.1,65,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,"Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia",,11.38,True,True,14-00487,positive,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.118124078919649,High
14-00495,1246,Male,Male,White,2,n,62.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,64.0,254,Post-Chemotherapy|Post-Transplant|Residual Disease,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide",5,Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,24.0,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,141.0,Dead,568.0,Dead-Unknown,False,False,,-28,,,,,,,,,,23,26.0,2.9,,,27.9,9.6,"45,XY,der(12;16)(q10;p10)[2]/46,XY[18]",,,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200]",30.0,,5.0,27.4,False,False,,positive,positive,,,,,,,,,,,,P203S; MAF unlisted,,,T367fs*15; MAF unlisted,,,,,,R882H; MAF unlisted,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.9991363268375592,High
14-00496,1683,Male,Male,White,3,n,55.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,55.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin) ",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,HiDAC,Consolidation,129.0,Unknown,,,True,False,14-00497,-1,,37,20,,,,,,,,,,,,,,"46,XY[20]",,,Normal,283.0,"Increased atypical CD117 positive myeloid blasts (weak CD7  positive, HLA-DR negative), representing 18% of the total  leukocytes, consistent with a myeloid neoplasm",,16.11,True,False,14-00497,negative,positive,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.1815040291649348,High
14-00504,1693,Male,Male,White,2,n,35.0,False,True,False,MLLT3-KMT2A,False,False,n,,y,n,n,n,n,n,n,n,MLL-MLLT3,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,35.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide, Thymoglobulin",Allogeneic - Matched Unrelated Donor,-1.0,Alive,1226.0,Alive,False,False,,-2,,,,,,,,,,,,,,,,,"46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1]",,,"nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]",,,,,False,False,,positive,positive,,D943fs*6; MAF 25%,,,,,,,,,,,,negative,,,,,,,,,,,,D835,,,negative,negative,,,,,,,MLL-AF9 fusion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.9098984804663752,Low
14-00514,1696,Male,Male,White,2,n,71.0,False,False,True,Unknown,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71.0,0,Post-Chemotherapy|Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,107.0,Dead,53.0,Dead-Disease,False,False,,0,0.0,,50,1.0,,17.0,1.0,13.0,,19,42.0,3.2,1.83,,23.7,7.7,,766.0,92.2,,11.0,,7.1,45.6,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.1894228217187266,High
14-00528,1533,Female,Female,White,2,n,57.0,True,False,False,Complex,False,False,y,Ovarian cancer|Ovarian cancer,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,58.0,111,Post-Chemotherapy|Relapse,Peripheral Blood,y,n,y,y,n,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea",4,Consolidation|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,5.0,Supportive/Palliative Care,"Decitabine, Hydroxyurea",Supportive/Palliative Care,-1.0,Dead,138.0,Dead-Unknown,True,True,14-00231,-111,0.0,,58,0.0,,14.0,3.0,19.0,,24,116.0,3.7,,,21.4,7.7,"46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",10.0,"CD2(-), CD4(+), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +),CD15(variably +), CD16(-), CD33(variably +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56 (variable +), CD64(partial +), CD117(-), HLA-DR(+).",6.0,11.2,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.5533856979814673,Low
14-00542,1710,Female,Female,HispNative,4,n,27.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,27.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,2,HiDAC|SWOG S1203 (7+3 +/- Vorinostat),2,Consolidation|Induction,Complete Response,Standard Chemotherapy,8.0,Standard Chemotherapy,HiDAC,Consolidation,137.0,Alive,250.0,Alive,True,True,14-00543,0,,69,68,,,,1.0,,,,,,,M2,,,"48,XX,+3,+10[2]/46,XX[18]",,,,,"CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7",,5.1,True,True,14-00543,negative,positive,,,,,,,negative,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.2986339932128295,High
14-00546,1711,Female,Female,White,1,n,69.0,False,True,False,PML-RARA,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,69.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,1,"APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)",Induction,-1.0,Unknown,,,False,False,,0,0.0,83,77,0.0,0.0,16.1,5.3,4.5,1.2,31,51.0,3.2,1.05,M3,22.7,8.1,"45,XX,dic(12;18)(p11.2;p11.2),t(15;17)(q22;q21)[19]/46,XX[1]",1816.0,92.3,PML/RARA fusion,33.0,"dim CD2, CD13, CD33, CD34 (variable), CD56, CD58, CD64, CD117, CD123 and cytoplasmic MPO positive; HLA-DR negative",5.7,16.03,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.24576595943398463,Low
14-00559,1721,Male,Male,White,2,n,68.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Consolidation|Induction|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,Azacitidine,Maintenance,-1.0,Alive,976.0,Alive,False,False,,0,0.0,79,54,,,10.0,42.0,30.0,,8,26.0,4.0,,,20.8,6.8,"46,XY",,,IGH-MYEOV and IGH-CCND1 rearrangement; MAF unlisted,61.0,"CD2(-), CD4(equivocal), CD7(partial +), CD11b (equivocal), CD13(+), CD14(-), CD15(-), CD16(equivocal), CD33(-), CD34(bright +), CD36(-), CD38(dim +), CD45(+), CD56(equivocal), CD64(-), CD117(+), CD123(equivocal), HLA-DR(dim +), MPO(partial +), TdT(-)",7.1,41.4,False,False,,negative,positive,,,,,,,,,,,,,,negative,,,,,,,R882C; MAF 50%,,,,,negative,,,negative,negative,,,,,,,,,,,,,,,,G13D; MAF 44%,,,,,,,,,,,,,,,,,,,,,,,,,-1.2427546721739564,Low
14-00564,1719,Male,Male,White,1,n,57.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,57.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,Decitabine,1,Induction,Unknown,Standard Chemotherapy,10.0,Standard Chemotherapy,Decitabine,Induction,10.0,Dead,35.0,Dead-Unknown,False,False,,0,0.0,45,,0.9,27.8,18.2,12.2,40.9,0.0,32,19.0,2.0,0.83,,26.9,9.1,"44~48,XY,-5,del(7)(q22),+11,idic(11)(p11.2)x2,-12,der(13)t(1;13)(p13;p12),add(17)(q25),der(18)t(12;18)(q13;q11.2),-22,+2mar[cp14]/44~47,sl,-9,+16[cp3]/46~47,sl,der(1)t(1;3)(q21;q21),der(3)t(1;3)(q21;q21)ins(3)(3;?)(p21;?),-idic(11)(p11.2)[cp4]/46,XY[1]",,97.1,"EGR1/5p; 88% of cells were missing a signal for both probes, consistent with monosomy 5 ",77.0,"CD13, CD33, CD34, CD71, CD117, dim CD123 and HLA-DR+",6.7,5.92,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,negative,,,negative,p.R248Q; MAF 80%,,,negative,,0.24029728757394217,High
14-00567,1723,Female,Female,White,1,n,71.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,71.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Mismatched Unrelated Donor,-1.0,Dead,462.0,Dead-Treatment,False,False,,-3,0.0,,,0.0,0.0,6.7,5.1,0.0,0.1,20,20.0,2.6,0.62,M5,21.4,7.0,"46,XX,idic(7)(q11.2)[20]",373.0,93.9,,19.0,"CD11b, CD13, CD33, partial CD34,      CD38, CD58, CD64, CD117, CD123, partial HLA-DR and cMPO positive",5.8,78.71,False,False,,negative,negative,,,,,p.T870fs*46 (2 bp deletion); MAF 50%,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,p.R132C; MAF 50%,negative,,,negative,,,negative,PTD,,negative,,,,,,,negative,,,,,,p.S502L; MAF 50% ,,,,,,,,,,,,,,negative,,,,,0.7381488284155076,High
14-00578,1730,Male,Male,White,1,n,75.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,IntermediateOrAdverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,75.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Fludarabine, TBI|Decitabine",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Fludarabine, TBI",Allogeneic - Mismatched Unrelated Donor,-1.0,Dead,327.0,Dead-Disease,False,False,,0,0.0,90,,0.0,0.0,6.0,2.6,0.0,0.1,18,49.0,2.6,0.94,M5,26.8,9.1,"46,XY[20]",1173.0,105.5,Normal,45.0,"dim partial CD11b, dim variable CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, CD123, HLA-DR, partial TdT, dim MPO positive",6.8,98.9,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,p.P777L; MAF 50%,,,,,negative,,,negative,p.R140Q; MAF 45%,,,negative,,,negative,PTD; no MAF available,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,Intron 1 splice site (at invariant AG splice donor); MAF 90% ,,0.3072402344823977,High
14-00581,1731,Female,Female,Black,4,n,68.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,68.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,CPX-351 (Liposomal Cytarabine + Daunorubicin),1,Induction,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,CPX-351 (Liposomal Cytarabine + Daunorubicin),Induction,-1.0,Dead,70.0,Dead-Disease,True,False,14-00580,-1,,33,37,,,,8.0,,,,,,,,,,"42~45,XX,-18[cp14]/43~45,idem,+2~3mar[cp3]/47,XX,+8[cp2]/45,X,-X[1]",,,,,"CD34+ BLAST POPULATION, 33%, EXPRESSING PARTIAL CD38, PARTIAL CD4, PARTIAL CD11C, HLA-DR, CD117, PARTIAL CD13, PARTIAL CD33, PARTIAL CD15, AND MPO",,29.1,True,False,14-00580,negative,negative,,,,,,,negative,,,,,,,Triple positive,,,,,,,,,,,,negative,,,negative,positive,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.8528197850651072,High
14-00588,1737,Female,Female,White,2,n,53.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute erythroid leukaemia,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute erythroid leukaemia,53.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin|Fludarabine, Cyclophosphamide, TBI ",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Allogeneic - Matched Unrelated Donor,-1.0,Dead,137.0,Dead-Treatment,False,False,,-1,0.0,9,4,0.0,,61.0,10.0,22.0,,14,40.0,3.3,0.65,,22.1,7.4,"46,XX,del(9)(q22q34)[20].",,93.4,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",38.0,"CD34 (partial +), CD2(partial dim +), CD13(dim +), CD33(variably to bright +), CD25(-), CD38(+), CD45(moderately +), CD15 (partial +), CD117(+), CD123(dim +), HLA-DR(partial +), MPO(+), TdT(-), other myeloid and lymphoid antigens (-)",5.8,2.1,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,R882C; MAF 43%,,,,,,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,splice site 1099-6_1104delCTGCAGGATGTG; MAF 28%,,-0.12214576119431904,Low
14-00597,1604,Male,Male,White,3,n,58.0,False,False,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,58.0,100,Post-Chemotherapy,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin) ",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,Standard Chemotherapy,HiDAC,Consolidation,210.0,Alive,761.0,Alive,True,False,14-00596,0,,0.4,,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,,,29.18,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.7338614734150386,Low
14-00599,1739,Male,Male,White,1,n,69.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,69.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,3,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,MiDAC,Consolidation,63.0,Dead,470.0,Dead-Disease,False,False,,0,0.0,,,0.0,0.0,78.5,15.1,6.4,2.9,21,15.0,3.1,1.01,M0,23.5,7.5,"47,XY,+8[2]/46,XY[18]",,101.7,Consistent with karyotype,47.0,"dim CD13, dimCD33, CD34, dim CD38, CD58, dimCD64, CD117, CD123, dim HLA-DR, TdT positive",6.7,2.05,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,PTD,,negative,,negative,,,,,negative,,,,,,,,,p.H242fs*14; MAF 42% ,,,,,,,,,,,negative,,p.S34F; MAF 40%,negative,,-0.5567653628447095,Low
14-00602,1746,Male,Male,White,4,n,69.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,IntermediateOrAdverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,69.0,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,4,"CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,79.0,Standard Chemotherapy,"MEC, Lenalidomide",Salvage,5.0,Dead,304.0,Dead-Disease,False,False,,-8,,,,,,,,,,,,,,,,,"46,XY[22]",,,,,,,,False,False,,positive,negative,,,,,,,negative,,,,,,,negative,,,,,,,,,,,,negative,,,positive,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.7522693296269879,Low
14-00608,1749,Female,Female,White,4,n,75.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,77.0,716,Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,1131.0,Dead,1134.0,Dead-Other,False,False,,-710,,,,,,,,,,,,,,,,,"46,XX[8]",,,,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.28042047611678034,Low
14-00613,1752,Male,Male,White,2,n,31.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,31.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,Standard Chemotherapy,HiDAC,Consolidation,5.0,Unknown,,,False,False,,-1,,80,56,2.0,,17.0,21.0,3.0,,63,39.0,3.9,0.91,,28.8,10.2,"46,XY,inv(16)(p13.1q22)[7]/46,idem,add(17)(p11.2)[13]",434.0,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[198],(CBFBx2)(5’CBFB sep 3’CBFBx1)[164/200]",34.0,"CD2(partial +), CD4(partial +), CD5(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CDCD33(variably +), CD34(variably +), CD36(few +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(partial +),CD117(+), CD123(variably +), HLA-DR(partial +), MPO(+), TdT(few +).",8.2,41.35,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.7597010059787895,Low
14-00618,1754,Male,Male,White,2,n,77.0,False,False,False,None,False,False,y,Lung Cancer,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,78.0,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,5,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Bortezomib|Decitabine|Fludarabine, Cytarabine",4,Hypomethylating/Low Dose Cytarabine|Unknown|Induction|Experimental,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1.0,Unknown,,,False,False,,0,,73,84,,,10.0,,6.0,,9,13.0,4.2,0.82,,,,"46,XY[20]",165.0,,,,,6.5,13.8,False,False,,negative,negative,,,,S1993fs*23; MAF 44%,,,,,,,,,,L81fs*72; MAF 92%,,,,,,,,,,,,,,,negative,negative,,,,,,,,,,,,G382D; MAF 49%,,,,,,,,,,,,,,,,,,,R1205*; MAF 92%,,,,M823fs*1; MAF 47%,,,,,,-0.7252615052970728,Low
14-00632,1761,Female,Female,White,1,n,64.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,64.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,6,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |R-CHOP (Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine)",4,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,"R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)",Induction,3.0,Alive,569.0,Alive,False,False,,0,0.0,90,30,0.0,0.0,37.5,27.7,0.0,2.6,37,31.0,1.8,0.52,M4,23.5,7.7,"46,XX,del(17)(q25)[3]/46,sl,del(3)(q12q21)[cp17]",452.0,94.4,,56.0,"dim CD4, partial variable CD7, CD13, CD33, partial CD34, CD38, partial CD58, CD117, CD123, HLA-DR, TDT and partial MPO positive.",6.2,6.44,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,p.G12V; MAF 30%,,,,,,,p.G12D; MAF 7%,,,,,,,,,p.R162K; MAF 85% ,,,,,,,,,,,negative,,,,,-0.566338811524137,Low
14-00643,1763,Male,Male,Asian,1,n,37.0,False,True,False,RUNX1-RUNX1T1,False,False,n,,y,n,n,n,n,n,n,n,RUNX1-RUNX1T1,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,37.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Busulfan, Cyclophosphamide",4,Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,0.0,Alive,566.0,Alive,False,False,,0,0.8,,,0.0,7.5,17.5,0.0,37.5,0.4,22,13.0,3.0,0.89,M2,15.8,5.5,"45,X,-Y,t(8;21)(q22;q22)[20]",411.0,100.6,"RUNX1T1/RUNX1:   94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.",42.0,"dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive",7.0,8.15,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,p.F445fs*3; MAF 30% ,,negative,,,negative,negative,,,negative,,,p.Y418_D419insFL (exon 8); MAF 29%     ;p.N822K (exon 17); MAF 5% ,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,p.G1160E; MAF 49% ,negative,,,,,-1.1215068626584033,Low
14-00658,1775,Female,Female,White,3,n,59.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Azacitidine, Sorafenib|Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"Azacitidine, Sorafenib",Hypomethylating/Low Dose Cytarabine,-1.0,Dead,254.0,Dead-Disease,False,False,,-1,,51.5,72,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,"Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia.",,89.17,False,False,,positive,positive,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.8036910652548301,High
14-00667,1783,Male,Male,White,1,n,57.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,57.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, TBI",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,371.0,Bone Marrow Transplant,"Fludarabine, Melphalan, TBI",Allogeneic - Sibling,-1.0,Dead,245.0,Dead-Treatment,False,False,,-1,0.3,,,0.0,0.6,32.6,14.7,51.8,0.0,82,52.0,3.4,0.78,,29.6,10.1,"46,XY[20]",160.0,93.7,Normal,91.0,"CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+",7.5,3.53,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,p.I114fs*25; MAF ~50% ,,,,,,,,,,,negative,,p.S34F; MAF 43%,negative,,-0.6471570091284462,Low
14-00670,1787,Male,Male,Black,2,n,63.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,3,"AG-221|Azacitidine|Fludarabine, Melphalan, TBI, ATG",3,Hypomethylating/Low Dose Cytarabine|Experimental|Allogeneic - Child,,,,Bone Marrow Transplant,"Fludarabine, Melphalan, TBI, ATG",Allogeneic - Child,-1.0,Alive,1059.0,Alive,False,False,,0,0.0,20,0,0.0,,76.0,0.0,24.0,,18,16.0,4.1,1.24,,24.9,8.3,"46,XY[20]",148.0,100.4,,72.0,,7.4,1.8,False,False,,negative,negative,,G646fs*12; MAF 30%,,,,,,,,,,,Y325*; MAF 46%,,,Q320fs*41; MAF 51%,,,,P442fs*16; MAF 38%,,,,,,,,,negative,R140Q; MAF 46%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P95H; MAF 40%,R614*; MAF 90%,,,,,,,,,,-0.03609612589044408,Low
14-00672,1786,Male,Male,White,7,n,64.0,False,False,False,None,True,False,n,,y,n,n,n,n,n,y,n,,MYELOPROLIFERATIVE NEOPLASMS,Essential thrombocythaemia,Intermediate,,MYELOPROLIFERATIVE NEOPLASMS,Essential thrombocythaemia,77.0,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,Ruxolitinib|Imatinib|Hydroxyurea,2,Induction|Re-induction,Refractory,Standard Chemotherapy,4626.0,Standard Chemotherapy,Ruxolitinib,Re-induction,-1.0,Alive,5305.0,Alive,False,False,,0,,15,,,,,,,,,,,,,,,"47,XY,+der(1;9)(q10;p10)[17]/94,idemx2[2]/46,XY[1]",,,Nineteen of twenty metaphase cells examined had an extra derivative chromosome composed of a chromosome 1 long arm and a chromosome 9 short arm; two of these cells were in the tetraploid state with two copies of the derivative chromosome. ,,"dimCD7, CD13, dim CD33, CD34, CD71, and CD117 positive",,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0941191488633487,High
14-00676,1561,Male,Male,White,1,n,23.0,False,False,False,None,False,False,y,mediastinum mass,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,24.0,163,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,"Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin) ",3,Consolidation|Induction|Experimental,Complete Response,Standard Chemotherapy,8.0,Targeted Therapy - Kinase Inhibitor(s),Trametinib,Experimental,197.0,Dead,318.0,Dead-Disease,True,True,14-00289,0,0.0,5,10,0.0,2.9,36.2,1.5,47.8,,30,146.0,3.4,0.82,,25.5,7.9,"48,XY,add(6)(p22),der(7)t(7;19)(p11.2;p12),del(9)(p13p22),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp2]/46~48,sl,add(17)(p1?3),add(22)(q13)[cp9]/46~48,sl,add(21)(p11.2)[cp6]/47~48,sl,add(1)(p36.1)[cp2]/48,sl,t(2;17)(p21;p11.2)[1]",,98.5,Low-level tetraploidy or near-tetraploidy,48.0,"A CD34 positive blasts population comprises approximately 4% of cellular gated events. Approximately 3% of cells are lymphocytes composed of 28% B cells, 45% T cells and 27% NK cells.",6.1,11.28,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.G12C; MAF 97%,,,,,,,,,,,,,,,,,,,,p.G245S; MAF 96%,,,,,1.6049616083525198,High
14-00681,1797,Male,Male,White,1,n,65.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,65.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|Cytarabine",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,Cytarabine,Consolidation,133.0,Alive,323.0,Alive,False,False,,0,0.0,,,0.0,0.0,31.2,0.9,0.0,0.0,19,25.0,3.3,0.78,M1,21.4,7.4,"46,XY,del(13)(q12q2?1)[14]",509.0,103.4,"all 100 interphase cells scored (100%) were missing one set of 13S319 and RB1 probe signals, consistent with deleted 13q and the metaphase karyotype",17.0,"CD13, partial/dim CD33, CD38, CD58, CD117 and MPO",6.6,5.39,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,p.R882H; MAF 44% ,,,,,negative,,,negative,p.R172K; MAF 43%,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.6180615286295942,High
14-00690,1800,Female,Female,White,3,n,49.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,49.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Matched Unrelated Donor,-1.0,Alive,462.0,Alive,False,False,,-1,,54,3,,,,,,,,,,,M5,,,"46,XX,del(17)(p11.2)[15]/46,XX[5]",,,consistent with karyotype (68% del 17p13),,"Most of the atypical cells (data not shown) are myeloid blasts that express CD117, partial CD7 (about 30% positive), CD13, CD33, HLA-DR, weak CD4, and partial CD15 (about 50% positive), but do not express CD34, CD14(MO2), or CD64.",,,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.0491709478199374,Low
14-00712,1810,Male,Male,White,1,n,65.0,False,False,False,None,False,False,y,Pancreatic adenocarcinoma,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,65.0,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Other,3,"3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin)",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,Decitabine,Salvage,9.0,Dead,158.0,Dead-Disease,False,False,,0,0.0,18,12,0.9,32.0,7.4,35.2,18.5,4.8,44,165.0,2.9,1.65,,20.1,6.7,"46,XY,i(17)(q10)[20]",3923.0,81.0,"TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metaphase analysis.",40.0,"CD13, CD33, CD34, CD117, and HLA-DR positive",5.7,161.89,False,False,,negative,negative,,p.R693fs*10; MAF 49% ,,,,,,,,,,,,negative,,,p.S893L; MAF 52% ,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,p.G12D; MAF 46% ,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.36714711964793456,Low
14-00714,1811,Female,Female,White,4,n,50.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,55.0,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,n,n,y,n,n,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine|MEC, Lenalidomide",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,6.0,Supportive/Palliative Care,Decitabine,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,1938.0,Dead-Disease,True,True,14-00715,0,,72,81,,,,,,,,,,,,,,"50,XX,del(1)(q32),+8,+9,t(15;16)(q15~21;q12~22),+19,+21[cp20]",,,,,"ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT",,3.8,True,True,14-00715,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.747816189423261,High
14-00725,1814,Female,Female,White,2,n,32.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",32.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,Bone Marrow Transplant,Bu/Cy/ATG,Allogeneic - Matched Unrelated Donor,-1.0,Alive,833.0,Alive,False,False,,0,0.0,24,2,2.0,,54.0,0.0,44.0,,10,22.0,4.4,0.49,,25.9,9.0,"47,XX,+8[13]/46,XX[7].",125.0,97.1,"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[197],(D8Z2x3,D20S108x2)[101/200], (RUNX1T1x3,RUNX1x2)[91/200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[188], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]",67.0,"CD2(-), CD4(dim +), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD41(-), CD45(+), CD56(-), CD64(-), CD71(+), CD117(+), CD123(+), GLy-A(-), HLA-DR(partial + and variable), TdT(-), MPO(+).",7.1,1.4,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,G60A; MAF 18%,,,,,,,,,,,,,,,,,,,-0.6506593413002556,Low
14-00730,1817,Female,Female,HispNative,1,n,40.0,False,True,False,PML-RARA,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,40.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,33.0,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Consolidation,193.0,Alive,587.0,Alive,False,False,,0,0.0,90,20,0.0,0.8,75.9,0.0,2.6,2.6,24,15.0,3.2,0.68,M3,20.3,7.1,"46,XX,t(15;17)(q22;q21)[17]/46,XX[3]",259.0,85.3,58% PML-RARA  (c/w karyotype),53.0,"CD13, CD33, CD58, CD64, CD117, CD123 and MPO positive",7.3,1.9,False,False,,negative,negative,,negative,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,p.E80X; MAF 37%,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,p.E340X; MAF 32%,,-1.7967664791484677,Low
14-00735,1818,Male,Male,Asian,4,n,83.0,False,False,True,None,False,False,n,,y,n,n,n,y,y,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,83.0,1,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,"Azacitidine|Decitabine, Midostaurin",2,Hypomethylating/Low Dose Cytarabine|Induction,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,"Decitabine, Midostaurin",Induction,-1.0,Dead,47.0,Dead-Disease,False,False,,-6,,,,,,,,,,,,,,,,,"46,XY[13]",,,,,,,,False,False,,positive,positive,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.4415914336880094,Low
14-00739,1820,Male,Male,White,1,n,39.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,MLL-MLLT4,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",39.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Intrathecal,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Methotrexate",3,Induction|CNS|Re-induction,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,4.0,Dead,216.0,Dead-Disease,False,False,,0,0.0,,,0.0,0.0,28.3,17.7,3.5,0.0,19,14.0,3.0,0.97,,31.1,10.7,"46,XY,t(6;11)(q27;q23)[20]",,98.4,MLL: 80% of cells had a split signal pattern consistent with the disruption of MLL due to the t(6;11).,31.0,,6.2,21.12,False,False,,negative,negative,,negative,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,negative,,,negative,PTD,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,1.6893172270989372,High
14-00742,1821,Female,Female,White,2,n,51.0,False,False,False,Complex,True,False,y,Breast Cancer,y,n,y,n,n,n,n,n,,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",Adverse,Adverse,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",51.0,0,Unknown,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,Decitabine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,4.0,Unknown,,,False,False,,0,0.0,9,11,0.8,,28.2,13.7,43.6,,19,28.0,2.6,0.7,,27.2,9.1,"44,XX,der(5)t(5;9)(p15;q22)del(5)(q11.2q15),-7,-9,-18,del(20)(q11.2q13.1),+mar[cp8]/43~44,XX,-der(5),del(7)(q11.2q32),add(11)(p15),del(12)(p11.2p13),der(15)t(15;17)(p12;q11.2),-16,-18,+mar[cp9]/43,XX,del(5)(q13q33),del(7),add(11),del(12),der(15),-16,-18,+mar[cp3].ishder(15)(PML+,RARA+)[1].",517.0,92.4,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[108/200]",74.0,"CD2 (-), CD4(- to dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD25(dim +), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), CD123(dim +), HLA-DR(variably+), MPO(-), TdT(-)",6.2,,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.9124126383071186,High
14-00757,1495,Male,Male,White,3,n,75.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,75.0,265,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,n,n,y,n,n,1,Standard Chemotherapy,5,"7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,21.0,Standard Chemotherapy,"CLAG (Cladribine, Cytarabine, Filgrastim)",Consolidation,-1.0,Dead,335.0,Dead-Disease,True,True,14-00622;14-00152,-77,,,,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,,,9.7,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.5591830796301462,Low
14-00761,1833,Female,Female,White,4,n,72.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72.0,0,Residual Disease,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine, Midostaurin",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,186.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Re-induction,62.0,Alive,417.0,Alive,True,False,14-00760,-22,,,,,,,,,,,,,,,,,"46,XX[20]",,,,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.18830411106336561,High
14-00774,1843,Male,Male,White,4,n,84.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,84.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Decitabine, Midostaurin",1,Induction,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,"Decitabine, Midostaurin",Induction,-1.0,Dead,67.0,Dead-Disease,False,False,,0,,85,88,,,,,,,,,,,M0,,,"46,XY[20]",,,,,"CD34, CD38, CD117, CD13, CD4, HLA-DR, AND TDT",,30.0,False,False,,positive,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.26885860008582585,Low
14-00780,1098,Female,Female,White,2,n,31.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,38.0,1496,Post-Chemotherapy|Post-Transplant|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,4,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),9,"Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide",7,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,-1.0,Targeted Therapy - Kinase Inhibitor(s),Dasatinib,Experimental,24.0,Dead,2661.0,Dead-Unknown,True,True,13-00294,-480,,7,1,,,,,,,15,21.0,4.2,,,31.9,11.0,"46,XX",,,nuc ish(DXZ1x2)[200],45.0,,6.2,2.2,False,False,,negative,negative,,,,,S259fs*10; MAF 15%,,,,,,P281R; MAF 19%,,,,,,,,,,,,,,,D835E; MAF 13%,,N297S; MAF 18%,,,Q44*; MAF 14%,,,,,,,Y2907*; MAF 7%,,,,,,,,,,,,,,E76V; MAF 17%,,,,H1100R; MAF 51%,K700E; MAF 18%,,,,,,,,,,,,,,1.112174066899802,High
14-00781,1847,Male,Male,White,1,n,71.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,MLL-EPS15,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,71.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,Standard Chemotherapy,MiDAC,Consolidation,5.0,Dead,162.0,Dead-Disease,False,False,,0,0.0,95,80,0.0,2.0,21.0,4.0,1.0,0.8,29,282.0,3.2,1.61,M5,31.8,10.0,"47,XY,t(1;11)(p32;q23),+8[cp20]",7759.0,102.3,c/w karyotype,59.0,"CD11b, CD13, partial CD14, CD15, CD33,CD38, CD45, CD56, CD58, CD64, HLA-DR and MPO-positive",6.1,71.19,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,p.Q1765*; MAF 4% ,,,,negative,,,,,negative,,,,,,,,,,negative,negative,,p.G13D; MAF 27%,,negative,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-1.4707034653932847,Low
14-00787,1848,Male,Male,White,1,n,61.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,61.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1.0,Alive,442.0,Alive,False,False,,0,0.0,90,90.5,0.0,0.0,8.2,2.2,0.9,0.8,22,43.0,3.1,1.21,M1,17.3,5.2,"46,XY[20]",1873.0,96.1,Normal,34.0,"CD7, CD13, CD33, CD34, CD117, HLA-DR, cMPO (+)",6.9,427.46,False,False,,negative,negative,,,,,,,,,,,,,,p.N307_V308ins; MAF 50%,,,,,,,negative,,,,,,,,negative,negative,,,,,,negative,negative,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-1.9201492242159888,Low
14-00798,1852,Female,Female,White,1,n,36.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,36.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,6.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6.0,Dead,15.0,Dead-Other,False,False,,0,0.0,74,82,1.7,1.7,6.7,82.3,3.4,0.0,45,36.0,2.7,0.68,M4,20.4,7.1,"46,XX,inv(16)(p13.1q22)[20]",,87.6,"CBFB; 76/100 cells (76%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement. ",12.0,,5.8,117.53,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,p.G12D; MAF 9% ,,negative,,,,,p.G12D; MAF 10%,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-1.0018195934697793,Low
14-00815,1814,Female,Female,White,2,n,32.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",32.0,46,Post-Chemotherapy,Bone Marrow Aspirate,y,n,y,y,n,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,Bone Marrow Transplant,Bu/Cy/ATG,Allogeneic - Matched Unrelated Donor,-1.0,Alive,833.0,Alive,False,False,,-7,0.0,2,0,0.0,,,44.0,56.0,,,,,,,23.2,7.7,"47,XX,+8[3]/46,XX[17].",130.0,89.9,"nuc ish(D8Z2x3,D20S108x2)[27/200]",113.0,,,0.9,True,True,14-00725,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,positive,,,,,,,,,,,,,,,,,,,-0.21907157174712033,Low
14-00817,1865,Male,Male,White,3,n,53.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,53.0,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,n,y,y,n,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,-1.0,Unknown,,,True,False,14-00818,-1,,66,56,,,,,,,,,,,,,,"46,XY[20]",,,Normal,123.0,"large population of atypical CD117 positive myeloblasts (partial CD34+, weak CD4+, weak partial CD7+, partial CD64+), representing approximately 57% of the leukocytes and increased   promonocytes/monoblasts representing approximately 13% of the total leukocytes",,180.0,True,False,14-00818,positive,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.006840503224116893,Low
14-00831,1866,Male,Male,HispNative,2,n,26.0,False,True,False,PML-RARA,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,26.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Consolidation,5.0,Unknown,,,False,False,,0,,81,37,3.0,,33.0,1.0,15.0,,47,44.0,4.4,0.8,,18.6,6.3,"46,XY,t(15;17)(q24;q21.1)[10]/46,XY[10]",484.0,,"nuc ish(PML,RARA)x3(PML con RARAx2)[173/200]",105.0,"CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-/small subset +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(equivocal/appears partial dim +), CD117(+), CD123(-), HLA-DR(-), MPO(appears partial +), TdT(few +).",6.7,4.95,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.29576176358560774,Low
14-00832,1868,Female,Female,White,1,n,65.0,False,True,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,IntermediateOrAdverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,65.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,0.0,Alive,450.0,Alive,False,False,,0,0.8,,30,0.0,12.5,24.2,28.3,18.4,0.0,23,29.0,3.0,0.78,,22.4,7.4,,561.0,107.2,,60.0,"CD7, minor subset CD11b, CD13, minor subset CD14,      dim CD33, CD34, CD38, CD58, minor subset CD64, CD117, CD123, HLA-DR, subset      myeloperoxidase positive",6.6,31.66,False,False,,positive,negative,negative,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,,,,negative,,0.7773164267040266,High
14-00901,1870,Male,Male,White,1,n,61.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",61.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,MiDAC,Consolidation,44.0,Dead,104.0,Dead-Unknown,False,False,,-2,0.0,,,0.0,0.0,45.5,0.8,0.0,0.3,14,18.0,2.4,0.73,,21.3,6.9,"46,XY,t(1;4)(q21;p14)[20]",178.0,103.4,Normal,57.0,,7.0,13.68,False,False,,negative,negative,,,,,p.S571*; MAF 90% ,,,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,negative,,,negative,PTD,,negative,,negative,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,p.C181F; MAF 88%,-0.31651349833224357,Low
15-00014,1877,Female,Female,White,1,n,77.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,77.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,Azacitidine|Decitabine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,6.0,Dead,16.0,Dead-Unknown,False,False,,1,0.0,95,9,0.0,0.9,53.0,0.0,28.7,0.8,10,16.0,4.0,1.02,M5,25.8,8.6,"47,XX,+1,add(1)(p22)[15]/47,XX,+1,i(1)(q10)[5]",601.0,97.0,"1p36/1q25: 81% of cells had three signals for 1q25 and two for 1p36, consistent with the larger clone above (ie. the clone with add(1)(p22). Another 13% of cells had four signals for 1q25 and two signals for 1p36, consistent with the smaller clone above (ie. the clone with the i(1)(q10)).",8.0,"CD4, CD11b, CD15, CD33, CD38, CD58, CD64, CD123 and partial HLA-DR positive",8.2,3.65,False,False,,negative,positive,,negative,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative;p.V491L; MAF 9%,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,p.S502L; MAF 44%,,,,,,,,,,,,,,negative,,,,,-1.1808115384395945,Low
15-00018,1889,Male,Male,White,4,n,57.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",58.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Other,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Binimetinib (MEK162)",3,Consolidation|Induction|Experimental,Refractory,Standard Chemotherapy,-1.0,Targeted Therapy - Other,Binimetinib (MEK162),Experimental,-1.0,Dead,111.0,Dead-Disease,True,False,15-00017,0,,70,8,,,,10.0,,,,,,,,,,"46,XY[14]",,,,,,,7.1,True,False,15-00017,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.24865786877664903,Low
15-00024,1916,Female,Female,White,4,n,75.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,75.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,"Decitabine, Midostaurin",1,Induction,Refractory,Standard Chemotherapy,206.0,Standard Chemotherapy,"Decitabine, Midostaurin",Induction,206.0,Dead,320.0,Dead-Unknown,True,False,15-00027,-6,,,,,,,,,,,,,,,,,"46,XX,t(5;16)(q31;p13)[3]/46,XX[14]",,,,,,,,True,False,15-00027,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.390617828378801,High
15-00029,1919,Male,Male,White,2,n,80.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",80.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,"Decitabine, ABT-199|Hydroxyurea",2,Unknown|Supportive/Palliative Care,,,,Standard Chemotherapy,"Decitabine, ABT-199",Unknown,-1.0,Dead,364.0,Dead-Disease,False,False,,0,0.0,21,47,0.0,,5.0,10.0,41.0,,25,52.0,4.1,1.26,,35.0,11.1,"46,XY[20]",639.0,90.4,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",110.0,"CD2(-), CD4(-), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(few +), CD16 (-), CD33(variably +), CD34(+), CD36(-), CD38(partial + with an unusual pattern of expression vs. CD34), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), HLA-DR(dim +).",7.5,64.6,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.03453665390938154,High
15-00043,1924,Female,Female,White,5,n,43.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,44.0,0,Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Induction|Re-induction,Refractory,Standard Chemotherapy,12.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1.0,Alive,420.0,Alive,False,False,,-46,,,,,,,,,,,,,,,,,"46,XX,add(3)(q21)[12]/52,sl,+6,+8,+10,+13,+20,+21[8]",,,Positive for an EVI1 rearrangement,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.14136401589330802,Low
15-00045,1925,Female,Female,White,2,n,30.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,30.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,40.0,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,-1.0,Alive,854.0,Alive,False,False,,0,0.0,36,22,0.0,,12.0,44.0,5.0,,61,44.0,4.2,0.59,,31.8,11.0,"46,XX,inv(16)(p13q22)[20]",441.0,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(RUNX1T1,RUNX1)x2[200],(PML,RARA)x2[200], (5'CBFBx2,3'CBFBx1)(5’CBFB sep 3'CBFBx1)[195/200],(ABL1,BCR)x2[200]",33.0,"CD34, CD13, partialCD15, CD38, CD45, CD117, CD123, HLA-DR, dimMPO",7.0,55.0,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.3118543919248897,Low
15-00051,1929,Female,Female,White,1,n,66.0,False,False,False,Unknown,False,False,y,Breast Cancer,y,y,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,66.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Matched Unrelated Donor,2.0,Alive,534.0,Alive,False,False,,0,0.0,95,90.2,0.0,2.5,4.9,0.8,1.6,0.6,19,23.0,3.0,0.5,,18.9,6.1,,501.0,100.5,Normal,10.0,"CD13, CD33, dim CD71, CD117, CD123, and MPO",6.4,66.67,False,False,,negative,positive,negative,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,p.R140Q; MAF 46%,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-0.693000474981316,Low
15-00057,1933,Male,Male,White,5,n,76.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,76.0,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,2,AG-221|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Experimental,,,,Targeted Therapy - Other,AG-221,Experimental,-1.0,Dead,680.0,Dead-Disease,True,True,15-00056,0,,70,55,,,,,,,,,,,,,,"46,XY[20]",,,Normal,46.0,"positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers",,4.5,True,True,15-00056,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,negative,C.G419A (p.R140Q),,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.7423741672641362,High
15-00073,1963,Male,Male,White,2,n,81.0,False,True,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",81.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Supportive/Palliative Care|Targeted Therapy - Other,2,AG-221|Hydroxyurea,2,Experimental|Supportive/Palliative Care,,,,Targeted Therapy - Other,AG-221,Experimental,14.0,Dead,72.0,Dead-Disease,False,False,,-8,0.0,,12,0.0,,69.0,5.0,12.0,,30,41.0,3.3,0.76,,30.3,10.5,"46,XY[20]",227.0,85.6,"nuc ish(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(CCND1,IGH)x2[199]",117.0,,8.8,33.1,False,False,,negative,negative,,"Foundation, G646fs*12; MAF 33%",,,,,,,,,,,,,,,,,,,,,,,,"Foundation, E596_Y597INSYEYDLPYDPRS; MAF 27%",,,,"Foundation, R140Q; MAF 45%",,,,,,,,,,,,,,,,,,,,,,,,,"Foundation, Q213fs24; MAF 82%",,,,,"FOUNDATION, P95R; MAF 48%",,,,,,,,,,,0.17436082703427105,High
15-00075,1964,Male,Male,White,5,n,80.0,False,False,True,None,False,False,n,,n,n,n,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,80.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Targeted Therapy - Other,1,AG-221,1,Experimental,,,,Targeted Therapy - Other,AG-221,Experimental,-1.0,Dead,34.0,Dead-Disease,False,False,,1,,90,48,,,,,,,,,,,,,,"46,XY,del(20)(q11.2q13.1)[12]/45,sl,-7[3]/45,XY,-7[5]/46,XY[2]",,,Tetrasomy 5p/q; Monosomy 7; Loss 20q12 (15.5%); Tetrasomy 8cen and 20q12 (7,65.0,"positive for CD13, dim CD33, CD34, CD38, dim CD45, CD117, HLA-DR and TdT",,6.6,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C.G395A; p.R132H; MAF unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.3352078856519787,High
15-00081,1757,Male,Male,White,3,n,48.0,False,False,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,49.0,152,Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,6,"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|FLAG-IDA, Gemtuzumab|Cytarabine, Methotrexate",5,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|CNS|Re-induction,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)",Allogeneic - Mismatched Unrelated Donor,-1.0,Dead,443.0,Dead-Disease,False,False,,-2,,,,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.205319475362351,Low
15-00084,1953,Female,Female,White,1,n,82.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,82.0,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,122.0,Dead,35.0,Dead-Disease,False,False,,-21,7.6,,,4.2,8.5,28.0,6.8,12.7,0.1,24,22.0,3.1,0.96,,31.5,11.0,"43~46,XX,add(2)(q11.2),-4,del(5)(q23),add(7)(q32),+8,add(11)(q23),-16,del(17)(p12),-18,+22[cp19]/46,XX[1]",1304.0,86.8,,21.0,,7.3,17.63,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.251515516972653,High
15-00123,1969,Male,Male,White,2,n,42.0,False,True,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,42.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5.0,Bone Marrow Transplant,Bu/Cy/ATG,Allogeneic - Matched Unrelated Donor,-1.0,Alive,832.0,Alive,False,False,,0,,81,85,,,4.0,7.0,4.0,,89,50.0,3.0,0.94,,27.8,9.5,,945.0,95.5,,39.0,"partialCD4, partial/dimCD7, partialCDllb, CD13, partialCD15, partialCD22, partialCD25, brightCD33, partialCD34, CD38, CD45, CD117, partialCD123, HLA-DR, partialMPO, partialTdT",5.7,48.03,False,False,,positive,positive,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.8679181711106556,High
15-00140,1721,Male,Male,White,2,n,68.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68.0,184,Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Consolidation|Induction|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,Azacitidine,Maintenance,-1.0,Alive,976.0,Alive,False,False,,0,,1,0,,,,,,,23,24.0,4.6,,,35.4,12.0,"46,XY",,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",61.0,"CD38(bright +), CD45(-), CD56(+), intracellular kappa(+), intracellular lambda(-)",7.5,2.6,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.7703836381360764,Low
15-00147,1981,Female,Female,HispNative,1,n,28.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,30.0,2,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,5,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) ",Salvage,5.0,Dead,843.0,Dead-Disease,True,False,15-00137,-27,0.0,,,0.0,0.0,4.1,0.0,2.1,32.3,54,37.0,3.7,0.3,NOS,27.3,9.2,"46,XX,t(2;9)(q31;p21)[17]/46,X,t(X;9)(q22;p21)[3]",,91.3,,8.0,,6.3,20.18,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.6744756151342013,Low
15-00169,2001,Female,Female,Black,2,n,67.0,False,False,False,None,False,False,y,Not specified,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,67.0,0,Post-Chemotherapy|Post-Transplant|Post-DLI|Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,4,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,4,"AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea",3,Salvage|Experimental|Supportive/Palliative Care,,,,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1.0,Dead,449.0,Dead-Disease,False,False,,0,0.0,24,6,0.0,,77.0,10.0,7.0,,29,37.0,4.1,0.89,,30.1,9.9,"46,XX[20]",511.0,,"nuc ish(DXZ1x2)[182]//(DXZ1,DYZ3)x1[18]. nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2) [200]",288.0,"CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD33(variably +), CD34(+), CD36 (-), CD38(+), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+)",8.0,3.3,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.01986482205492035,High
15-00171,2002,Male,Male,White,5,n,80.0,False,False,False,None,False,False,y,Not specified,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,80.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),3,"Cytarabine|Decitabine|PF-04449913 (Hedgehog Inhibitor), LDAC",3,Consolidation|Salvage|Experimental,,,,Targeted Therapy - Kinase Inhibitor(s),Decitabine,Salvage,-1.0,Dead,309.0,Dead-Disease,False,False,,1,,80,86,,,,,,,,,,,,,,"46,XY,del(20)(q11.2q13.1)[15]/46,XY[5]",,,Positive for deletion of 20q12 in 11.5% of 200 cells,4.0,"positive for dim CD7, dim CD10, CD34, CD38, dim CD45, cCD79a, CD99, HLA-DR, TdT, dim PAX5",,,False,False,,negative,negative,,p.718_724del; MAF 50.3%,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,,,,,,,,,,,,,,,,,p.S114X; MAF 44.8%,,,,,p.P95H; MAF 45.1%,,,,,,negative,,,,,-0.21031880080974266,Low
15-00175,1999,Male,Male,HispNative,1,n,50.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,50.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Salvage|Induction,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,4.0,Dead,99.0,Dead-Disease,False,False,,0,0.0,76,93,0.0,0.0,6.1,1.7,1.8,0.0,7,10.0,2.2,0.44,,18.8,6.3,"43~47,XY,del(1)(q42),r(2)(p2?3q37),t(3;5)(q27;q31),del(4)(q31),+del(5)(q31),add(5)(q11.2),-7,del(11)(q23),add(12)(p13),-22,+mar[cp11]/43~46,idem,add(14)(q24)[cp8]",,85.8,deleted 5q and three short arm signals;  monosomy 7 and the metaphase karyotype;  no evidence for MLL deletion or rearrangement,14.0,,5.9,50.74,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,,,,negative,negative,,,negative,,,,,,negative,,negative,,,,, p.Q61K; MAF 37%,,,,,,,,,,,,,,,,,,,,p.R273H; MAF 44%,,,negative,,1.597479712505895,High
15-00194,1973,Male,Male,White,1,n,70.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,70.0,15,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",3,Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6.0,Supportive/Palliative Care,Decitabine,Hypomethylating/Low Dose Cytarabine,-1.0,Alive,523.0,Alive,True,False,15-00131,1,0.0,,,0.0,0.0,78.1,0.9,1.7,0.0,46,27.0,2.0,0.74,,24.4,8.1,"47,XY,+4[9]/46,XY[11]",,103.8,,23.0,,4.7,4.85,True,False,15-00131,negative,negative,,p.Q588*; MAF 43% ,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,2.1713391139161624,High
15-00201,2016,Female,Female,White,5,n,71.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,71.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,n,y,n,n,2,Standard Chemotherapy|Targeted Therapy - Other,2,"Azacitidine|Venetoclax (ABT-199), Azacitidine",2,Induction|Experimental,Complete Response,Standard Chemotherapy,-1.0,Targeted Therapy - Other,"Venetoclax (ABT-199), Azacitidine",Experimental,115.0,Alive,868.0,Alive,True,True,15-00200,0,,65,,,,,,,,,,,,,,,"46,XX[20]",,,,96.0,"positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR",,1.6,True,True,15-00200,negative,positive,,p.A1312V; MAF 33.6%,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,p.A1312V; MAF 32.1%,negative,,,negative,,,negative,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.4784914081567781,Low
15-00229,2024,Male,Male,White,1,n,25.0,False,True,False,PML-RARA,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,25.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,n,y,n,n,1,Standard Chemotherapy,1,"APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,28.0,Standard Chemotherapy,"APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)",Induction,28.0,Alive,28.0,Alive,False,False,,0,0.0,,,0.0,0.0,22.3,0.0,0.9,0.7,25,50.0,3.2,0.9,M3,21.3,7.7,"46,XY,t(4;15;17)(q21;q22;q21),add(12)(p12)[1]/46,idem,t(5;22)(q11.2;q11.2)[18]/46,XY[1]",921.0,92.2,FISH c/w PML/RARA fusion,16.0,,6.8,18.25,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.6306855695386824,High
15-00231,1727,Male,Male,HispNative,1,n,45.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,46.0,196,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Supportive/Palliative Care,5,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",4,Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) ",Salvage,4.0,Dead,259.0,Dead-Disease,True,True,14-00803,-86,0.0,,,0.0,1.7,7.8,51.3,18.3,0.0,29,19.0,3.0,0.52,,20.6,7.0,"47,XY,der(7)t(1;7)(q10;p10)+8[20]",,87.3,,5.0,,5.8,11.13,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.8364319719456007,High
15-00237,2028,Female,Female,White,1,n,29.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",IntermediateOrAdverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",29.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide|Transplant",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,24.0,Bone Marrow Transplant,Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,476.0,Alive,False,False,,0,0.0,95,78,0.9,0.0,11.7,0.0,13.5,1.8,20,25.0,3.0,0.54,,23.0,7.9,"46,XX[20]",1119.0,95.8,Normal,12.0,"dim CD2, dim CD7, CD13, dim CD19, dim CD20,      CD33, partial CD34, variable CD38, dim CD64, CD117, CD123, and HLA-DR      positive.",6.1,68.79,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PTD,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.4009520452180726,High
15-00246,2032,Male,Male,White,2,n,65.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,Decitabine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,214.0,Dead,269.0,Dead-Unknown,False,False,,0,,10,1,0.0,,80.0,2.0,17.0,,24,27.0,4.3,1.48,,20.4,7.2,"46,XY[20]",275.0,93.3,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199](RUNX1T1, RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",23.0,"CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33 (bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR (+), GLy-A(-), MPO(partial +), TdT(-).",6.9,1.6,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,W297*; MAF 44%,,,,,D835Y; MAF 6%,,P161A; MAF 51%,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.7339994233932198,Low
15-00248,2033,Male,Male,HispNative,2,n,61.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,61.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine",3,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1.0,Unknown,,,False,False,,0,0.0,64,47.4,1.7,,23.3,27.6,0.0,,29,26.0,3.7,1.01,,32.9,10.3,"46,XY[20]",578.0,99.7,"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",20.0,"CD2(-), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD19(few appear very dim +), CD25(-), CD33(variably +), CD34(variably +), CD36(subset +), CD38(+), CD45 (variably +), CD56(+), CD64(partial +), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(-).",7.2,20.8,False,False,,negative,negative,,G967DEL; MAF 45%,,,,,,,,,,,,A111FS*56; MAF 48%,,,,,,,,,,,,,,A318V; MAf 37%,negative,negative,,,,,,,,,,,,,,,,G13V; MAF 37%,,,,,,,,,,,,,,,,,,,,,,,,,-1.4643686791295385,Low
15-00261,2052,Female,Female,White,1,n,43.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,43.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6.0,Supportive/Palliative Care,Cytarabine,Supportive/Palliative Care,125.0,Dead,245.0,Dead-Disease,False,False,,0,0.0,,,0.0,0.0,31.9,12.4,2.6,0.1,26,16.0,3.0,0.77,M4,22.1,7.5,"46,XY[20]",297.0,95.7,Normal,59.0,,6.5,22.95,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,,,,,,,,,,,negative,,,,,,,negative,,,,,,,,,p.K110Q; MAF 38%,,,,,,,,p.E261fs*2; MAF 52%,,,negative,,,,,0.09484032514045894,High
15-00269,2053,Male,Male,White,2,n,59.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,HiDAC,Consolidation,107.0,Dead,430.0,Dead-Unknown,False,False,,-1,0.0,35,27.4,0.0,,36.8,6.6,29.2,,13,25.0,2.9,1.4,,23.6,7.6,"46,XY[20]",383.0,,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",35.0,,6.0,3.6,False,False,,negative,positive,,,,,,,,,,,,,,Y181*; MAF 15%,,,,,,,,,,,,,,,,R140Q; MAF 35%,,,,,,,,,,,,,,,,,,,,splice site 1164-1G>A; MAF 48%,,,,,,,,,,P95R; MAF 37%,,,,,,,,,,,-0.07387280583964458,Low
15-00275,1992,Female,Female,White,5,n,53.0,False,False,False,None,False,False,y,Ovarian cancer,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,53.0,33,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,29.0,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Re-induction,17.0,Dead,72.0,Dead-Disease,True,False,15-00157,-33,,,,,,,,,,,,,,,,,"53~55,XX,+1,+2,der(5)t(5;13)(q13;q12),+6,add(7)(q32),+8,+11,-13,+14,i(17)(q10),+19,+19,+21,+mar[cp7]/46,XX[7]",,,Gain of 8 (4/301 cells); Gain of 8q22/21q22 (7.7/301 cells); Gain 11q23 (5/200 cells),,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.1459758593285896,Low
15-00276,2059,Male,Male,White,1,n,60.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Other,3,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)",3,Salvage|Induction|Re-induction,Complete Response,Other,167.0,Standard Chemotherapy,Azacitidine,Salvage,6.0,Dead,870.0,Dead-Unknown,False,False,,0,0.0,90,39.6,1.0,4.0,47.0,10.0,1.0,0.1,30,26.0,2.4,1.17,M4,14.0,4.6,"46,XY[20]",612.0,104.5,Normal,80.0,"dim CD4, dim CD7, dim CD11b,      CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT",5.8,70.84,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,p.V491L; MAF 51%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.K666Q; MAF 47%,,,,,,,,,,,,p.Y395fs*51; MAF 49%,,-0.042955839225495604,Low
15-00279,2087,Female,Female,White,3,n,48.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,48.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|TBI, VP-16",4,Consolidation|Induction|CNS|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"TBI, VP-16",Allogeneic - Matched Unrelated Donor,-1.0,Alive,435.0,Alive,True,False,15-00278;15-00322,0,,86,77,,,,,,,,,,,M5b,,,"46,XX",,,,,"Large population of atypical monocytic cells (weaker than  normal CD33, partial loss of CD13) including  promonocytes/monoblasts representing approximately 50% of  the leukocytes suggestive of acute monoblastic or monocytic  leukemia.",,81.0,True,False,15-00278;15-00322,positive,positive,,,,,,,,,,,,,,negative,,,,,,,p.Arg882Cys; MAF 47.1%,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.8323870892486747,Low
15-00287,2073,Male,Male,White,1,n,85.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,85.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,105.0,Dead,167.0,Dead-Disease,False,False,,2,0.0,,,2.5,0.0,14.6,2.4,0.0,0.5,14,15.0,3.5,0.98,,33.2,10.7,"46,XY[20]",289.0,89.5,Normal,8.0,,7.4,25.63,False,False,,negative,negative,,,,,,,,,,,,,,p.K313_V314insK; MAF 50%,,,,,,,negative,,,,,negative,,,,,,,,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,p.I1025L; MAF 50%,negative,,,,,-1.5513035477804842,Low
15-00296,2079,Female,Female,White,1,n,16.0,False,True,False,MLLT3-KMT2A,False,False,n,,y,n,n,n,n,n,n,n,MLL-MLLT3,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,16.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",1,Induction,Complete Response,Standard Chemotherapy,10.0,Standard Chemotherapy,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",Induction,10.0,Alive,318.0,Alive,False,False,,0,0.0,93,0,0.0,0.0,33.0,67.0,0.0,0.0,,,,0.72,M5,18.2,6.1,"46,XX,t(9;11)(p22;q23)[3]/50,sl,+6,+8,+der(9)t(9;11),+19[14]/51,sdl1,+5[3]",934.0,100.0,"MLL:   14% of cells had a 1 red / 1 green / 1 fused split pattern consistent with the t(9;11) seen on metaphase analysis.  An addition 65% of cells had two red / 1 green / 1 fused signal pattern, consistent with the clone with the +der(9).",39.0,"CD11b, dim CD13, dim CD15, CD33, CD38, dim CD45, CD56,      CD58, bright CD64, dim CD117, CD123, HLA-DR, and variable MPO positive",,24.72,False,False,,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,p.G13D; MAF 6%    ,,negative,,,,,p.Q61H; MAF 19%,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-1.5113344867083927,Low
15-00300,2067,Male,Male,White,5,n,76.0,False,True,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,76.0,1,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,,False,False,,0,,20,,,,,,,,,,,,,,,"41~42,XY,del(3)(p13p21),add(4)(q21),add(5)(q11.2),-7,-10,add(12)(p11.2),-15,add(15)(q21),add(17)(p11.2),-19,-20,-22,+2mar[cp6]/42~43,sl,+21[cp5]/42,sl,i(21)(q10)[cp2]/43~44,sl,+add(7)(p11)[cp2]/43~46,sl,+add(7)(p11),+21[cp4]/81~87<4n>,slx2[cp2]",,,"Loss of chromosome 5q31 sequences (73.5%)                Loss of chromosome 7 sequences (monosomy 7) (61.5%)                Gain of 21q22 (AML1) sequences (11.5%)                Polysomy for 8, 20q (7.5%), 11q, 15q, 16q and 17q sequences",91.0,,,5.6,False,False,,negative,negative,,p.E1102D; MAF 31.1%,,,,,,,,,,,,negative,,,,,,,p.F543C; MAF 35.7%,,,,,negative,,,negative,negative,,,negative,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,0.4520073334725612,High
15-00302,2068,Female,Female,White,3,n,65.0,False,True,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,UNKNOWN,Standard Chemotherapy,-1.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,-1.0,Dead,21.0,Dead-Other,False,False,,0,,,,,,,,,,,,,,,,,,,,,,"Large population of atypical myeloblasts (CD56 positive,  weak CD117 positive, CD34 negative, HLA-DR negative),  representing approximately 87% of the leukocytes,  consistent with acute myeloid leukemia",,,False,False,,negative,positive,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,p.Ile3572Ser (NM_001197104.1); MAF 44.1%,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,p.His724fs; MAF 43.5%,negative,,,,,-1.4024834152082981,Low
15-00303,2069,Male,Male,White,1,n,64.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,64.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Re-induction,5.0,Alive,68.0,Alive,False,False,,-8,0.0,,,0.0,0.9,48.7,30.1,5.3,0.0,10,7.0,2.6,1.33,,23.2,7.7,"46,XY,inv(16)(p13q22)[17]/46,XY[3]",,87.2,c/w karyotype,53.0,,5.9,8.69,False,False,,negative,negative,,,,,,,negative,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,p.G12D; MAF 27%,,negative,,,,p.G2299S; MAF 47%,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-0.6734422119696005,Low
15-00312,1967,Male,Male,White,5,n,69.0,False,False,True,None,False,False,y,Squamous cell carcinoma,y,y,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,70.0,55,Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Other,3,"7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Rituximab",2,Induction|Experimental,Unknown,Standard Chemotherapy,-1.0,Targeted Therapy - Other,Rituximab,Experimental,-1.0,Unknown,,,True,False,15-00082,-54,,,,,,,,,,,,,,,,,"46,XY[18]",,,Normal,,,,,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.5057147752167576,Low
15-00320,2084,Female,Female,White,2,n,57.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,57.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin) plus Crenolanib",1,Induction,Complete Response i,Standard Chemotherapy,-1.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin) plus Crenolanib",Induction,-1.0,Dead,81.0,Dead-Treatment,False,False,,0,,55,47,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,"It reveals 0.23% CD34 (+) myeloid blasts with the following immunophenotype: CD2(-), CD7(-), CD13(+), CD15(-/few +), CD33 (bright +), CD36(few +), CD38(partial +), CD45(+), CD64(-), CD117(+), HLA-DR(-), MPO (partial +).",,26.5,False,False,,positive,positive,,E981G; MAF 49%,,,,,,,,,,,,,,,,,,,F290fs*24; MAF 40%,,,,,,,,,,,,N322I; MAF 51%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.9570485232305052,High
15-00331,2091,Male,Male,White,5,n,60.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,60.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"HiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, Thiotepa, TBI",3,Consolidation|Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, Thiotepa, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Dead,581.0,Dead-Disease,False,False,,0,,33,23,,,,,,,,,,,,,,"46,XY,inv(16)(p13.1q22)[18]/47,sl,+22[2]",,,FISH positive for CBFB rearrangement in 49% of cells,42.0,"Flow cytometry shows the large majority of analyzed cells fall within the monocyte gate, which are predominantly mature as evidenced by coexpression of CD14 and CD64. A smaller subset of cells within the monocyte gate consists of immature monocytes with decreased expression of CD14 and/or CD64.",,29.0,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,negative,,,negative,,,,,,,,,,p.Q61K; MAF 24.1%,,,,,,,,,,,,,,,,,,,,,,,,,-1.8011509293719594,Low
15-00338,2094,Female,Female,White,2,n,42.0,False,True,False,PML-RARA,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,42.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Targeted Therapy - Other|Intrathecal,3,"ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate|Methotrexate",3,Induction|Experimental|Maintenance,Unknown,Intrathecal,22.0,Standard Chemotherapy,"ATRA, 6-MP, Methotrexate",Maintenance,-1.0,Alive,155.0,Alive,False,False,,0,0.0,92,83,0.0,,11.0,4.0,0.0,,35,35.0,3.9,0.66,,22.2,7.6,"46,XX,t(15;17)(q24;q21.1)[1]",475.0,88.4,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x3(PML con RARAx2)[154/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",35.0,"CD2(-), CD4(partial +), CD11b(few dim +), CD13(+), CD14(-), CD15(-), CD16 (-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(+), CD117(variably +), CD123(+), HLA-DR(-), myeloperoxidase(+), and TdT(-).",5.8,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.579060944525025,Low
15-00351,2102,Female,Female,White,1,n,48.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,MLL-MLLT11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",56.0,0,Residual Relapse|Post-Chemotherapy|Post-DLI|Post-Transplant,Bone Marrow Aspirate,y,y,n,y,y,n,3,DLI|Standard Chemotherapy|Bone Marrow Transplant,7,"7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Mitoxantrone|Busulfan, Cyclophosphamide",5,Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,5.0,Dead,3069.0,Dead-Disease,False,False,,0,0.0,62,5,0.0,0.0,83.2,1.8,0.0,0.0,28,21.0,2.5,0.8,,24.1,8.3,"46,XX,t(1;11)(q44;q13),del(6)(p23)[9]/46,idem,t(17;20)(q25;q11.2)[11]",290.0,94.5,"All probe results were within normal laboratory limits.      *Note: while it was not disrupted, MLL (11q23) was observed on the end of      the derivative chromosome 1 on available metaphase cells, reflecting the      t(1;11).",53.0,"dim CD2, CD13, CD33, CD34, CD38, CD117, dim CD123, dim      HLA-DR, and TdT positive",6.5,1.46,False,False,,negative,negative,,,,,p.A1262S; MAF 45% ,,,,,,,,,,,,,,,,p.R882H; MAF 15% ,,,,,,c.-12C>T; MAF 35%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.1779641043966635,High
15-00353,2104,Male,Male,White,5,n,60.0,False,False,True,None,False,False,n,,y,n,n,n,n,n,y,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute megakaryoblastic leukaemia,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute megakaryoblastic leukaemia,60.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,204.0,Dead-Disease,False,False,,-6,,13,rare,,,,,,,,,,,,,,"46,XY,del(13)(q12q14)[3]/46,XY[17]",,,Normal,136.0,"CD3  - Scattered cells positive, 5-10% of marrow cells CD20  - Scattered cells positive, 5-10% of marrow cells CD34  - Rare cells positive, <1% of marrow cells CD30  - Negative CD43  - Positive in >60% of marrow cells, including the clusters of immature cells",,3.1,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,p.V617F; MAF 3.8%,,,negative,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,p.R1261L; MAF 27.7%,,,,,,0.36850730008337496,High
15-00371,2113,Male,Male,White,2,n,74.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,75.0,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",3,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,HiDAC,Consolidation,48.0,Dead,324.0,Dead-Unknown,False,False,,0,0.0,32,5,0.0,,69.0,8.0,18.0,,23,22.0,4.3,1.21,,32.9,11.1,"46,XY[18]",199.0,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[198],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",178.0,"CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD22 (-), CD25(-), CD33(variably +), CD34(bright +), CD36(-), CD38(bright +), CD45(moderate/dim +), CD56(-), CD64(-), CD79a (-), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(partial +)",7.1,2.3,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.31275317956359816,Low
15-00377,2116,Female,Female,White,1,n,10.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,10.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,33.0,Standard Chemotherapy,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Re-induction,-1.0,Alive,569.0,Alive,False,False,,0,0.0,80,75,1.7,6.1,17.4,7.8,11.3,0.7,24,22.0,3.7,0.51,,30.3,9.1,"46,XX[20]",688.0,83.7,Normal,74.0,"variable CD7, variable CD13, CD33, partial CD34, bright CD38, partial CD56, CD58, variable CD71, CD117, CD123, HLA-DR, and MPO positive",7.3,39.69,False,False,,negative,negative,,,,,,,,,,,,,,p.G96fs*12; MAF ~50%,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,PTD (low level mutation),,negative,,,,,,,p.G12D; MAF 5%,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.6309858328294348,Low
15-00383,2127,Male,Male,Black,2,n,63.0,False,False,True,None,False,False,n,,n,n,n,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,63.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,2,Ruxolitinib|Hydroxyurea,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,103.0,Dead,8.0,Dead-Disease,False,False,,0,1.0,9,15.4,2.9,,20.2,16.3,42.3,,,,,0.6,,22.7,7.0,"46,XY[20]",1086.0,,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",126.0,"CD34(+), CD7(partial +), CD13(+), CD33(+), CD38(partial +), CD45(moderately +), CD56 (+), CD117(+), HLA-DR(variably +), other myeloid and lymphoid antigens(-).",,73.4,False,False,,positive,positive,,Foundation; W898*; MAF 47%,,,,,,,,,,,,,,,,,,,,,,,,negative,,,negative,negative,,,,,,,,,Foundation; A59T mutation; MAF 47%,,,,,,,,,,,,,,,,,,,,,,,,Foundation; W617*; MAF 49%,,,,,,,,1.2850054423910202,High
15-00395,2119,Male,Male,White,1,n,76.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,76.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,3,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor),2,Consolidation|Induction,Complete Response,Standard Chemotherapy,35.0,Standard Chemotherapy,Incyte trial (azacitidine and JAK 1 inhibitor),Induction,77.0,Dead,520.0,Dead-Unknown,False,False,,0,0.0,50,<5,2.0,0.2,52.2,37.1,8.5,0.0,18,16.0,3.7,1.45,M0,22.3,7.6,"47,XY,+8[3]/46,XY[17]",,118.6,5% trisomy 8 (c/w karyotype),104.0,"#1 Immunophenotype: CD13, CD34, CD38, dim CD45, CD58, CD117, HLA-DR and TdT positive",7.7,4.48,False,False,,negative,negative,,,,,,,,,,p.Y371H; MAF 43%,,,,negative,,,,,,,negative,,,p.K30fs*8; MAF 48%,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,p.A338fs*; MAF 41%,,p.H662Q; MAF 28%,,,,,,,,,negative,,,negative,,0.8037402193963541,High
15-00417,2135,Male,Male,White,2,n,44.0,False,False,True,None,False,False,n,,n,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,44.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,,False,False,,0,0.0,62,19,1.0,,18.0,35.0,25.0,,24,90.0,1.8,0.73,,22.4,7.2,"47,XY,+21[19]/46,XY[1]",,,"nuc ish(RUNX1T1x2,RUNX1x3)[140/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",18.0,"CD2(-­), CD7(dim + to -­), CD11b(-­), CD13(+), CD14(-­), CD15 (partial +), CD33(bright +), CD34(partial +), CD36(-­), CD38(variably +), CD45(+), CD56(-­), CD64(partial +), CD117(+), HLA-­DR(variably +)",7.1,8.0,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.7170912861032888,Low
15-00464,2147,Male,Male,White,2,n,71.0,False,True,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Supportive/Palliative Care,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,288.0,Dead-Unknown,False,False,,-3,0.9,,,2.8,,,,,,28,27.0,4.2,1.18,,29.3,9.8,"46,XY,inv(4)(p14p16.1)[3]/46,XY[16]",194.0,,"nuc ish(D5S2064,D5S630,EGR1)x4[32/200],(D7Z1,D7S522)x4[17/200],(D8Z2, D20S108)x4[27/200],(RUNX1T1,RUNX1)x4[32/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[21/200],(PML,RARA)x4 [34/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[35/200]",73.0,,7.1,,False,False,,negative,negative,,,,,Foundation; Q1337*; MAF 56%,,,,,,,,,,,,,,Foundation; R49H; MAF 19%,,,,,,,negative,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,"Foundation; loss, splice site 477_508+22>GGG; MAF 50%",,,,,Foundation; R94_S101del;MAF 39%,,,,,Foundation; splice site 3409+2T>G; MAF 51%,,,,,,0.3589582309708549,High
15-00470,2144,Male,Male,HispNative,1,n,32.0,False,True,False,PML-RARA,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,32.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,1,"ATRA, Arsenic Trioxide",2,Consolidation|Experimental,,,,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Consolidation,232.0,Alive,292.0,Alive,False,False,,-2,0.0,,,0.0,19.6,56.3,0.9,3.6,0.1,31,20.0,3.0,0.84,,19.1,6.3,"46,XY,t(15;17)(q22;q21)[20]",,96.5,70% PML/RARA,49.0,,6.9,7.19,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,"p.E484G, MAF 3%",,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,p.F451C; MAF 51% ,,-1.2067982550275373,Low
15-00471,2142,Male,Male,White,3,y,69.0,False,True,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,69.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,250.0,Dead-Disease,False,False,,0,,60,,,,,,,,,,,,,,,,,,,,"weak  CD7, CD13, partial CD15, weak CD33, CD34, weak CD64, CD117,  myeloperoxidase, and HLA-DR, but do not express CD14(MO2),  CD42b, or CD61.",,33.0,False,False,,negative,negative,,,,,,,,,,,,,,c.117delC; MAF 27.2%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,c.3454G>T; MAF 40.9%,,,,c.1137_1138insA; MAF 43.7%,,-1.7957010057461391,Low
15-00479,2167,Male,Male,White,5,n,65.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,65.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,4,"7+3 (Cytarabine, Idarubicin)|Azacitidine|Fludarabine, Cyclophosphamide, TBI |Venetoclax (ABT-199)",4,Hypomethylating/Low Dose Cytarabine|Experimental|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),,,,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Dead,210.0,Dead-Disease,True,False,15-00478,-1,,95,62,,,,,,,,,,,,,,"48,XY,+8,der(11)t(11;?)(q23;?),+21[19]/46,XY[1]",,,Gain of 8q22 and 21q22 (88%),33.0,"positive for CD11b, CD13, CD33, CD38, dim CD45, dim CD56, CD64, and HLA-DR",,19.8,True,False,15-00478,negative,negative,,p.W960X; MAF 29.4%,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,negative,,,negative,,,,,negative,,,,,,,,,,,p.E76V; MAF 29.5%,,,,,,,,,,,,,,,,,,,-1.3217027954162766,Low
15-00482,1532,Female,Female,White,1,n,46.0,True,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47.0,424,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,7.0,Standard Chemotherapy,Azacitidine,Consolidation,339.0,Alive,788.0,Alive,False,False,,0,0.0,70,64.6,3.5,0.9,17.7,0.0,13.3,0.0,184,77.0,2.8,0.72,,37.0,12.6,"46,XX[20]",,94.4,Normal,138.0,"CD13, CD33, partial CD34, partial CD38, dim partial  CD64, CD117 and CD123 positive",5.7,16.95,False,False,,negative,positive,,,,,,,,,,,,,,negative,,,,,,,p.R882C; MAF 39%,,,,,,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,p.E76Q; MAF 41%,,,negative,,,,,,,,,,,negative,,,negative,,0.6175309256912832,High
15-00491,2172,Male,Male,White,1,n,83.0,False,False,False,Unknown,False,False,y,Prostate Cancer,y,y,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,83.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,50.0,Dead-Unknown,False,False,,0,,,,,,,,,,,,,,,,,,,,,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.28534572313795903,Low
15-00525,2192,Female,Female,Black,1,n,36.0,False,True,False,PML-RARA,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,36.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Other,2,"ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)",2,Induction|Experimental,Complete Response,Standard Chemotherapy,27.0,Targeted Therapy - Other,"ATRA, Arsenic Trioxide",Experimental,-1.0,Alive,283.0,Alive,False,False,,2,0.0,90,69.14,0.0,28.8,1.8,1.8,0.9,0.4,37,27.0,3.9,0.76,M3,26.3,8.2,"46,XX,der(15)t(15;17)(q22;q21),der(17)t(15;17)del(17)(q21)[15]/46,XX[1]",605.0,89.2,95% of cells had a variant abnormal signal pattern with PML/RARA fusion.  PML (15q22) (SO) / RARA (17q21) (SG) t(15;17),25.0,"Immunophenotype: CD13, CD33, partial CD34, CD64, CD117, CD123 and MPO positive",7.5,103.66,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-1.3327053606778643,Low
15-00534,2195,Male,Male,White,5,n,87.0,False,False,True,None,False,False,n,,y,n,n,n,n,n,y,y,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,87.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,2,AG-120|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Experimental,,,,Targeted Therapy - Other,AG-120,Experimental,-1.0,Dead,249.0,Dead-Disease,False,False,,1,,60,39,,,,2.0,,,,,,,,,,"47,XY,+21[3]/46,XY[9]",,,9.5% gain 21q22,43.0,"A distinct blastic population, expressing CD7, CD13, CD15, CD33, CD34, CD38, dim CD45, CD64, MPO, and HLA-DR",,139.9,False,False,,negative,negative,,p.G642fs; MAF 31.6%,,,,,,,,,,,,p.A66fs; MAF 37.3%,,,,,,,,,,,,,,,p.R132C; MAF 48.7%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.N107D; MAF 97.6%,,,,,-1.0449418453584916,Low
15-00539,2196,Female,Female,White,2,n,72.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,73.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Other,4,"Lenalidomide|Azacitidine|Decitabine|Clofarabine, Cytarabine",2,Hypomethylating/Low Dose Cytarabine|Maintenance,,,,Other,"Clofarabine, Cytarabine",Hypomethylating/Low Dose Cytarabine,-1.0,Dead,465.0,Dead-Disease,False,False,,-79,0.0,,25,0.0,,2.0,54.0,18.0,,41,34.0,3.6,0.58,,27.5,8.8,"46,XX,+1,der(1;21)(q10;q10)[6]/46,XX[14]",,,"nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200]",,,6.2,58.2,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PB,,PB,,,,,,,,,,,,,,0.7995390404419618,High
15-00556,2202,Male,Male,White,1,n,10.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,IntermediateOrAdverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,10.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Intrathecal|Other,3,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|MiDAC",2,Induction|Re-induction,Refractory,Intrathecal,10.0,Standard Chemotherapy,MiDAC,Re-induction,31.0,Alive,75.0,Alive,False,False,,1,0.0,75,86,0.0,0.0,7.5,1.8,4.7,0.1,13,23.0,3.6,0.47,,21.6,6.9,"46,XY[20]",970.0,96.0,,42.0,"variable CD7, dim CD11b, CD13, CD33, partial CD34, dim CD64, CD117, CD123, HLA-DR, and dim MPO positive",7.8,133.63,False,False,,positive,negative,,,,,,,,,,,,,,p.R142fs*19; MAF 52%,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,1.0449043769058406,High
15-00559,2205,Female,Female,HispNative,5,n,42.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,42.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,3,"7+3 (Cytarabine, Idarubicin)|AG-221|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",3,Salvage|Induction|Experimental,Refractory,Standard Chemotherapy,-1.0,Targeted Therapy - Other,AG-221,Experimental,-1.0,Dead,448.0,Dead-Unknown,True,False,15-00560,0,,50,51,,,,,,,,,,,,,,"46,XX[20]",,,Normal,256.0,"positive for CD13, CD34, CD38, dim CD45, CD117, HLA-DR, and MPO",,10.7,True,False,15-00560,negative,negative,,p.G652S; MAF 41.3%,,,,,,,,,,,,negative,,,,,,,p.S307fs; MAF 45.6%,,,,,negative,,,c.C315T; p.G105G; MAF 46.6%,p.R140Q; MAF 43.8%,,,negative,,,negative,,,,,negative,,,,,,,,,,,,,,,,,,,p.P95H; MAF 42.2%,,,,,,,,,,,0.5209422088933908,High
15-00563,2204,Female,Female,White,1,n,2.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,MLL-MLLT4,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,2.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide",3,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,136.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1.0,Alive,428.0,Alive,False,False,,0,0.0,80,52.2,0.0,1.8,46.0,0.0,0.0,0.2,22,53.0,,0.24,M1,22.0,6.9,"46,XX,t(6;11)(q27;q23)[19]/46,XX[1]",,92.8,,40.0,"CD4, CD11b, variable CD13, CD15, CD33, variable CD56, CD58, CD64, lysozyme, and dim HLA-DR positive",,57.08,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.1850976377560627,Low
15-00572,2213,Male,Male,White,3,n,61.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,61.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,-1.0,Alive,36.0,Alive,True,True,15-00571,0,,84,91,,,,,,,,,,,M2,,,"46,XY[20]",,,Normal,,"partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)",,25.0,False,False,,negative,negative,,p.Glu635Argfs*15; MAF 9%,,,,,,,,,,,,,,,,p.Tyr779*; MAF 5.4%,,,,,,,,,,,,p.Arg140Gln; 37.7%,,,,,,,,,,,,,,,,,,,p.Arg319*; MAF 88.6%,,,,,,p.Arg166Gln; MAF 35.3%,,,p.Arg790Gln; 9.2%,,,,,,,,,,p.Gln157Pro; MAF 51.3%,,,-0.1416674586261346,Low
15-00578,2214,Female,Female,White,1,n,62.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,MLL-Other,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Other,4,"3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Child,Complete Response,Standard Chemotherapy,7.0,Bone Marrow Transplant,"Fludarabine, Melphalan, TBI, ATG",Allogeneic - Child,-1.0,Alive,27.0,Alive,False,False,,0,0.0,95,67.25,0.0,0.0,9.5,23.3,0.0,0.1,54,57.0,3.3,0.78,M5,27.4,9.1,"46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2]",861.0,93.2,"MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia",26.0,"CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR",6.8,87.72,False,False,,negative,negative,,p.R693*; MAF 19%,,,p.S209L (possibly a benign germline polymorphism); MAF 48%,,,,,,,,,negative,,,,,,,negative,,,,,p.I836delI (in-frame deletion of one amino acid in TK domain); MAF 11%;negative,,,negative,negative,,,negative,,,negative,negative,,negative,,,,,,,p.G12S; MAF 19%,,,,,,,,,,,,,,,,,,,,negative,,,,,-1.0826617916583612,Low
15-00593,2225,Female,Female,White,3,n,71.0,False,False,False,None,False,False,y,Follicular lymphoma,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,71.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone",4,Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,-1.0,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1.0,Dead,280.0,Dead-Disease,False,False,,-1,,82,66,,,,,,,,,,,,,,"46,XX,del(7)(q22q36)[20]",,,"ABNORMAL FISH RESULT 7cen (D7Z1), 7q31 (D7S486): deletion present",,"CD7, CD13, weak CD33, CD34, CD117, and HLA-DR",,133.7,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,c.1138delinsAA; MAF 31.2%,,0.7347962656269624,High
15-00595,2226,Male,Male,White,2,n,55.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,Intermediate,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,55.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,8.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,8.0,Unknown,,,False,False,,0,0.0,91,61,0.0,,46.1,1.7,9.4,,391,343.0,2.8,0.74,M1,22.8,7.1,"92<4n>,XXYY[13]/46,XY[7]",,,"nuc ish(D5S2064,D5S630,EGR1)x3~4[193/200],(D7Z1,D7S522)x3~4[194/200],(D8Z2, D20S108)x3~4[195/200],(RUNX1T1,RUNX1)x3~4[191/200],(ABL1,BCR)x3~4[191/200],(5'MLL,3'MLL)x3~4(5'MLL con 3'MLLx3~4)[193/200],(PML,RARA)x3~4[191/200],(5'CBFB,3'CBFB)x3~4(5’CBFB con 3’CBFBx3~4)[192/200]",34.0,"CD2(-), CD4(partial dim +), CD7(-), CD11b (variably +), CD13(variably +), CD14(predominantly -), CD15(predominantly -/few scattered +), CD16(-), CD20(small subset +), CD33(partial +), CD34(variably +), CD36(small subset +), CD38(variably +), CD45(variably +), CD56(-), CD61 (-), CD64(-), (cont.above)",5.8,9.4,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,p.R132C; MAF unlisted,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.3658112749168975,High
15-00608,2232,Female,Female,White,5,n,61.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,61.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Cyclophosphamide, Fludarabine, TBI|7+3 (Cytarabine, Idarubicin) plus Sorafenib",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Cyclophosphamide, Fludarabine, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Alive,464.0,Alive,True,False,15-00606,1,,40,28,,,,,,,,,,,,,,"46,XX,del(5)(q31q33),der(21)(qter->q22::p11.2->qter),del(21)(q22)[19]",,,"65% Loss 5q31; 14.5% Gain of 8 centromere, trisomy; Trisomy for 21q22  (40.5%), and trisomy for 8q22 and 21q22 (7.0%)",26.0,"positive CD13, CD34, dim CD45, CD117 and HLA-DR",,4.8,True,False,15-00606,negative,negative,,,,,p.1189_1192del; MAF 33.1%,,,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,negative,,,negative,,,,,negative,,,,,p.G12D; MAF 10%,,,,,,,,,,,,,,p.P95H; MAF 34.4%,,,,,,,,,,,1.061306811880755,High
15-00610,2233,Female,Female,White,5,n,42.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,42.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, TBI ",3,Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Refractory,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Alive,505.0,Alive,False,False,,0,,35,2,,,,,,,,,,,,,,"46,XX[20]",,,Normal,35.0,"The immature cells were positive for CD13, CD33, and many showed aberrant expression of CD7. The myeloblast portion was positive for CD34, CD117, and HLA-DR.  The immature monocyte portion was negative for CD34 and CD117, and expressed variable CD64 (including some cells with bright CD64), CD11b, an",,49.7,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,negative,negative,,,negative,,,negative,,,,,negative,,,,,,,,,,,,,,p.L29S; MAF 52.7%,,,,,,,,,,,,,,,,0.4470183754499073,High
15-00614,2234,Male,Male,White,1,n,51.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,51.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,HiDAC|SWOG S1203 (7+3 +/- Vorinostat)|Bu/Cy/TBI,4,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Standard Chemotherapy,6.0,Bone Marrow Transplant,Bu/Cy/TBI,Allogeneic - Mismatched Unrelated Donor,-1.0,Alive,296.0,Alive,False,False,,0,0.0,,,0.0,0.0,85.8,1.9,8.5,0.0,25,25.0,3.0,0.93,M0,25.1,8.2,"60~61<3n>,XYY,-1,-2,-3,-4,-5,del(5)(q13q33),-6,-7,+8,-9,+11,-12,+13,-15,-16,-17,-18,+21,+22[cp15]/70~73,idem,+Y,+1,+2,+5,+del(5)(q13q33),+6,+9,+11,+12,+20,+20[cp4]/46,XY[1]",634.0,81.8,"EGR-1/ D5S23, D5S721: 60/100 cells (60%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the first clone, above; 38 cells (38%) had a 2 red/ 4 green signal pattern, consistent with two copies of the deleted 5q in the second clone.",77.0,,6.5,0.5,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,p.G13D; MAF ~40%,,,,,,,,,,,,,,,,,,,,Splice site (5' splice site mutation in intron 4); MAF 44%,,,,,1.4956145338079545,High
15-00615,2235,Female,Female,Asian,3,n,24.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,24.0,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,6,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)",5,Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1.0,Dead,633.0,Dead-Disease,False,False,,-3,,,,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,,,,False,False,,positive,negative,,,,,,,,,,,,,,p.Gln41fs; MAF 4%,,,,,,,,,,,,,,,,,,,,p.Gln865Glu; MAF 48.9%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.27092566940359575,High
15-00616,2236,Female,Female,White,1,n,68.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1.0,Dead,314.0,Dead-Disease,False,False,,-14,2.6,,49,5.1,6.8,36.8,0.9,14.5,0.2,18,16.0,2.8,0.67,,21.9,7.5,"43-45,XX,del(5)(q16q33),der(7)t(7;12)(q11.1;q12)ins(7;?)(q11.1;?),-12,der(21;22)(q10;q10),+mar[cp20]/46,XX[1]",821.0,88.7,,8.0,"CD13, CD33, CD34, CD71, CD117, dimCD123, HLA-DR, and dim CD 64 positive",7.2,11.01,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.I254N; MAF 40%,,,,,1.9416795944891256,High
15-00626,2239,Male,Male,White,5,n,77.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,77.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Other,3,AG-221|Azacitidine|Decitabine,3,Hypomethylating/Low Dose Cytarabine|Induction|Experimental,Refractory,Standard Chemotherapy,212.0,Targeted Therapy - Other,AG-221,Experimental,-1.0,Dead,38.0,Dead-Disease,False,False,,0,,70,72,,,,,,,,,,,,,,"47,XY,+11[8]/46,XY[12]",,,35% gain of 11q23,174.0,"CD34, CD117, HLA-DR, CD13, and CD33. A subset of the myeloblasts showed aberrant co-expression of CD34 and myeloperoxidase.  A subset of the myeloblasts showed aberrant expression of CD56.",,33.1,False,False,,negative,negative,,p.G642fs; MAF 32.1%,,,,,,,,,,,,p.K90fs; MAF 39.1%,,,,,,,,,,p.F246fx; MAF 91.4%,,negative,,,negative,p.R140Q; MAF 49.2%,,,negative,,,negative,,,,,negative,,,,,,,,,,,,,,p.L29S; MAF 52.9%,,,,,,p.D884fs; MAF 89.8%,,,,p.P1723S; MAF 48.4%,,,,,,0.8301120023804255,High
15-00633,2241,Female,Female,White,3,n,52.0,False,False,False,MLLT3-KMT2A,False,False,y,Breast Cancer,y,n,n,n,n,n,n,n,MLL-MLLT3,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,52.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, ATG, Methotrexate",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG, Methotrexate",Allogeneic - Matched Unrelated Donor,-1.0,Alive,544.0,Alive,False,False,,-3,,,,,,,,,,,,,,,,,"46,XX,t(9;11)(p22;q23)[5]",,,11q23 (MLL): rearrangement present,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.Gly13Asp; MAF 38.9%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.41517296193032227,Low
15-00650,2251,Male,Male,White,1,n,85.0,False,False,True,None,False,False,n,,y,n,n,n,y,y,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,85.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Induction,Refractory,Standard Chemotherapy,232.0,Standard Chemotherapy,Azacitidine,Induction,232.0,Dead,80.0,Dead-Unknown,False,False,,0,0.0,36,23.7,0.0,8.7,20.2,27.2,20.2,1.6,24,23.0,3.4,0.88,M4,31.5,9.6,"46,XY,del(12)(p11.2p13)[20]",200.0,95.7,"ETV6: 84% of cells were missing a signal for ETV6 (12p13), consistent with the deletion seen on metaphase analysis. ",46.0,"CD34, CD117, dim CD123, CD33, dim HLA-DR, CD13, and CD58.",7.0,40.53,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.Q61R; MAF 30%,,,,,,,,,,,,,,,,,,,,,,p.S34F ; MAF 50%,,,0.42458806712395786,High
15-00653,2254,Female,Female,White,2,n,52.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",52.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,7.0,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,-1.0,Dead,633.0,Dead-Disease,False,False,,-1,0.0,83,48.6,0.0,,9.4,0.9,40.2,,21,47.0,3.3,0.55,M1,25.3,8.3,"46,XX[20]",,,"nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",48.0,"CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+ and dim +), CD14(-), CD15(+), CD16(-), CD25(-), CD33(slightly bright +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(small subset +), CD64(-), CD117(dim and variably +), CD123(variably +), HLA-DR(+), TdT(-), MPO(+).",6.6,22.1,False,False,,negative,positive,,,,,,,,,,,,,,negative,,,,,,,,,,,,Foundation; A680V; MAF 6%,,,negative,negative,,,,,Foundation; P738fs*2;MAF 31%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Foundation; Q742*; MAF 45%,,,,,,-1.6241669289440972,Low
15-00670,2265,Male,Male,White,1,n,61.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",IntermediateOrAdverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",61.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea",4,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1.0,Alive,276.0,Alive,False,False,,-1,0.0,92,98,0.0,0.8,2.6,0.0,0.0,0.1,35,23.0,3.2,0.86,,19.9,6.8,"46,XY[7]",330.0,106.4,Normal,49.0,"dim CD33, CD34, CD38, dim CD45, CD117, and MPO",8.0,84.96,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,p.R882H; MAF ~50%,,,,,negative,,,p.R132S; MAF ~50%,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,p.P95L; MAF ~40% ,,,,,,negative,,,,,0.5420857395942875,High
15-00674,2269,Female,Female,White,5,n,54.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,54.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin) plus Sorafenib",1,Induction,Complete Response,Standard Chemotherapy,19.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin) plus Sorafenib",Induction,19.0,Dead,36.0,Dead-Other,False,False,,0,,75,,,,,39.0,,,,,,,,,,"50,XX,+8,+10,+12,+21[20]",,,- Gain of chromosome 8 in 55% of cells - Gain of 8q22 (ETO) sequence in 77.8% of cells; 21q22 (AML1) gain in 12% and loss in 77.8% cells,9.0,"CD11b, CD13, CD14 (subset), CD33, CD34 (subset), CD38, CD45, CD64 (subset), HLA-DR and MPO",,37.2,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,p.D146H; MAF 51.6%,,negative,,,negative,negative,,,negative,,,negative,,,,,negative,,,,,,,,,,,,,,p.D171N; MAF 19.8%,,,,,,,,,,,,,,,,0.1968952422299124,High
15-00680,2272,Male,Male,White,1,n,68.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,23.0,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Matched Unrelated Donor,-1.0,Alive,447.0,Alive,False,False,,0,0.9,86,74.8,0.0,0.0,2.6,20.8,0.9,0.2,20,28.0,2.9,1.49,M5,33.0,10.8,"46,XY[20]",1211.0,95.9,Normal,83.0,"Variable CD13, variable CD14, CD33, variable CD64, CD117, CD123, and partial HLA-DR positive",7.2,134.36,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.Q156H; MAF 45%,,,,,,,,,,,,,,,,,,,,,,,,,,p.K666Q; MAF 50%,,,,,,,,,,,,,,-0.22003627698560466,Low
15-00683,2273,Female,Female,White,5,n,83.0,False,False,False,None,False,False,y,Squamous cell carcinoma|Lung Cancer,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,83.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,n,y,n,n,1,Targeted Therapy - Other,1,AG-221,1,Experimental,,,,Targeted Therapy - Other,AG-221,Experimental,-1.0,Unknown,,,False,False,,0,,45,,,,,,,,,,,,,,,"46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.1),del(19)(p13.3)[20]",,,"FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells.",133.0,"positive for CD34, CD117, HLA-DR, and CD13, with aberrant loss of CD33, and with a subset of the blasts showing aberrant co-expression of CD34 and myeloperoxidase",,2.2,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,p.G105G; MAF 50%,p.R140Q; MAF 37.8%,,,negative,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.2698445066795905,High
15-00688,2276,Female,Female,White,1,n,63.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Unknown,Standard Chemotherapy,9.0,Standard Chemotherapy,Decitabine,Induction,9.0,Dead,25.0,Dead-Other,False,False,,0,1.8,41,2.6,0.9,0.0,79.6,0.9,14.2,0.0,21,19.0,2.7,0.98,,27.7,9.4,"45~46,XX,add(1)(q42),del(5)(q31q35),del(6)(q13),del(9)(q13q34),del(17)(p13),i(21)(q10)[cp12]/46~47,idem,+mar[cp6]/46,XX[2]",404.0,88.5,"EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUNX1 (21q22): 77% of cells had three signals fo",6.0,"CD13, dimCD33, CD34, CD38, CD58, partial CD64, CD117, CD123, and HLA-DR positive.",7.6,1.61,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,p.R248Q; MAF 56%,,p.Q157P; MAF 41%,,,-0.35509854239687544,Low
15-00692,2277,Female,Female,White,2,n,72.0,True,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,73.0,0,Post-Chemotherapy|Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1.0,Supportive/Palliative Care,Azacitidine,Hypomethylating/Low Dose Cytarabine,112.0,Dead,565.0,Dead-Disease,True,False,15-00690,0,0.0,81,43,0.0,,51.0,3.0,2.0,,11,16.0,4.5,0.99,M0,28.2,9.6,"46,XX,der(3)t(3;17)(q29;q21)[19]/46,XX,t(3;21)(q26.2;q22)[2]",,,"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1, D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",10.0,"CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD19 (-/few dim +), CD25(-), CD33(partial +), CD34(partial +), CD36(-), CD38(bright and variably +), CD45(+), CD56(variably +), CD64(-), CD117(variably +), CD123(-/few +), MPO(+), TdT(-/few dim +)",6.9,35.0,False,False,,negative,negative,,,,,,,,,,,,,,Foundation; M1fs*60; MAF 34%,,,,,,,,,,,,negative,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Foundation; splice site 560-2insA; MAF 44%,,,,,-0.2568507027522988,Low
15-00693,2279,Female,Female,White,1,n,66.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",66.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,4,"Bortezomib|3+7 (Cytarabine, Daunorubicin)|MiDAC|Fludarabine, Cytarabine",4,Allogeneic - Sibling|Consolidation|Induction|Experimental,Refractory,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Fludarabine, Cytarabine",Allogeneic - Sibling,-1.0,Alive,838.0,Alive,False,False,,0,0.0,60,,0.0,0.9,29.8,54.4,1.8,0.5,23,19.0,2.5,0.84,,24.2,7.7,"47,XX,+6[6]/46,XX[19]",453.0,104.8,"IGH/MAF: 74/100 cells (74%) had variant abnormal 0-1 red/ 1-4 green/ 2-7 yellow signal patterns reflecting IGH/MAF fusion. The majority of cells (56%) were 0 red/ 1 green/ 3 yellow. IGH: 68/100 (68%) cells scored had signal patterns consistent with IGH rearrangement and the 14;16 translocation,above",92.0,"dimCD4, CD11b, CD13, dimCD14, CD33, CD56, CD58, CD64, dimCD123 and HLA-DR positive; Minor subset of blasts with immunophenotype: CD13, CD33, CD34, CD58, CD117, dimCD123, HLA-DR and MPO positive.",7.4,14.94,False,False,,positive,negative,,,,,"p.G1659E MAF ~10%,",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.Q61R MAF ~5%,,,,,,,,,"p.P240fs*22; MAF 37%, RUNX1: splice site [at invariant AG (G>A) splice acceptor site at end of Intron 6];  MAF 36% ",,,,,,,,,,,,,,,,0.11186260507089549,High
15-00701,2280,Female,Female,White,1,n,50.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,50.0,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Other,6,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,Other,Hydroxyurea,Hypomethylating/Low Dose Cytarabine,365.0,Dead,302.0,Dead-Unknown,False,False,,-111,0.0,,,0.0,2.6,8.8,17.6,2.6,0.0,,,,,M0,19.8,6.4,"48,XX,+11,+13[19]",,93.4,,31.0,,,206.64,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.1911444088020508,High
15-00702,2281,Female,Female,White,1,n,35.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,35.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,10.0,Standard Chemotherapy,HiDAC,Consolidation,112.0,Alive,188.0,Alive,False,False,,0,1.7,42,29.6,0.9,0.0,40.0,18.3,7.8,0.2,54,23.0,3.5,0.6,,20.3,6.8,"46,XX,inv(16)(p13.3q22)[21]",319.0,102.5,"CBFB:  83/100 cells (83%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and consistent with the inverted  chromosome 16 in the metaphase karyotype.",63.0,"Partial CD2, CD33, CD34, CD38, CD117, CD123, partial HLA-DR, dim MPO and partial TdT positive.",6.7,12.78,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,,,,,negative,,,negative,,,negative,,,,,,,p.Q61P; MAF 15% ,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.23647576813481336,Low
15-00717,2295,Male,Male,White,1,n,61.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6.0,Alive,123.0,Alive,False,False,,0,0.4,68,0,0.1,3.0,17.0,62.6,16.9,0.1,29,17.0,3.7,1.51,M5,27.7,8.9,"46,XY[20]",296.0,104.9,Normal,74.0,"dim CD4, CD11b, partial CD14, CD15, dim CD33, CD38, CD56, CD58, CD64 and HLA-DR positive",8.0,16.84,False,False,,negative,positive,,negative,,,,,,,,,,,,,,,,,,,p.S714C; MAF 35%,,,,,negative,,,negative,negative,,,negative,,,,,,negative,,negative,,,,,p.G13V; MAF 6%,,,,,,p.A72V; MAF 10%,,,,,,,,,,,,,p.Q876*; MAF 6%,negative,,,,,-1.0237718663779156,Low
15-00724,2287,Male,Male,HispNative,3,n,51.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,51.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Allogeneic - Sibling|Consolidation|Induction,Refractory,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1.0,Alive,452.0,Alive,False,False,,0,,51,54,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,"CD13, partial CD15, CD33, CD117,  myeloperoxidase, and partial HLA-DR",,12.0,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,R140Q; MAF 42.3%,,,,,,,,,,,,,,,,,,,,,,c.1508G>A; MAF 15.4%,,,,,,,,,,,,,,,,,,,-1.1624468904534482,Low
15-00734,2293,Female,Female,White,1,n,53.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,53.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,SWOG S1203 (7+3 +/- Vorinostat),1,Induction,Complete Response,Standard Chemotherapy,153.0,Standard Chemotherapy,SWOG S1203 (7+3 +/- Vorinostat),Induction,153.0,Alive,202.0,Alive,False,False,,0,0.0,93,80,0.0,1.7,19.3,20.2,13.2,0.6,47,37.0,3.1,0.79,M5,26.8,8.8,"46,XX[20]",977.0,92.1,Normal,36.0,"Blast immunophenotype: partial CD11b, CD13, CD33, CD38, CD58, partial CD64, partial CD117 and a subset with MPO - Blast/promonocyte immunophenotype: CD11b, CD13, partial CD14, CD15, CD33, CD38, CD58 and CD64",6.0,42.34,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,p.D835Y; MAF: 40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.6388749854389987,Low
15-00755,2304,Male,Male,White,3,n,59.0,True,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59.0,0,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Azacitidine, Sorafenib|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"Azacitidine, Sorafenib",Re-induction,-1.0,Dead,256.0,Dead-Treatment,False,False,,-1,,93.2,47.5,,,,,,,,,,,,,,"46,XY,t(3;4)(p21;q25)[3]/46,XY[17]",,,,,"CD4, CD7, CD11b, CD13,  CD33, partial CD34, CD117, HLA-DR, partial weak TdT and  partial CD64",,42.91,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,c.2251T>C; MAF 36.9% (33.1% on 3/13/15),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.5816032797242876,High
15-00756,2305,Male,Male,White,1,n,36.0,False,True,False,RUNX1-RUNX1T1,False,False,n,,y,n,n,n,n,n,n,n,RUNX1-RUNX1T1,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,36.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Hydroxyurea",2,Consolidation|Induction,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,HiDAC,Consolidation,103.0,Alive,213.0,Alive,False,False,,0,0.0,25,38,0.0,3.4,29.1,2.6,23.9,0.0,32,39.0,2.3,0.7,,21.0,7.5,"45,X,-Y,t(8;2;21)(q22;p21;q22)[20]",,104.5,RUNX1T1/RUNX1: (92%),29.0,"CD13, CD33, partial CD34, CD64, CD19 dim, CD71, CD117 partial, HLA-DR, dim CD123, CD58 and MPO",6.7,24.98,False,False,,negative,negative,,,,,,,,,,p.E369_Y371delinsH; MAF 31%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-2.033597057609823,Low
15-00763,2307,Male,Male,White,3,n,23.0,False,True,False,RUNX1-RUNX1T1,False,False,n,,y,n,n,n,n,n,n,n,RUNX1-RUNX1T1,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,23.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin)|Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)",2,Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)",Allogeneic - Matched Unrelated Donor,-1.0,Alive,466.0,Alive,False,False,,-4,,,,,,,,,,,,,,,,,"46,XY,add(6)(q23),del(7)(q33),t(8;21)(q22;q22)[2]/46,sl,add(17)(p11.1)[5]/46,sdl1,add(16)(p11.2)[2]/46,sdl2,add(3)(q21)[8]/46,sdl3,add(20)(q11.2)[3]",,,62% t(8;21) (RUNX1T1;RUNX1) translocation present,,,,,False,False,,negative,negative,,,,,,,,c.6275_6276delTT; MAF unlisted,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.1318644006203364,Low
15-00766,2310,Male,Male,White,5,n,71.0,False,False,True,None,False,False,y,Non-Hodgkins Lymphoma,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,71.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,Lenalidomide|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,11.0,Dead-Other,False,False,,0,,60,14,,,,7.0,,,,,,,,,,"45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q22)x2,-6,+8,+8,add(8)(p23)x2,",,,"FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells.",17.0,"Flow cytometry was negative for increased myeloblasts. The flow showed a mild increase in   immature monocytic cells, but not to the degree seen in the marrow smears. This is likely   attributable to hemodilution of the sample received for flow cytometry.",,21.6,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,p.G355D; MAF 33.8%,p.P19H; MAF 8.9%,,,,,0.611216418692993,High
15-00767,2311,Male,Male,White,2,n,78.0,False,False,True,None,False,False,n,,y,n,n,n,y,y,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,78.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,347.0,Dead-Disease,False,False,,0,0.2,25,4,1.0,,25.0,10.0,60.0,,22,21.0,4.5,0.82,,47.3,15.3,"46,XY[20]",,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",15.0,"CD2(-), CD7 (-), CD10(-), CD11b(-), CD13(dim +), CD14(-), CD15(+), CD16(-), CD19(-), CD22(partial +), CD33(-), CD34(bright +), CD36 (-), CD38(variably +), CD45(partial dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(partial +), MPO(-) and TdT(+)",7.5,5.79,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.2514494653471284,High
15-00777,2314,Male,Male,White,1,n,68.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68.0,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Leukapheresis,y,y,y,y,y,y,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Induction,Refractory,Standard Chemotherapy,7.0,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,7.0,Dead,122.0,Dead-Unknown,False,False,,-1,0.0,,83,0.0,0.8,8.1,9.8,1.6,0.7,29,137.0,3.3,2.67,M5,35.5,11.4,"46,XY[20]",3615.0,92.4,normal,104.0,"CD11b, partial CD13, partial CD14, CD33, partial CD56, CD58, CD64, subset HLA-DR (20%) and partial MPO positive",6.4,140.18,False,False,,negative,negative,,p.G645fs*12; MAF 52%,,,,,,,,,,,,,,,,,,,,,,,,,,,p.R132L; MAF 47%,,,,,,,,Partial tandem duplication ,,p.G12A; MAF 36%,,,,,,,,,,,,,,,,,,,,,p.P95H; MAF 49%,,,,,,,,,,,-0.07320049018417031,Low
15-00778,2315,Male,Male,White,1,n,62.0,False,False,True,None,False,False,n,,y,n,y,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,Decitabine|Hydroxyurea,2,Induction|Re-induction,Complete Response i,Standard Chemotherapy,-1.0,Standard Chemotherapy,Hydroxyurea,Re-induction,-1.0,Dead,424.0,Dead-Disease,False,False,,0,0.0,21,2.5,1.7,0.0,68.3,1.7,25.0,0.0,22,9.0,3.2,0.81,,20.6,6.8,"46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]",,100.5,EGR1 (73.5%) ;  TP53: (85.5%),174.0,"CD7, CD34, CD117, HLA-DR, CD13, CD33, dim CD123, variable CD15 and subset MPO",5.8,3.74,False,False,,negative,negative,,,,,,,,,negative,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,V617F Mutation (~3% mutant allele burden);p.V617F; MAF 1.5%,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,p.G742D; MAF 35%,,,,,,,,,p.G266V; MAF 55%,,,negative,,0.8988736051168962,High
15-00782,2320,Male,Male,White,2,n,61.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",61.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,-1.0,Unknown,,,False,False,,0,0.0,45,48,2.0,,69.0,4.0,2.0,,12,15.0,3.8,,,22.7,7.6,"46,XY[19]",,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]",27.0,"CD2(-), CD4(-), CD7(subset +), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).",6.8,1.39,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,R132C; MAF 42%,negative,,,,,,,,,,,,,,N935H; MAF 49%,,,,,,,,,,,N260fs*223+; MAF 26%,,,,,P95L; MAF 38%,,,,,,,,,,,0.26849893744964054,High
15-00786,2322,Male,Male,White,1,y,40.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,40.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,HiDAC,Consolidation,5.0,Alive,164.0,Alive,False,False,,0,0.0,80,27.8,0.0,0.0,62.6,4.4,5.2,0.0,26,22.0,3.9,0.78,,37.6,13.2,"46,XY[20]",,91.7,normal,66.0,"dim CD7, CD13, CD33, CD34, CD38, partial CD56 (25%), CD58, dim CD64, CD117, dim CD123, HLA-DR, and MPO+.",7.4,2.68,False,False,,negative,negative,,,,,,,,,,,,,,p.S28fs*81; MAF 28%,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.R378W; VAF 100%,-1.4125966337884261,Low
15-00807,2333,Female,Female,HispNative,1,n,14.0,False,True,False,RUNX1-RUNX1T1,False,False,n,,y,n,n,n,n,n,n,n,RUNX1-RUNX1T1,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,14.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Busulfan, Cyclophosphamide",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,189.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1.0,Alive,252.0,Alive,False,False,,-3,,,,,,,,,,,,,,,,,"46,XX,t(8;21)(q21.3;q22)[17]/49,sl,+4,+15,+der(21)t(8;21)[2]/53,sdl,-4,+13,+18,+19,+20,+21[4]",,,"All twenty-three metaphase cells examined were abnormal, with t(8;21), leading to RUNX1/RUNX1T1 fusion.   Two subclones, comprising 6 cells total, had an additional copy of the der(21).",,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,p.G79S; MAF 50%,,,,,,,,,,,p.D816Y; MAF 45%,,,,,,,,,,p.G12D; MAF 45%,,,,,,,,,,,,,,,,,,,,,,,,,-1.2705340321243714,Low
15-00811,2337,Male,Male,White,1,n,53.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,54.0,7,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea",4,Induction|Experimental|Re-induction|Maintenance,Unknown,Standard Chemotherapy,6.0,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1.0,Dead,168.0,Dead-Disease,True,False,15-00799,-7,0.0,,,1.7,0.9,6.1,8.8,43.0,0.4,38,29.0,3.4,0.71,,27.0,9.1,"46,XY,add(3)(p24)[cp4]/46,XY[14]",321.0,95.1,normal,170.0,,6.7,16.65,False,False,,positive,positive,,,,,,,,,,p.I423N; MAF <0.5%,,,,,,,,,,,p.R882C; MAF 0.9%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.Q548*; MAF 0.7%,,,,,,1.8781367245935725,High
15-00813,2339,Female,Female,White,1,n,53.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",53.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,4.0,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,7.0,Alive,119.0,Alive,False,False,,1,0.0,45,50,0.0,19.4,6.4,1.6,11.3,0.0,73,83.0,3.3,0.88,,29.4,9.6,"46,XX[20]",2008.0,109.3,Normal,33.0,"partial CD7, CD13, CD33, CD34, variable CD38, CD117, CD123, partial HLA-DR and dim MPO",6.8,137.54,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,p.R882H; MAF 45%,,,,,p.D835Y; MAF 3%,,,,,,,,,,,Partial Tandem Duplication,,,,,,,,,p.G13D; MAF 35%,,,,,,,,,,,,,,,,,,,,,,,,,0.39071140844839236,High
15-00819,2342,Male,Male,White,1,n,64.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,64.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Intrathecal,4,"7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|Cytarabine, Methotrexate",3,Consolidation|Induction|CNS,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,MiDAC,Consolidation,82.0,Alive,197.0,Alive,False,False,,0,0.9,90,25.2,4.3,0.9,9.6,44.3,13.9,0.1,31,45.0,2.6,0.79,M5,22.7,7.7,"46,XY,inv(16)(p13q22)[20]",1151.0,93.8,CBFB,10.0,"dim CD2, variable CD5, CD13, CD33, CD34, CD38, variable CD64, CD117, dim CD123, HLA-DR, and MPO",5.5,24.64,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,p.D816V; MAF 45% ,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,,,-1.6480748020103946,Low
15-00821,2343,Male,Male,White,1,n,66.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,66.0,0,Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1.0,Dead,231.0,Dead-Disease,False,False,,-20,0.8,0,0,0.0,2.0,18.6,9.3,69.3,0.0,,,,,,32.1,10.2,"46,XY[20]",,94.7,Normal,345.0,The analysis was performed by flow cytometry on the bone marrow aspiratespecimen. The analysis shows CD34+ blasts account for 1% of CD45+ events. Maturing myeloid precursors and monocytic cells demonstrate a normal pattern of myelomonocytic antigen expression.,,8.94,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.6561753179480571,Low
15-00829,2001,Female,Male,Black,2,n,67.0,False,False,False,None,False,False,y,Not specified,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,68.0,254,Post-Chemotherapy|Post-DLI|Post-Transplant|Residual Disease,Peripheral Blood,y,y,y,y,y,y,4,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,4,"AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea",3,Salvage|Experimental|Supportive/Palliative Care,,,,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1.0,Dead,449.0,Dead-Disease,True,False,15-00797,-17,,,,,,,,,,18,25.0,4.1,,,20.4,6.8,"47,XX,+11[5]/48,idem,+19[15]",,,"nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]",24.0,,7.4,27.5,True,False,15-00797,positive,negative,,,,,,,,,,,,,p.Y325*; MAF 52%,,,,,,,,,,,,,negative,,,p.R132G; MAF 51%,negative,,,,,,,MLL-PTD (exons 2-10),,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.R283C; MAF 49%,,,,,0.37975280372047443,High
15-00837,2350,Male,Male,White,3,n,72.0,False,False,True,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,y,y,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,72.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,Azacitidine|Momelotinib,2,Hypomethylating/Low Dose Cytarabine|Experimental,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,188.0,Dead-Disease,False,False,,-141,,,58,,,,,,,,,,,,,,"46,XY,inv(16)(p13.1q22)[20]",,,,,,,8.21,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.8346520481637391,High
15-00839,2347,Male,Male,White,1,n,48.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,48.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"ADE (Cytarabine, Daunorubicin & Etoposide)",1,Induction,Unknown,Standard Chemotherapy,7.0,Standard Chemotherapy,"ADE (Cytarabine, Daunorubicin & Etoposide)",Induction,7.0,Dead,33.0,Dead-Disease,False,False,,0,0.2,13,,0.0,0.5,10.2,4.4,84.7,0.0,84,28.0,3.9,0.95,,42.1,14.0,"46,XY[20]",231.0,89.2,Normal,330.0,"CD33, CD117 positive, negative for CD34 and HLA-DR",8.2,6.3,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.R140Q; MAF 40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.3040797179564064,Low
15-00850,2357,Male,Male,White,5,n,62.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,62.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,-1.0,Unknown,,,False,False,,1,,50,20,,,,,,,,,,,,,,"46,XY,inv(16)(p13.1q22)[20]",,,positive for rearrangement of CBFB in 60.5% of cells.,32.0,"positive for CD13, CD33, HLA-DR, CD34, and CD117, with partial aberrant expression of CD7.",,52.8,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,p.D146H; MAF 50%,,negative,,,negative,negative,,,negative,,,negative,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,-1.0371487441577552,Low
15-00855,2360,Male,Male,HispNative,1,n,8.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid leukaemia associated with Down syndrome,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid leukaemia associated with Down syndrome,8.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Intrathecal,2,"ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine",2,Induction|CNS,Complete Response,Standard Chemotherapy,151.0,Intrathecal,Cytarabine,CNS,151.0,Alive,172.0,Alive,False,False,,-2,10.8,,,0.0,1.8,8.1,13.5,8.1,0.0,13,25.0,3.2,0.72,,26.8,9.3,"47,XY,+21c[20]",,90.5,RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis.,40.0,,8.2,67.53,False,False,,negative,positive,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-1.6887218066055236,Low
15-00858,2362,Female,Female,White,1,n,76.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,76.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"5+2 (Cytarabine, Idarubicin)|Decitabine",2,Induction|Re-induction,Refractory,Standard Chemotherapy,8.0,Standard Chemotherapy,"5+2 (Cytarabine, Idarubicin)",Re-induction,4.0,Dead,26.0,Dead-Disease,False,False,,0,0.0,95,0,0.0,0.9,16.8,3.5,24.8,1.1,23,22.0,3.5,1.33,,31.5,10.3,"46,XX[22]",244.0,92.6,Normal,29.0,"dimCD13, CD33, CD45, CD56, dimCD117 and MPO positive",7.0,27.17,False,False,,positive,positive,,p.G966delG; MAF 50%,,,,,,,,,,,,negative,,,,,,,p.R736H; MAF 45%,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.5121564035652533,Low
15-00864,2337,Male,Male,White,1,n,53.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,54.0,30,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea",4,Induction|Experimental|Re-induction|Maintenance,Unknown,Standard Chemotherapy,6.0,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1.0,Dead,168.0,Dead-Disease,True,False,15-00863;15-00860;15-00799,0,0.0,8,1,4.7,0.9,40.6,10.4,43.4,0.0,40,34.0,3.8,0.73,,20.2,7.1,"46,XY[12]",235.0,93.5,normal,17.0,"dim variable CD7, dim CD11b, CD13, CD33, CD34, CD58, CD117, and CD123",6.8,1.06,True,True,15-00811;15-00863,positive,positive,,,,,,,,,,p.I423N; MAF <0.5%,,,,,,,,,,,"p.R882C, MAF 6%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p.Q548*, MAF 6%",,,,,,1.2676610473658494,High
15-00870,2364,Male,Male,White,6,n,71.0,False,False,True,None,False,False,y,Non-Hodgkins Lymphoma,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71.0,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,Vidaza|Rituximab|Decitabine,2,Consolidation|Maintenance,,,,Standard Chemotherapy,Decitabine,Maintenance,86.0,Dead,51.0,Dead-Disease,False,False,,0,,20,10,1.0,,22.0,48.0,16.0,,6,33.0,3.7,1.57,,26.0,8.1,"46,XY[20]",,91.9,,13.0,"Positive for CD34, CD117, HLADR, CD33, CD13 but negative for CD14, CD64, CD11b, CD19, and CD3",7.0,44.8,False,False,,negative,negative,,,,,p.A603pfs*66; MAF55%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.G12V; MAF 49%,,,,,,,,,,,,,,,,pR320*; MAF 47%,,,,,p.P95H; MAF 49%,p.Y636*; MAF 96%,,,,,,,,,,0.2583876542770156,High
15-00872,2367,Female,Female,White,1,n,65.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Other,4,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea",4,Consolidation|Unknown|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1.0,Alive,181.0,Alive,False,False,,0,0.0,74,60,1.9,15.1,21.7,50.0,11.3,0.0,23,32.0,2.6,0.78,,21.6,7.2,"46,XX[20]",905.0,100.5,Normal,150.0,"partial variable CD7, subset CD11b (75%), CD13, CD33, partial CD14 (30%), partial CD64 (70%), CD38, CD58, partial CD117 (30%), CD123, HLA-DR, and partial (50%) MPO positive",6.7,84.69,False,False,,positive,positive,,,,,,,,,,,,,,p.K298Q; MAF 25%,,,,,,,p.R882C; MAF 44%,,,,,,,,,p.R140Q; MAF 18%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.3491436219647384,Low
15-00874,1973,Male,Male,White,1,n,70.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,71.0,281,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",3,Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6.0,Supportive/Palliative Care,Decitabine,Hypomethylating/Low Dose Cytarabine,-1.0,Alive,523.0,Alive,False,False,,0,0.0,90,90,0.0,0.0,27.8,2.9,8.6,0.4,81,43.0,3.3,,,31.9,10.2,"47,XY,+4[2]/46,XY[18]",235.0,94.7,"Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.",91.0,"partial CD7 (~35%), CD13, partial dim CD33, CD34, CD38, variable CD56, and CD117",6.6,73.42,False,False,,negative,negative,,p.Q588*; MAF 49%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.9512676317209938,High
15-00883,2416,Female,Female,White,1,n,72.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,"7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib",2,Induction|Experimental,Refractory,Standard Chemotherapy,10.0,Targeted Therapy - Kinase Inhibitor(s),Ponatinib,Experimental,15.0,Dead,118.0,Dead-Disease,False,False,,0,0.9,90,78,0.0,0.0,2.7,3.6,17.3,1.4,28,23.0,2.8,0.56,,31.7,9.9,"46,XX[20]",261.0,98.1,Normal,211.0,"CD13, CD33, CD38, partial CD56, partialCD64, CD117, dimCD123, and MPO",6.5,24.01,True,False,15-00884,positive,positive,,,,,,,,,,,,,,p.E163*; MAF 39%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.7493928056100781,High
15-00892,2421,Female,Female,White,3,n,72.0,False,True,False,Unknown,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Targeted Therapy - Other,1,SGN-CD33A,1,Experimental,,,,Targeted Therapy - Other,SGN-CD33A,Experimental,-1.0,Dead,179.0,Dead-Disease,False,False,,0,,,,,,,,,,,,,,,,,,,,Normal,,,,,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,c.2645G>A; MAF 45.4%,,,,,c.2503G>T (D835Y); MAF 15.5%,,,,,,,,,,,,,,,,,,,,,,,,,,c.178G>C; MAF 8.4%,,,,,,,,,,,,,c.3955-2A>G; MAF 45.4%,,,,,,-0.9427087071548929,Low
15-00900,2420,Male,Male,White,1,n,24.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,24.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Decitabine|Busulfan, Cyclophosphamide",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Standard Chemotherapy,7.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Mismatched Unrelated Donor,-1.0,Alive,187.0,Alive,False,False,,0,0.0,,,1.8,0.9,23.9,23.0,7.9,0.0,37,28.0,3.7,0.95,,32.3,11.3,"46,XY[20]",243.0,92.8,Normal,102.0,,7.1,21.84,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.G12C; MAF 40%,,,,,,,,,,,,,,,,,,,,,,,,,0.8257738021431791,High
15-00903,2423,Male,Female;Male,White,3,n,73.0,False,False,False,None,False,False,y,Lung Cancer,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,73.0,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,7.0,Dead,36.0,Dead-Disease,False,False,,-24,,,79,,,,,,,,,,,,,,"45,X,-Y[20]",,,Normal,,,,19.64,False,False,,negative,negative,,c.1940dup; MAF 37.9%,,,,c.3496dup: MAF 7.5%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,c.319C>G; MAF 73.9%,,,,,,,,,,c.3803+1G>A; MAF 39.3%,,,,,,0.2147272295945382,High
15-00909,2425,Female,Female,Black,6,n,44.0,False,False,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,47.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Targeted Therapy - Other,1,Radiation,1,Unknown,,,,Targeted Therapy - Other,Radiation,Unknown,14.0,Unknown,,,True,False,15-00910,0,,90,45,0.0,,28.0,5.0,1.0,,30,41.0,3.3,0.82,,29.3,9.6,"46,XX[20]",,89.9,This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small precentage of tumor cells with chromosome abnormalities may not be detected due to the cells examined.,5.0,"The blasts are positive for HLA-DR, CD34, CD117 (PARTIAL), CD13, CD(PARTIAL/DIM), CD33, TDT (DIM, SUBSET) and are negative for CD11b, CD14, CD64, MPO and all B and T cell markers.",7.3,6.5,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.3641316928041234,High
15-00912,2426,Female,Female,White,6,n,76.0,False,False,False,None,False,False,y,Breast Cancer,y,y,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,77.0,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Unknown,1,Azacitidine,1,Unknown,,,,Unknown,Azacitidine,Unknown,424.0,Dead,151.0,Dead-Unknown,False,False,,0,,86,50,1.0,,14.0,5.0,20.0,,32,20.0,2.9,0.62,,24.3,7.8,"48-51,XX,del(4)(q25),del(5)(q11.2),-17,-18,+22,+3-5mar[20]",,84.1,,27.0,"POSITIVE FOR DIM CD45, HLADR, CD34, CD117, CD13, CD33, CD43, CD81, CD58.",5.4,14.3,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.07340401817207945,Low
15-00921,2429,Female,Female,White,1,n,74.0,False,False,False,None,False,False,y,Not specified,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Unknown,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",74.0,0,Post-Chemotherapy,Peripheral Blood,y,n,n,y,n,n,1,Standard Chemotherapy,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|MiDAC",2,Consolidation|Induction,Refractory,Standard Chemotherapy,8.0,Standard Chemotherapy,MiDAC,Consolidation,3.0,Alive,151.0,Alive,False,False,,-105,0.9,,,1.9,0.2,27.7,3.5,65.8,0.0,30,36.0,4.3,0.8,,38.7,13.0,"46,XX[20]",,102.9,normal,206.0,,7.3,4.26,False,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.8239205152734603,Low
15-00929,2433,Female,Female,White,3,n,50.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,50.0,0,Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|MiDAC",4,Consolidation|Induction|Re-induction|Maintenance,Refractory,Standard Chemotherapy,-1.0,Standard Chemotherapy,Azacitidine,Maintenance,8.0,Dead,425.0,Dead-Treatment,True,False,15-00930,-1,,,,,,,,,,,,,,,,,"46,XX[20]",,,"""showed multiple RUNX1 signals as well as a 3rd RUNX1 signal at 7p consistent with t(7;21)(p22;q22).""",,,,10.08,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.4021701730949994,Low
15-00936,2337,Male,Male,White,1,n,53.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,54.0,63,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea",4,Induction|Experimental|Re-induction|Maintenance,Unknown,Standard Chemotherapy,6.0,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1.0,Dead,168.0,Dead-Disease,True,False,15-00938;15-00799,2,1.8,,,3.6,6.2,23.2,18.7,17.0,1.3,29,41.0,3.6,1.0,,20.9,6.9,"46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]",,96.3,normal,21.0,,6.8,20.77,True,False,15-00938,positive,positive,,,,,,,,,,,,,,,,,,,,,p.R882C; MAF 45%,,,,,p.D835H; MAF 15%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.Q548*; MAF 45%,,,,,,1.6490456224844654,High
15-00939,2314,Male,Male,White,1,n,68.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68.0,72,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Induction,Refractory,Standard Chemotherapy,7.0,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,7.0,Dead,122.0,Dead-Unknown,True,True,15-00777,-39,0.8,,,0.9,0.0,9.3,0.0,0.0,0.5,12,14.0,2.5,0.9,,20.6,6.4,"46,XY[19]",,90.4,normal,60.0,,6.3,6.21,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.8827167689266241,High
15-00961,2444,Female,Female,White,1,n,52.0,False,True,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,52.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,8.0,Standard Chemotherapy,HiDAC,Consolidation,81.0,Alive,181.0,Alive,False,False,,0,0.0,,,30.0,13.0,9.0,21.0,19.0,0.1,54,50.0,2.2,0.84,,18.8,6.5,,,98.9,,21.0,,6.5,65.58,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.K2181R ; MAF 50%,,,,,,,,,,,,,,,p.P95H ; MAF 50%,,,,,,,,,,,-1.212873128988934,Low
15-00965,2447,Female,Female,White,1,n,61.0,False,True,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC",4,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1.0,Alive,187.0,Alive,False,False,,0,0.0,,,0.0,0.0,89.9,9.3,0.8,0.0,43,31.0,2.4,0.5,,19.5,6.5,,313.0,92.4,normal,32.0,,5.8,67.36,False,False,,negative,positive,,,,,,,,,,,,,,,,,p.R2353Q; MAF 51%,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.Q270*; MAF 90%,,,,,,-1.643473033631996,Low
15-00967,2416,Female,Female,White,1,n,72.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72.0,40,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,"7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib",2,Induction|Experimental,Refractory,Standard Chemotherapy,10.0,Targeted Therapy - Kinase Inhibitor(s),Ponatinib,Experimental,15.0,Dead,118.0,Dead-Disease,True,False,15-00933,-15,0.0,70,3.56,0.0,1.8,34.8,3.6,0.9,23.2,13,40.0,3.2,0.55,,22.7,7.5,"46,XX[5]",339.0,89.7,Normal,32.0,"CD13+, CD33+, CD38+, variable partial CD56+, partial CD64+, CD117+, dimCD123+, and MPO+",6.4,6.04,True,False,15-00933,positive,positive,,,,,,,,,,,,,,p.E163*; MAF 40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.5695266209472618,Low
15-00974,1745,Female,Female,White,1,n,36.0,False,False,False,GATA2-MECOM,False,False,n,,y,n,n,n,n,n,n,n,EVI1_F,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,38.0,494,Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant,Peripheral Blood,y,y,y,y,y,y,3,DLI|Standard Chemotherapy|Bone Marrow Transplant,7,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide",5,Hypomethylating/Low Dose Cytarabine|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,4.0,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,4.0,Dead,533.0,Dead-Disease,False,False,,-11,0.0,,,0.9,0.0,13.9,0.0,0.9,0.4,59,28.0,2.8,,,32.6,10.3,"46,XX,inv(3)(q21q26)[5]",,99.4,FISH) was performed with a MECOM/RPN1 probe set. 125/200 (62.5%) interphase cells scored had a 1 red/ 1 green/ 2 yellow double fusion signal pattern reflecting MECOM/RPN1 fusion and the paracentric inversion of the long arm of a chromosome 3 observed in the metaphase karyotype.  FISH was also perfor,38.0,,6.7,7.08,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.960611952750544,High
15-00975,2452,Female,Female,White,6,n,70.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",70.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Induction,Unknown,Standard Chemotherapy,37.0,Standard Chemotherapy,Azacitidine,Induction,37.0,Unknown,,,False,False,,0,,90,17,,,20.0,18.0,2.0,,24,26.0,3.8,0.76,,25.0,8.2,"46,XX,del(5)(q22q35)[20]",,87.7,Positive for 5q deletion in 91% of cells.,35.0,"POSITIVE FOR CD34, HLA-DR, CD117 AND CD33, AND NEGATIVE FOR MPO, TdT, CD13, CD19, CD20 AND CD10.",6.2,7.7,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,PTD,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.S34F; MAF 35%,,,1.1908385906982215,High
15-00976,2453,Male,Male,White,1,n,83.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,83.0,0,Residual Relapse|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,2,"AG-221|Azacitidine, SGN-CD33A",2,Induction|Experimental,Refractory,Standard Chemotherapy,-1.0,Targeted Therapy - Other,AG-221,Experimental,-1.0,Dead,434.0,Dead-Disease,False,False,,0,0.3,12,3,0.0,9.4,26.9,24.5,38.9,0.0,42,47.0,3.2,1.3,,21.1,6.8,"46,XY[20]",,87.9,Normal,213.0,"CD13, CD33, CD34, CD38, dim CD58, CD117, and dim HLA-DR positive",6.0,3.72,False,False,,negative,negative,,,,,,,,,,,,,,,,,p.M2408V; MAF 48%,,,,,,,,,,,,,p.R140Q; MAF 47%,,,,,,,,,,,,,,,,p.G12D; MAF 49%,,,,,,,,,,,,,,,,,,,,,,,,,-0.0577540388273949,Low
15-00979,2455,Female,Female,White,1,n,44.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,44.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6,"Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea|Busulfan, Cyclophosphamide|7+3 (Cytarabine, Idarubicin) plus Dasatinib ",5,Allogeneic - Sibling|Induction|Experimental|Re-induction|Post-Transplant Relapse,Complete Response i,Standard Chemotherapy,28.0,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1.0,Dead,319.0,Dead-Disease,False,False,,0,0.0,75,80,0.0,7.7,10.3,22.2,6.8,0.0,21,25.0,2.4,1.25,,22.9,7.4,"46,XX[20]",705.0,96.2,Normal,42.0,"CD13, CD33, subset CD34, variable CD117, CD123, HLA-DR, and variable MPO positive - Monocytic/blast equivalent immunophenotype: CD11b, CD13, subset CD14, variable CD16, CD33, CD64, dim CD123, and HLA-DR positive",6.2,69.84,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,p.R882H; MAF 48%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.3263077354669754,High
15-00981,2454,Male,Male,White,1,n,75.0,False,False,False,None,False,False,y,Rectal Cancer,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,75.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Supportive/Palliative Care,2,Hydroxyurea|Decitabine,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,4.0,Dead,17.0,Dead-Disease,False,False,,0,0.0,90,90,0.0,0.0,5.1,0.8,0.9,1.0,23,51.0,2.9,0.97,,25.3,8.5,"46,XY[20]",728.0,91.3,Normal,28.0,"CD33, dim CD38, variable CD56, CD58, dim CD64, CD117, CD123, and MPO positive.",6.6,62.87,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.R140Q; MAF 47%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.P95L; MAF 37%,,,,,,,,,,,-1.103033382229828,Low
15-00990,2459,Female,Female,White,1,n,81.0,False,True,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,81.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Azacitidine,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Azacitidine,Supportive/Palliative Care,6.0,Dead,14.0,Dead-Disease,False,False,,0,0.0,90,70,0.0,0.8,6.1,72.2,12.2,0.4,62,50.0,2.9,4.22,M5,22.8,7.3,"46,XX[20]",262.0,90.8,Normal,29.0,"CD11b, variable CD13, variable CD14, CD33, CD56, CD64, dim CD123 and dim HLA-DR positive",5.8,97.26,False,False,,negative,positive,,p.W796fs*22; MAF 48%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.S825fs*1; MAF 49%,,,,,,-0.9889950884659044,Low
16-00001,2460,Female,Female,White,1,n,36.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,36.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|Hydroxyurea",3,Consolidation|Induction|Experimental,Refractory,Standard Chemotherapy,1.0,Standard Chemotherapy,HiDAC,Consolidation,122.0,Alive,209.0,Alive,False,False,,-2,0.0,40,60,1.7,0.0,33.4,5.1,18.8,0.1,38,28.0,3.2,0.53,,22.9,7.6,"46,XX,t(16;16)(p13.2;q22)[20]",508.0,99.6,"CBFB: 191/200 cells (95.5%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement, consistent with the 16;16 translocation observed in the metaphase karyotype.",24.0,"Immunophenotype: CD13, partial CD15, dim CD33, CD34, CD38, dim CD45, CD58, variable CD64, variable CD117, CD123, and dim HLA-DR positive.",7.3,20.44,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.T417_D419delinsY; MAF 33%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.306949886463804,Low
16-00003,2461,Male,Male,White,3,n,26.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,27.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,16.0,Standard Chemotherapy,HiDAC,Consolidation,-1.0,Alive,603.0,Alive,False,False,,-7,,,,,,,,,,,,,,,,,"46,XY[15]",,,Normal,,,,,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.Arg140Gln; MAF 45.9%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.5911919165402308,Low
16-00004,2462,Female,Female,White,1,n,82.0,False,False,False,None,False,False,y,Breast Cancer,y,y,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,82.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,268.0,Dead-Disease,False,False,,0,0.0,50,,0.0,1.8,42.8,0.0,5.4,3.7,13,18.0,2.8,1.03,,27.7,9.2,"46,XX",279.0,91.1,trisomy 8 in 5 of 20 metaphase cells ,44.0,,7.0,1.36,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,p.R882H; MAF 39%,,,,,,p.R191C; MAF 51%,,,p.R172K; MAF 36%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.189539418344709,High
16-00007,2464,Male,Male,White,4,n,77.0,False,False,True,None,False,False,n,,y,n,n,n,y,y,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Azacitidine, Sorafenib|Decitabine, Midostaurin",2,Induction|Re-induction,Refractory,Standard Chemotherapy,165.0,Standard Chemotherapy,"Azacitidine, Sorafenib",Re-induction,-1.0,Alive,217.0,Alive,True,True,16-00006,0,,41,18,,,,,,,,,,,,,,"46,XY[20]",,,"CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)",,"ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56",,2.2,True,True,16-00006,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.799373513285224,High
16-00010,2437,Female,Female,AdmixedBlack,6,n,30.0,False,False,False,MLLT3-KMT2A,False,False,n,,y,n,n,n,n,n,n,n,MLL-MLLT3,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,31.0,25,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response i,Standard Chemotherapy,27.0,Standard Chemotherapy,HiDAC,Consolidation,93.0,Unknown,,,True,False,16-00009;15-00943,0,,79,64,,,2.0,15.0,1.0,,44,53.0,4.0,0.52,,29.5,9.6,"46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[20]",,89.4,"This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on previous sample.",69.0,"POSITIVE FOR CD33, CD11B, CD64, CD4 AND MPO (SUBSET/DIM) AND ARE NEGATIVE FOR CD117, CD13, CD34, HLA-DR AND TDT",7.3,20.3,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.04498873609932161,Low
16-00027,2473,Male,Male,AdmixedWhite,2,n,55.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",55.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI |7+3 (Cytarabine, Idarubicin) plus Crenolanib",4,Consolidation|Induction|Allogeneic - Child|Maintenance,Complete Response,Standard Chemotherapy,7.0,Standard Chemotherapy,Cyclophosphamide,Maintenance,1.0,Alive,393.0,Alive,False,False,,0,0.0,91,99.2,0.0,,0.8,0.0,0.0,,33,27.0,3.0,0.85,,18.8,6.2,"46,XY[29]",808.0,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",28.0,"CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(dim +), CD14(-), CD15(-/few dim +), CD16(-), CD33(+), CD34 (partial +), CD36(equivocal/small subset appears +), CD38(partial +), CD45(+), CD56(-), CD64(-/few dim +), CD117(+), HLA-DR(+ and variable), TDT(-), MPO(+)",6.1,181.08,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,R132H; MAF 47.0%,negative,,,,,,,Foundation; MLL-PTD Exons 2-8; not GeneTrails,,,,,,,,,,,,,,,,,,,,,,,,,,,,SPLICE SITE 3500+1G>A; MAF 48.0%,,,,,,1.2012463612699966,High
16-00031,2477,Male,Male,White,6,n,50.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",50.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Allogeneic - Sibling|Induction|Re-induction,Unknown,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,97.0,Alive,576.0,Alive,True,False,16-00030,0,,75,73,,,6.0,6.0,8.0,,44,20.0,3.5,1.0,,24.8,8.0,"46,XY[20]",,91.5,Not Available (no FISH done),26.0,"These are postive for CD34, CD117, HLADR, CD13 and CD33. These are negative for CD3, CD20, CD4, CD11b.",5.8,17.1,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.1230728120816609,High
16-00048,2483,Female,Female,Asian,1,n,46.0,False,False,False,None,False,False,y,Anaplastic Astrocytoma,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,46.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,7,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG",4,Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Refractory,Standard Chemotherapy,1.0,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Dead,637.0,Dead-Disease,False,False,,0,0.9,25,26.7,1.7,4.3,6.1,32.2,48.7,0.2,14,15.0,3.1,0.64,,32.0,9.5,"46,XX,del(3)(p25),add(6)(p22),t(10;12)(p15;q13)[5]/46,XX[18]",440.0,80.6,Normal,92.0,"Immunophenotype: CD13, CD34, CD38, CD58, CD117, CD123, HLA-DR and TdT-positive; small subset of blasts also express CD19, CD22, and CD79a",6.8,42.57,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,p.I824V; VAF 50%,,,,,,p.S412R; MAF 60%,,,,,,,,,,,,,,,,,,,p.G13R; MAF 50%,,,,,,,,,p.T196I ; MAF 50%,,,,,,,,,,,,,p.I24T; MAF 5%,,,0.3781325654225781,High
16-00050,2485,Female,Female,White,1,n,77.0,False,False,False,Unknown,False,False,y,Breast Cancer,y,y,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,77.0,0,Residual Disease,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,253.0,Dead,341.0,Dead-Unknown,False,False,,0,0.8,,,2.5,0.0,15.8,0.0,70.9,0.0,62,28.0,3.3,1.01,,24.2,7.9,,241.0,87.7,"EGR-1/ D5S23, D5S721: 58/200 cells (29%) had a 1 red/ 2 green signal pattern, consistent with a deleted 5q. D7S522/CEP 7: 38/200 cells (19%) had a 1 red/ 2 green signal pattern, consistent with a deleted 7q. CBFB: 40/200 cells (20%) had a single signal indicating deleted 16q22. TP53/CEP 17: 12/200 c",16.0,,8.0,8.29,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,p.E285D; MAF 40% ,,,,,,,,,,,,,,p.Y215fs*2; MAF 40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.V272_R273insL; MAF 75% (previously 71% in 4/21/15 peripheral blood),,,,,1.655707003890362,High
16-00056,2490,Female,Female,White,1,n,51.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,51.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"HiDAC|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,2.0,Standard Chemotherapy,HiDAC,Consolidation,-1.0,Alive,201.0,Alive,False,False,,0,0.0,95,95,0.0,0.0,7.8,0.0,3.1,0.1,22,12.0,2.9,0.93,,20.6,6.6,"46,XX[20]",189.0,112.6,Normal,57.0,"Immunophenotype: CD7, CD13, CD33, CD38, CD117, CD123 and MPO positive",6.5,25.02,False,False,,negative,positive,,,,,,,,,,p.R420Q; MAF ~20%,,,,,,,,,,,,,,,,p.N841K; MAF ~30%,,,,p.R140Q; MAF ~30%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.1687885119164745,Low
16-00067,2496,Female,Female,HispNative,2,n,53.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,53.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI ",4,Consolidation|Induction|Allogeneic - Child|Maintenance,Complete Response,Standard Chemotherapy,-1.0,Supportive/Palliative Care,Cyclophosphamide,Maintenance,1.0,Alive,517.0,Alive,False,False,,-1,0.0,20,8,0.0,,37.0,20.0,30.0,,18,23.0,3.3,0.86,,20.0,6.2,"46,XX[20]",426.0,105.3,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",38.0,"CD34(+), CD13(dim +), CD15(partial +), CD33(dim to partial +), CD34(+), CD38(variably +), CD45(dim +), CD56(-), CD64 (small subset +), CD117(+), HLA-DR(partial +), other myeloid and lymphoid antigens(-).",7.0,6.63,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,R140Q; MAF 51.0%,,,,,,,Foundation; MLL-PTD exons 2-10,,,,,,,,,,V26G; MAF 1.0%,,,,,,,,,,,,,R94_S101DEL; MAF 40.0%,,,,,,,,,,,-0.032654915053445525,Low
16-00073,2443,Female,Female,White,1,n,63.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64.0,44,Residual Relapse,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,6,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea",6,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Maintenance|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,-1.0,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,29.0,Dead,348.0,Dead-Disease,True,False,15-00954,-44,1.5,,38.5,0.0,0.0,55.0,3.5,1.5,0.0,25,22.0,3.8,1.3,,21.1,7.1,"48,XX,+8,+21[16]/46,XX[4]",,91.3,"RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn",18.0,,7.7,19.76,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.3098186541060566,High
16-00075,2498,Male,Male,White,4,n,69.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,69.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,7.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,7.0,Alive,13.0,Alive,False,False,,0,,39,11,,,,,,,,,,,,,,"45,XY,add(1)(p13),del(5)(q13q33),add(6)(q13),-7,del(7)(q11.2),der(9)t(1;9)(p13;q22),add(12)(p13),-15,-16,-17,+3mar[19]/43~45,idem,der(3)t(3;17)(p21;q11.2),-17[cp3]",,,"COMPLEX DEL(5q)/DEL(7q)/-7 CLONE OBSERVED, CONSISTENT WITH AML",,Positive,,1.6,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.28950398520792575,High
16-00077,2500,Male,Male,White,2,n,78.0,False,False,False,None,False,False,y,Esophageal Cancer,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,80.0,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,5,"AG-120|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",4,Consolidation|Induction|Experimental|Maintenance,Complete Response,Standard Chemotherapy,7.0,Targeted Therapy - Other,AG-120,Experimental,-1.0,Dead,605.0,Dead-Disease,False,False,,-29,0.0,,70,0.0,,7.0,3.0,9.0,,11,57.0,2.6,1.28,,25.6,8.1,"45,XY,-7[2]/45,XY,t(6;8)(q21;q21.2),-7,del(10)(q24q26),t(12;15)(p13;q15)[19]",1897.0,,"nuc ish(D5S2064,D5S630,EGR1)x2 [200],(D7Z1x2,D7S522x1)[1/200]/(D7Z1,D7S522)x1[185/200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",23.0,"CD2(subset +), CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial +), CD38(variably +), CD45(+), CD56(partial +), CD64(-), CD117(+), HLA-DR(partial +).",4.3,240.43,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.1358331393976704,High
16-00078,2499,Female,Female,White,2,n,67.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,67.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1.0,Unknown,,,False,False,,0,0.8,85,7.7,0.0,,5.1,42.7,40.2,,27,41.0,1.9,0.66,,28.7,9.5,"46,XX[20]",670.0,102.5,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",42.0,"CD2(-), CD4(partial dim +), CD7(few dim +), CD11b(-), CD13 (variably +), CD14(-), CD15(partial +), CD16(-), CD19(partial dim +), CD33(variably +), CD34(-), CD36(-), CD38(+), CD45 (moderate +), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+), MPO(+).",5.7,56.03,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,negative,,,,,,,,,,,,,,,,Q61K; MAF 43.0%,,,,,,,,,,,,,,,,,,,,,,,,,-0.2833989524174074,Low
16-00087,2495,Female,Female,White,1,n,24.0,False,False,False,Unknown,False,False,y,Not specified,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,FavorableOrIntermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,24.0,0,Post-Chemotherapy,Leukapheresis,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Other,3,"ATRA (Tretinoin)|HiDAC|3+7 (Cytarabine, Daunorubicin)",3,Consolidation|Induction|Experimental,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,HiDAC,Consolidation,114.0,Alive,261.0,Alive,False,False,,0,0.0,,97,0.0,0.0,1.9,0.0,1.9,0.2,14,18.0,2.7,0.51,,19.6,6.2,,364.0,108.3,normal,15.0,"CD13, CD33, CD38, CD58, CD117 and CD123 positive.",6.4,181.66,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,p.V592G; MAF 6%,,,p.W288fs*12; MAF 50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.3185667182496475,Low
16-00088,2442,Female,Female,AdmixedBlack,6,n,25.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",26.0,49,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Cladribine, Cytarabine, Idarubicin",3,Consolidation|Induction|Re-induction,Unknown,Standard Chemotherapy,-1.0,Standard Chemotherapy,"Azacitidine, Sorafenib",Re-induction,67.0,Dead,324.0,Dead-Unknown,False,False,,0,,98,95,,,2.0,3.0,,,46,30.0,4.1,0.54,,27.2,8.9,"46,XX,t(7;12)(q22;p13)[12]/46,XX,t(7;17)(p10;q10),-9,+mar[7]/46,XX[1]",,90.4,This test has detected a translocation between 7 and 12 in 12 cells; a translocation between 7 and 17 with loss of a chromosome 9 and a marker in 7 cells.,81.0,"These are positive for CD34, CD117, HLADR, CD33 but negative for CD13 and CD11b. TdT and CD79a are partially expressed.",6.9,67.7,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.8044493642872236,High
16-00094,2501,Female,Female,White,1,n,37.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",37.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Hydroxyurea",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,8.0,Standard Chemotherapy,Azacitidine,Consolidation,-1.0,Alive,17.0,Alive,False,False,,0,1.7,95,74,2.5,0.8,13.6,14.4,10.2,0.4,23,14.0,3.1,0.46,,27.9,9.2,"46,XX[20]",,89.4,Normal,49.0,"variable CD11b, CD13, dim CD19, dim CD33, CD34, variable CD64, CD117, CD123, and HLA-DR",7.0,26.57,False,False,,negative,negative,,p.A1312V; MAF 50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.K117N; MAF 48%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.R380fs*69 (1 bp deletion with frameshift); MAF 48%,,-0.19646266697701997,Low
16-00102,2508,Male,Male,White,4,n,72.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea,1,Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,CPX-351 (Liposomal Cytarabine + Daunorubicin),Induction,-1.0,Alive,95.0,Alive,False,False,,0,,97,96,,,,,,,,,,,M1,,,"46,XY[5]",,,"D5S721, EGR1  del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q)   ",,"CD117, MPO,CD38(PARTIAL), CD33(DIM) AND NOT EXPRESSING CD34 AND HLA-DR",,125.9,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,p.D839G; MAF~45%,,,,p.R140L; MAF ~50%,,,,,,negative,,p.V2338I; MAF ~50%,,,,,,,,,,,,,,,,,,,,,,"p.P95H, MAF~55%",,,,,,,,,,,-0.7726881810013895,Low
16-00109,2511,Male,Male,White,1,n,76.0,False,False,True,None,False,False,n,,n,n,n,n,y,y,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,76.0,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Hydroxyurea,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,7.0,Dead,8.0,Dead-Unknown,False,False,,-1,0.0,96,93.3,0.0,0.7,4.7,0.0,1.3,0.6,23,43.0,2.3,0.46,,31.0,10.4,"46,XY[20]",839.0,93.9,Normal,17.0,"CD13, CD33, CD38, variable CD56, CD58, CD117 and MPO positive",5.1,230.05,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.W564*; MAF 50%,,,,,,-0.520381082460329,Low
16-00113,2521,Male,Male,White,5,n,85.0,False,False,False,None,False,False,y,Not specified,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,85.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,,True,False,16-00114,0,1.5,2,,24.0,,11.5,8.0,55.0,,4,8.0,3.7,1.2,,48.8,16.1,"46,XY[20]",,,Normal,141.0,,6.3,11.4,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,c.436G>C; p.D146H,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,c.5182G>T; p.E1728X,negative,,,,,-0.6506977190380444,Low
16-00115,2522,Male,Male,White,6,n,74.0,False,True,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",74.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,14.0,Dead-Disease,False,False,,0,,19,7,4.0,,12.0,2.0,51.0,,29,38.0,3.7,0.86,,24.2,7.8,"45,XY,-7,del(12)(p11.2p13)[20]",,90.6,Monosomy 7 is detected in 87% of cells.,35.0,,6.6,47.5,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.3383403724263515,High
16-00118,2443,Female,Female,White,1,n,63.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64.0,58,Residual Relapse,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,6,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea",6,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Maintenance|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,-1.0,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,29.0,Dead,348.0,Dead-Disease,True,False,15-00954,-58,0.0,,,0.0,0.0,12.6,0.0,0.0,0.2,16,36.0,3.1,1.57,,20.9,7.0,"48,XX,+8,+21[16]/46,XX[4]",887.0,89.7,"RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn",21.0,,7.3,49.93,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.1868002940087135,High
16-00120,2515,Male,Male,White,3,n,36.0,False,True,False,PML-RARA,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,36.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Methotrexate, Mercaptopurine, Tretinoin|ATRA, Idarubicin|ATRA, Cytarabine, Idarubicin",3,Consolidation|Induction|Maintenance,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"Methotrexate, Mercaptopurine, Tretinoin",Maintenance,-1.0,Alive,514.0,Alive,False,False,,-1,,91.8,95,,,,,,,,,,,,,,"46,XY,t(15;17)(q24;q21)[18]/46,XY[2]",,,Normal,,"weak partial CD2, CD13, CD33, CD64, CD117, and  myeloperoxidase",,55.42,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.17138272799708704,Low
16-00124,2477,Male,Male,White,6,n,50.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",50.0,30,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Allogeneic - Sibling|Induction|Re-induction,Unknown,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,97.0,Alive,576.0,Alive,True,False,16-00123;16-00030,-30,,,68,,,12.0,,3.0,,20,11.0,3.8,0.81,,24.1,7.9,"46,XY[20]",,89.6,Not Available (no FISH done),39.0,,6.4,2.1,True,False,16-00123,positive,negative,,,,,,,,,,,,,,,,,,,,,p.r882H; MAF 45%,,,,,negative,,,,,,,,,,,PTD,,,,,,,,,,,,,,,,,,p.E454Gfs*149; MAF 51%,,,,,,,,,,,,,,,,1.5892809810531359,High
16-00129,2519,Female,Female,White,5,n,42.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,42.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,HiDAC,Consolidation,-1.0,Alive,104.0,Alive,False,False,,0,0.0,90,,0.0,,17.0,,20.0,,17,13.0,3.6,0.98,,21.7,7.3,"46,XX[19]",,,Normal,71.0,Positive,6.6,18.3,False,False,,negative,positive,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,c.933_934ins10; p.R312fs; c.938_939insCGGTC; p.A314fs,,-1.6643722679459125,Low
16-00132,2526,Male,Male,White,6,n,74.0,False,False,True,None,False,False,n,,y,n,y,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,75.0,0,Post-Chemotherapy,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,"Azacitidine, MLN4924",1,Induction,Complete Response,Standard Chemotherapy,498.0,Standard Chemotherapy,"Azacitidine, MLN4924",Induction,498.0,Unknown,,,True,False,16-00131,0,,6,,3.8,,48.1,9.5,38.1,,41,25.0,4.4,0.73,,36.5,12.7,"48,XY,+8,del(20)(q11.2),+21[14]/46,XY[6]",,94.8,"This test has detected a 20q deletion, trisomy 8, and trisomy 21 in 14 cells. All these abnormalities are commonly seen in AML and MDS.",43.0,"These are positive for CD34, CD117, HLA-DR, and CD33.",6.4,2.1,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.7340589956480262,High
16-00139,2530,Female,Female,White,6,n,73.0,False,False,True,Unknown,False,False,y,Breast Cancer,y,n,n,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73.0,0,Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Ruxolitinib,1,Induction,Unknown,Standard Chemotherapy,28.0,Standard Chemotherapy,Ruxolitinib,Induction,28.0,Dead,560.0,Dead-Unknown,False,False,,0,,,,0.5,,39.2,7.5,52.5,,10,21.0,4.5,0.87,,34.1,10.9,,,92.4,,6.0,,7.6,3.8,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.R140Q; MAF 32%,,,p.V617F; MAF 30%,,,,,,,,,,,,,,,,,,,,,,,,,,,p.R94dup; MAF 31%,,,,,,,,,p.R440Tfs*14; MAF 29%,,-0.6949624609567432,Low
16-00143,2532,Male,Male,HispNative,4,n,58.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,58.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),4,"Sorafenib|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Induction|Experimental,Refractory,Standard Chemotherapy,1.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1.0,Alive,192.0,Alive,False,False,,-1,,57,24,,,,,,,,,,,M2,,,"47,XY,t(8;22)(p11.2;q11.2),+19[20]",,,"t(8;22) clone observed, consistent with a neoplastic process ",,Positive,,100.2,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.2218153666599489,High
16-00145,2533,Male,Male,Asian,2,n,75.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,75.0,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Vidaza|Decitabine|Fludarabine, Cytarabine",2,Salvage|Supportive/Palliative Care,,,,Standard Chemotherapy,"Fludarabine, Cytarabine",Salvage,-1.0,Dead,159.0,Dead-Disease,False,False,,0,0.0,27,2,0.0,,60.2,8.4,29.4,,12,15.0,4.8,0.98,,30.7,9.3,"46,XY,t(1;12)(p32;p13)[3]/46,XY[17]",215.0,,"nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[194],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]",121.0,"CD2(-), CD4(-),CD7(-), CD10(partial +), CD11b(-), CD13(dim +), CD14(-), CD38(variably +/small subset -), CD45(dim to moderately +), CD56(-), CD64(-), CD117(variably +), HLA-DR(variably +).",7.5,3.09,False,False,,negative,negative,,G646fs*12; MAF 37.0%,,,S1608*; MAF 3.0%,,,,,,,,,,,,,,,,,,,,,negative,,,negative,negative,,,,,,,,,G12R; MAF 5.0%,,,,,,,,,,,,,,,,,,,,,,Q932fs*6; MAF 91.0%,,E601fs*10; MAF 38.0%,,C127fs*92; MAF 6.0%,,,,,,0.796943073319376,High
16-00150,2546,Male,Male,White,6,n,67.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,67.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,4,"Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,Decitabine,Salvage,106.0,Alive,112.0,Alive,False,False,,0,,60,,,,,0.0,,,,,,,,,,"46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7]",,,Trisomy 8 is detected in 28% of cells.,,"Positive for CD34, CD117, HLADR, CD33, CD13 and Negative for CD11b and CD64",,,False,False,,negative,negative,,,,,p.KB39Qfs*5; MAF 45%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.T916A; MAF 50%,,,,,,,,,,p.G12A; MAF 24%,,,,,,,,,,,,,,p.P95R; MAF 40%,,,,,,,,,,,1.0133317777989541,High
16-00151,2547,Male,Male,White,6,n,67.0,False,False,True,None,False,False,n,,y,n,n,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",67.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Unknown,,,,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Unknown,-1.0,Unknown,,,False,False,,0,,80,10,2.0,,68.0,4.0,8.0,,8,10.0,3.9,0.85,,21.2,7.2,"46,XY[20]",,110.4,The translocations commonly seen in AML are not detected. Loss of RARA and CBFB genes are detected in 14-39% of cells.,84.0,"These are positive for CD34, CD117, HLADR, CD33, CD13, CD14 and CD11b.",5.9,0.9,False,False,,negative,negative,,,,,MAF 49%,,,,,,,,,,,,,,,,,,,,,negative,,,p.R132C MAF 12%,,,,p.V617F; MAF 43%,,,,PTD,,,,,,,MAF 18%,,,,,,,,,,,,,,,,,,,,,,p.Y220C; MAF 35%,,,,,0.6617897269599349,High
16-00157,2538,Male,Male,White,1,n,67.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,67.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,4,"AG-120|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC",4,Consolidation|Salvage|Induction|Experimental,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,-1.0,Alive,528.0,Alive,False,False,,0,0.0,93,94,0.0,0.0,1.0,2.8,1.9,0.1,20,30.0,2.4,1.23,,31.2,10.1,"46,XY[20]",,96.3,Normal,30.0,"partial CD7, CD13, dim CD15, CD33, CD38, CD58, CD117, dim CD123, HLA-DR and partial MPO+.",,125.16,False,False,,negative,positive,,,,,,,,,,,,,,negative,,,,,,,p.R882H; MAF 46% ,,,,,p.V592D; MAF 43% ,,,p.R132H; MAF 46%  ,negative,,,,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,p.K459E; MAF 50% ,,,,,,,,,,negative,,,negative,,-0.73835161156411,Low
16-00217,2569,Male,Male,White,1,n,86.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,86.0,0,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,3,AG-221|Azacitidine|Hydroxyurea,3,Hypomethylating/Low Dose Cytarabine|Consolidation|Experimental,,,,Standard Chemotherapy,Hydroxyurea,Consolidation,55.0,Dead,596.0,Dead-Disease,False,False,,0,0.0,23,12.1,0.0,0.8,8.6,19.0,59.5,0.0,16,15.0,3.4,1.52,,27.8,9.0,"47,XY,+8[20]",398.0,97.5,"(FISH) was performed with a chromosome 8 probe, listed below. 95/100 (95%) interphase cells scored had three signals, consistent with trisomy 8 and the metaphase karyotype. ",299.0,"dimCD7, CD13, dimCD14, dimCD20, CD33, CD34, CD117, CD123, dim HLA-DR and MPO positive",7.6,10.0,False,False,,negative,negative,,,,,p.S1139*; MAF 80%,,,,,,,,,p.R343fs*79; MAF 40%,,,,,,,p.G707fs*72; MAF 45%,,,,,,,,,p.R140Q; MAF 40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.P95H; MAF 40%,,,,,,,,,,,0.30708591095412485,High
16-00220,2571,Male,Male,White,3,n,67.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,67.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|IDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,IDAC,Consolidation,-1.0,Alive,31.0,Alive,False,False,,0,,71.5,56,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,"CD33, CD38, CD56, CD117, and myeloperoxidase",,16.24,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.Leu1780fs; MAF 46.3%,,,,,p.Arg126*; MAF 97.7%,-2.0760770087052984,Low
16-00226,2503,Male,Male,White,1,n,79.0,False,False,True,None,False,False,n,,y,n,n,n,y,y,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,79.0,35,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,4,Azacitidine|Decitabine|Hydroxyurea|V212,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1.0,Alive,53.0,Alive,True,False,16-00092,-35,1.7,,35,0.0,0.0,0.9,64.4,8.7,0.2,9,22.0,3.1,2.11,,25.5,7.8,"46,XY[22]",722.0,95.5,Normal,438.0,"CD13, dim CD33, bright CD34, CD38, CD117, dim HLA-DR positive",5.8,116.52,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.775886615980231,High
16-00249,2581,Male,Male,White,6,n,75.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",75.0,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Vidaza,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Vidaza,Supportive/Palliative Care,-1.0,Alive,302.0,Alive,False,False,,0,,60,50,,,,2.0,,,,,,,,,,"46,XY[20]",,,,,"These are positive for HLA-DR, CD34,CD117, CD33, CD11B, CD64 but Negative for CD13, CD14, CD16, MPO, TDT and all B and T cell markers",,25.0,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.45453882425899633,High
16-00264,2225,Female,Female,White,3,n,71.0,False,False,False,None,False,False,y,Follicular lymphoma,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,72.0,249,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone",4,Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,-1.0,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1.0,Dead,280.0,Dead-Disease,False,False,,-37,,>95,99,,,,,,,,,,,,,,"46,XX,del(7)(q22q36)[18]/46,sl,t(1;10)(p13;q24)[2]",,,"- 3 copies of the MECOM locus at 3q26.2, suggestive of a  rearrangement or gain of this locus, in 156/200 (78.0  percent) cells scored.  - deletion 7q31 involving the D7S486 locus in 162/200 (81.0  percent) cells scored.",,,,20.39,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.2704977130222905,High
16-00269,2593,Female,Female,White,1,n,44.0,False,True,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,44.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,8.0,Standard Chemotherapy,HiDAC,Consolidation,99.0,Alive,170.0,Alive,True,False,16-00268,0,0.0,65,11.2,3.5,0.0,76.7,0.0,8.6,0.0,19,11.0,2.8,0.53,,23.7,7.8,,197.0,100.4,Normal,222.0,"CD13, CD33, CD117, CD123, dim HLA-DR and MPO",6.1,2.41,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.R132H; MAF 44%,,,,,,,,,,,,,,,,,,,,,,,p.R265Q; MAF 3%,,,,,,,,,,,,,,,,,,,-0.6859738330367,Low
16-00271,2594,Female,Female,White,2,n,22.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,22.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),3,"Fludarabine, Melphalan|Crenolanib|7+3 (Cytarabine, Idarubicin) plus Crenolanib",3,Allogeneic - Sibling|Induction|Experimental,Complete Response,Standard Chemotherapy,39.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1.0,Alive,464.0,Alive,False,False,,-1,0.0,63,42,0.0,,32.7,4.4,26.6,,27,39.0,3.1,0.68,,19.3,6.0,"46,XX[20]",,,"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200]",176.0,"CD2(-), CD4(partial dim +), CD7(variably +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +).",6.3,22.01,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,E54FS*28; MAF 44.0%,,,,,A382FS*4; MAF 40.0%,,0.7845610190417346,High
16-00273,2595,Female,Female,White,3,n,62.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,62.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,7.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,7.0,Dead,169.0,Dead-Disease,False,False,,-2,,,,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,,,,False,False,,negative,negative,,,,,,,,,,,,,,c.68dup; MAF 21%,,,,,,,c.2645G>A; MAF 43.9%,,,,,,,,,,,,,,,,,,,,,,,,,c.35G>A; MAF 30.2%,,,,,,,,,,,,,,,,,,,,,,,c.1142C>A; MAF 36.4%,,1.405543367458012,High
16-00278,2597,Male,Male,White,5,n,64.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,64.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,41.0,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, Thiotepa, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Alive,440.0,Alive,False,False,,0,0.0,83,74,0.0,,13.0,0.0,13.0,,15,45.0,4.0,1.27,,25.2,8.7,"46,XY[20]",,,Normal,39.0,Positive,6.0,53.3,False,False,,positive,positive,,,,,,,,,,,,,,negative,,,,,,,c.2645G>A; p.R882H,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.39335387635317887,High
16-00289,2606,Female,Female,White,1,n,65.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib",2,Consolidation|Induction,Complete Response i,Standard Chemotherapy,45.0,Standard Chemotherapy,Azacitidine,Consolidation,34.0,Dead,142.0,Dead-Disease,False,False,,0,0.0,95,92.9,0.0,0.7,3.6,1.4,1.4,0.1,101,55.0,3.2,0.83,,37.0,12.4,"46,XX[20]",697.0,95.1,normal,42.0,"CD13, CD33, CD38, CD56, CD58, partial CD64, CD117, CD123, and MPO positive",6.3,166.91,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.09184146521250429,Low
16-00292,2607,Female,Female,White,1,n,73.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,3.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,3.0,Dead,4.0,Dead-Disease,False,False,,0,0.0,90,98.4,0.0,0.0,0.8,0.0,0.8,0.1,18,36.0,2.9,1.44,,25.9,8.2,"46,XX[20]",,90.6,Normal,19.0,"CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, and MPO",7.7,122.89,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,p.R326P; MAF 50%,,,,,,,,,p.R140Q; MAF 40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.3077227415413613,Low
16-00303,2611,Female,Female,HispNative,5,n,56.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,56.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI",4,Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,27.0,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Salvage,-1.0,Dead,323.0,Dead-Disease,False,False,,0,0.0,1.5,2,0.0,,23.0,57.0,13.0,,67,33.0,3.0,1.87,,29.0,9.5,"46,XX[19]",,,Normal,28.0,Positive,7.5,58.7,False,False,,positive,positive,,c.1954G>A; p.G652S,,,,,,,,,,,,negative,,,,,,,c.2644C>T; p.R882C,,,,,c.2503G>T; p.D835Y,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,-0.3843707535162247,Low
16-00307,2612,Male,Male,White,6,n,71.0,False,False,True,None,False,False,n,,n,n,n,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,0,,0,,0,,,,,NONE,NONE,NONE,,Alive,402.0,Alive,True,False,16-00306,0,,75,26,2.0,,15.0,8.0,43.0,,118,53.0,3.8,1.26,,22.9,7.7,"46,XY,del(7)(q32),add(13)(p11.2)[15]",,81.8,"This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.",24.0,"These are positive for CD34, CD117, HLADR, CD33 and CD13",8.7,5.0,False,False,,negative,negative,,p.Q428*; MAF 44%,,,,,,,,,,,,negative,,,,,,,,,,,,negative,,,p.R132C; MAF 45%,,,,p.V617F; MAF 57%,,,,PTD,,,,,,,,,,,,,,,,,,p.G406Vfs*193; MAF 39%,,,,,,,,,,p.R1366S; MAF 40%,,,,,,1.031798905830179,High
16-00315,1973,Male,Male,White,1,n,70.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,72.0,423,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",3,Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6.0,Supportive/Palliative Care,Decitabine,Hypomethylating/Low Dose Cytarabine,-1.0,Alive,523.0,Alive,True,True,15-00874,-142,0.0,,,0.0,0.0,15.5,6.9,5.2,0.0,79,38.0,3.1,0.8,,27.9,9.1,"47,XY,+4[2]/46,XY[18]",,87.7,"Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.",44.0,,6.3,50.58,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.9991102763358266,High
16-00316,2615,Male,Male,HispNative,7,n,72.0,False,False,False,Unknown,False,True,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,unknown,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,unknown,73.0,0,Residual Disease,Bone Marrow Aspirate,y,y,n,y,y,n,0,,0,,0,,,,,NONE,NONE,NONE,,Alive,0.0,Alive,False,False,,0,,20,,,,,,,,,,,,,,,,,,,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.4893128279562646,High
16-00332,2621,Male,Male,White,6,n,72.0,False,False,False,Unknown,True,False,y,Lung Cancer,y,n,y,n,n,n,n,n,,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",Adverse,Not Enough Information,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",73.0,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Vidaza,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Vidaza,Supportive/Palliative Care,268.0,Dead,292.0,Dead-Unknown,False,False,,0,,,4,1.0,,13.0,5.0,23.0,,13,57.0,2.5,1.83,,25.0,8.2,,,105.9,,32.0,,5.8,66.7,False,False,,negative,negative,,p.R693* MAF 48%,,,,,,,,,,,,,,,,,,,,,,p.C565R MAF 27%,,,,,,,,,"p.V617F, MAF 26%",,,,,,"p.Q61P, MAF 13%",,,,,,,,,,,,,,,,"p.S322Nfs*277, MAF 42%",,,,,,,,,,"p.Q866Rfs*14, MAF 39%",,,,,"p.R295*, MAF 97%",0.21714691282472126,High
16-00339,2626,Female,Female,White,1,n,70.0,False,False,False,None,True,False,n,,n,n,n,n,n,n,y,n,,MYELOPROLIFERATIVE NEOPLASMS,"Atypical chronic myeloid leukaemia, BCR-ABL1 negative",Intermediate,,MYELOPROLIFERATIVE NEOPLASMS,"Atypical chronic myeloid leukaemia, BCR-ABL1 negative",70.0,0,Unknown,Bone Marrow Aspirate,y,y,y,y,y,y,1,Targeted Therapy - Kinase Inhibitor(s),1,Hydroxyurea,1,Induction,Unknown,Targeted Therapy - Kinase Inhibitor(s),-1.0,Targeted Therapy - Kinase Inhibitor(s),Hydroxyurea,Induction,-1.0,Alive,1.0,Alive,False,False,,0,1.6,13,6.8,0.8,0.0,5.7,2.5,72.1,5.7,24,36.0,2.9,0.95,,29.1,8.9,"46,XX[20]",953.0,105.1,Normal,208.0,"CD13, CD33, CD34, partial CD117, CD123, HLA-DR",6.7,109.77,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.N159S ; MAF 45%,,,,,,,,,,,,,,,,,,,,,,,,,,p.K666N ; MAF 45%,,,,,,,,,,,,,,1.5044438388717307,High
16-00344,2628,Male,Male,White,1,n,59.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,7.0,Standard Chemotherapy,HiDAC,Consolidation,96.0,Alive,188.0,Alive,True,False,16-00345,0,0.0,30,10.5,0.0,0.0,19.7,0.9,71.4,0.0,77,27.0,3.4,1.01,,26.4,8.9,"46,XY[20]",479.0,96.4,Normal,101.0,"CD13, CD33, CD117, CD123, and HLA-DR",6.4,4.4,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,p.R882C; MAF 40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.K70R; MAF 40%,,,,,,,p.Q210H ; MAF 55%,,,,,,,,,,,,-0.5846506116055297,Low
16-00351,2630,Female,Female,HispNative,1,y,46.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,46.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,Standard Chemotherapy,HiDAC,Consolidation,120.0,Alive,192.0,Alive,False,False,,-3,,,,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,,,,False,False,,negative,negative,,,,,,,,,,,,,,p.T98fs*10 ; MAF 40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.Q758*; MAF 45%,,,,,,-0.5157397962358639,Low
16-00354,2632,Male,Female;Male,White,3,n,79.0,False,True,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,79.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,,False,False,,-1,,86,87,,,,,,,,,,,,,,"43-45,X,-Y,del(5)(q22q35),del(7)(q22),+8,-9,add(9)(p13),+11,-13,-14,add(16)(q24),-17,-18,del(20)(q11.2q13.2),+2-3mar[cp21]",,,5q31 (EGR1): deletion present  8q22 (RUNX1T1): gain present  11q23 (KMT2A; also known as MLL): gain present ,27.0,,,70.01,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.Asp816Val; MAF 44.4%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.?; MAF 91%,,,,,0.9045067412599018,High
16-00356,2633,Male,Male,HispNative,6,n,59.0,False,False,True,Unknown,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,59.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Lenalidomide|3+7 (Cytarabine, Daunorubicin)",2,Unknown|Supportive/Palliative Care,,,,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Unknown,-1.0,Dead,207.0,Dead-Unknown,False,False,,0,,,1,9.0,,1.0,6.0,58.0,,135,44.0,3.2,0.79,,21.6,7.3,,,85.0,,22.0,,5.9,9.1,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p.Q61H, MAF 21%",,,,,,,"p.G273V ,MAF 64%",,,,,,,,,,,,,,,,,,0.10725072580904586,High
16-00358,2530,Female,Female,White,6,n,73.0,False,False,True,None,False,False,y,Breast Cancer,y,n,n,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73.0,56,Post-Chemotherapy,Bone Marrow Aspirate,y,n,y,y,n,y,1,Standard Chemotherapy,1,Ruxolitinib,1,Induction,Unknown,Standard Chemotherapy,28.0,Standard Chemotherapy,Ruxolitinib,Induction,28.0,Dead,560.0,Dead-Unknown,False,False,,1,,5,,,,,1.0,,,,,,,,,,"46,XX[20] ",,,This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited number of cells examined.,24.0,"CD34 positive blasts are rare, <1%",,1.8,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.8427607721668717,Low
16-00373,2653,Male,Male,White,1,n,37.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,37.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,3,Standard Chemotherapy|Bone Marrow Transplant|Other,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Radiation|Busulfan, Cyclophosphamide",4,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Supportive/Palliative Care,Unknown,Standard Chemotherapy,24.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Mismatched Unrelated Donor,-1.0,Alive,474.0,Alive,False,False,,0,1.1,1,0,2.8,0.2,30.3,5.2,60.4,0.0,34,20.0,4.2,0.93,,39.2,14.4,"46,XY[20]",154.0,94.9,Normal,162.0,"dim/partial CD1a, dimCD4, dimCD5, CD33, CD43, dimCD45, CD56, CD68, CD117, and lysozyme positive with Ki67 activity >90%.",7.5,5.35,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.L307R; MAF 51%,,,,,,-0.45146918373964723,Low
16-00392,2664,Female,Female,White,1,n,78.0,False,False,True,None,False,False,n,,y,n,n,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,78.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,Ruxolitinib|Hydroxyurea|Decitabine,2,Consolidation|Experimental,,,,Targeted Therapy - Kinase Inhibitor(s),Ruxolitinib,Experimental,7.0,Dead,24.0,Dead-Unknown,False,False,,-1,0.0,,,0.0,1.6,43.7,9.4,29.7,5.5,27,39.0,2.0,0.41,M7,26.2,8.2,"46,XX,t(7;13)(q22;q12),del(20)(q11.2)[1]/46,sl,dup(1)(p25),del(2)(q21q23),add(8)(q13q22)[3]/46,sdl,add(5)(p15)[8]/46,sdl,add(12)(p13)[3]/46,sdl,add(12)(p13),add(13)(p12)[4]/46,XX[1]",1024.0,89.4,RUNX1T1 (8q21.3): 35% of cells had three signals for RUNX1T1 on 8q. No evidence for t(8;21).,17.0,,5.5,6.28,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,p.M1V; MAF 32%,,,,,,,,,,,,,,p.S505N; MAF 70%,,,,,,,,,,,,,,,,,,,,,,,,p.V636fs*3; MAF 46%,,,,,,1.9862702241319816,High
16-00406,2675,Male,Male,White,1,n,75.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",75.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,3,"Vidaza|7+3 (Cytarabine, Idarubicin)|Azacitidine",3,Induction|Frontline|Re-induction,Complete Response,Standard Chemotherapy,7.0,Standard Chemotherapy,Vidaza,Re-induction,-1.0,Alive,151.0,Alive,False,False,,0,0.0,23,,1.0,,51.0,11.2,36.8,,23,16.0,3.4,0.55,,27.1,9.1,"46,XY[19]",178.0,88.0,Normal,28.0,"CD13, CD33, CD34, CD38, CD117, CD123, dim HLA-DR, TdT, and MPO positive",6.4,1.0,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,p.R882H; MAF 41%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.K700E; MAF 43%,,,,,,,,,,,,,,0.07089628659515858,High
16-00410,2678,Male,Male,White,1,n,62.0,False,True,False,PML-RARA,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,62.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide",1,Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Induction,-1.0,Alive,320.0,Alive,False,False,,0,0.0,90,53,0.9,3.5,35.7,1.7,5.2,0.7,28,24.0,2.8,1.12,M3,19.8,7.0,"46,XY,t(3;16)(p13;q22),t(13;14)(q32;q24),t(15;17)(q22;q21)[20]",519.0,85.7,"PML/RARA: 98/100 cells (98%) had a 1 red/ 1 green/ 2 yellow signal pattern, reflecting PML/RARA fusion and consistent with the 15;17 translocation observed in the metaphase karyotype.",38.0,"CD13, CD33, CD38, CD58, CD64, dim CD71, CD123, CD117, MPO positive -FISH for t(15;17)",5.4,9.87,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.3879269954398825,Low
16-00459,2687,Female,Female,HispNative,1,n,61.0,False,False,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea",4,Consolidation|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,7.0,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,55.0,Dead,263.0,Dead-Disease,False,False,,0,0.0,,,0.0,0.0,30.8,10.3,0.0,0.3,195,75.0,3.6,0.68,,25.4,8.2,,1033.0,95.5,,49.0,,6.7,73.28,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.77583499005893,High
16-00460,2688,Male,Male,White,3,n,58.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",58.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine",3,Salvage|Induction|Symptom Control,Refractory,Standard Chemotherapy,10.0,Supportive/Palliative Care,Azacitidine,Symptom Control,-1.0,Dead,278.0,Dead-Disease,False,False,,-3,,,,,,,,,,,,,,,,,"[46,XY]",,,Normal,,,,4.17,False,False,,negative,negative,,,p.Val1277Ala; MAF 89.5%,,,,,,,,,,,,,,,,,, p.Trp297* (NM_175629.2); MAF 82.1%,,,,,,,,p.Arg132Cys (NM_005896.3); MAF 39.1%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.4507481169873605,High
16-00465,2690,Male,Male,HispNative,1,n,12.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,12.0,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"Cytarabine|Sorafenib|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide",3,Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Intrathecal,0.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Mismatched Unrelated Donor,-1.0,Alive,233.0,Alive,False,False,,1,0.0,70,85,0.0,1.8,14.7,51.4,8.3,50.0,28,150.0,3.7,0.64,M4,14.3,4.6,"47,XY,+8[19]/46,XY[1]",,132.4,RUNX1T1 signal consistent with the trisomy 8 clone ,49.0,"dimCD11b, dimCD13, CD14, dimCD33, CD64, variable CD123, HLA-DR CD13,dimCD33, dim variable CD34, CD117, CD123, HLA-DR",7.1,214.49,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.20116554309814166,High
16-00474,2694,Male,Male,AdmixedBlack,6,n,50.0,False,True,False,RUNX1-RUNX1T1,False,False,n,,y,n,n,n,n,n,n,n,RUNX1-RUNX1T1,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,50.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Unknown,Standard Chemotherapy,20.0,Standard Chemotherapy,HiDAC,Consolidation,182.0,Alive,424.0,Alive,False,False,,-1,,70,91,0.0,,7.0,2.0,0.0,,23,25.0,2.4,0.66,,26.6,8.7,"46,XY,t(8;21)(q22;q22)[20]",,94.7,,28.0,,6.3,71.1,False,False,,negative,negative,,"p.P581R, MAF 46%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p.D111N, MAF 52%",,,,,,,,,,"ASXL1, PDGFRB, SMC1A",,,,,,,,,,,,,-2.0210243444363525,Low
16-00479,2697,Female,Female,White,3,n,39.0,False,False,True,None,False,False,y,Leiomyosarcoma,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,40.0,0,Residual Disease|Post-Chemotherapy|Post-Transplant,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)",5,Allogeneic - Sibling|Salvage|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,30.0,Standard Chemotherapy,Azacitidine,Salvage,4.0,Unknown,,,False,False,,0,,,,,,,,,,,,,,,,,"46,XX,der(7)t(3;7)(q26;q21)[9]/46,XX[11]",,,,,"Increased atypical CD34 positive, CD7 positive myeloblasts",,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.6448357579918357,High
16-00481,2699,Female,Female,White,3,n,60.0,False,False,False,CBFB-MYH11,False,False,y,Adenocarcinoma,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,61.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|IDAC",2,Consolidation|Induction,UNKNOWN,Standard Chemotherapy,-1.0,Standard Chemotherapy,IDAC,Consolidation,-1.0,Dead,336.0,Dead-Disease,False,False,,0,,,,,,,,,,,,,,,,,"46,XX,inv(16)(p13q22)[20]",,,,,Increased atypical CD34+myeloblasts representing 80%of leukocytes suggestive of recurrent AML.,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.7382053849842937,Low
16-00483,2612,Male,Male,White,6,n,71.0,False,False,True,None,False,False,n,,n,n,n,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71.0,57,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Alive,402.0,Alive,False,False,,0,,33,,,,,8.0,,,,,,,,,,"46,XY,del(7)(q32),add(13)(p11.2)[20]",,,"Not Available. Pathogenic alterations are DETECTED in the ASXL1, IDH1, JAK2 and RUNX1 genes. Genomic alterations of uncertain significance are DETECTED in the CEBPA and TET2 genes (not seeing specific mutations or MAF)",22.0,"They are positive for CD34, HLADR, CD117, CD13 and MPO and negative for TDT.",,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.15724602299907933,High
16-00491,2704,Female,Female,White,1,n,29.0,False,False,False,None,False,False,y,Basal Cell Carcinoma,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,29.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,3,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,5,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib",3,Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,5.0,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,2.0,Dead,129.0,Dead-Disease,False,False,,-1,0.0,98,3.1,2.0,1.0,60.0,13.0,24.0,1.7,393,350.0,2.5,0.69,,27.2,9.4,"47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]",,105.4,Normal,18.0,"CD11b, CD13, CD14, CD33, CD56 and bright CD64+",5.4,2.42,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.8072985522298384,Low
16-00494,2705,Female,Female,White,1,n,72.0,False,False,False,None,False,False,y,Non-Hodgkins Lymphoma,y,n,n,n,n,n,n,n,MLL-EPS15,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,72.0,1,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Salvage,5.0,Dead,148.0,Dead-Disease,False,False,,0,0.0,90,94,1.9,0.0,4.6,89.8,3.7,0.2,,,2.8,0.93,M5,37.1,11.9,"46,XX,t(1;11)(p32;q23)[20]",,96.6,MLL: 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal,33.0,"dim CD4, CD11b, partial CD13, partial CD14, CD15, CD33, partial CD56, CD58, bright CD64, partial CD123 and HLA-DR-positive",,104.44,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,p.E283*; MAF 30%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.5142039869367,Low
16-00498,2706,Female,Female,White,3,n,33.0,False,True,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,33.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Consolidation,-1.0,Alive,468.0,Alive,False,False,,0,,,,,,,,,,,,,,,,,,,,This analysis showed evidence of a PML-RARA rearrangement in 177/200 (88.5 percent) interphase cells scored.,26.0,"Large population of CD117pos, CD34neg, HLA-DR neg myeloblasts, representing 78% of leukocytes consistent w/AML.",,12.75,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.1914803864416457,High
16-00504,2708,Female,Female,White,2,n,60.0,False,False,False,None,False,False,y,Breast Cancer,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,60.0,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,5,"HiDAC|AG-221|3+7 (Cytarabine, Daunorubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Consolidation|Salvage|Induction|Experimental,Complete Response,Standard Chemotherapy,-1.0,Targeted Therapy - Other,AG-221,Experimental,-1.0,Dead,259.0,Dead-Disease,False,False,,0,2.0,2,0,1.0,,12.0,12.0,71.0,,27,,4.4,0.99,,33.5,11.4,"46,XX[20]",,95.4,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",219.0,The study reveals a minute subset of myeloblasts with mild immunophenotypic variation; the significance of this finding is unclear and it is not diagnostic for recurrent or persistent myeloid neoplasia.,7.1,5.54,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,R311Q; MAF 48%,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.055560023268861024,Low
16-00510,2712,Male,Male,HispNative,1,n,34.0,False,True,False,GATA2-MECOM,False,False,n,,y,n,n,n,n,n,n,n,EVI1_F,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,34.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5,"7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|anti-CD33|Azacitidine",3,Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,6.0,Targeted Therapy - Kinase Inhibitor(s),anti-CD33,Experimental,-1.0,Dead,291.0,Dead-Disease,False,False,,0,0.0,60,28.9,0.0,2.1,44.3,8.2,16.5,5.5,117,61.0,3.9,1.0,,35.6,11.7,"46,XY,t(3;3)(q21;q26),der(7)del(7)(p11.1)del(7)(q11.1)[13]/45,idem,-der(7)[6]/46,XY[1]",424.0,96.0,D7S522/CEP 7: 65/100 cells (65%) had a signal pattern consistent with the deleted chromosome 7 long arm from the small marker observed in the metaphase karyotype; 9 cells (9%) had a signal pattern consistent with the monosomy 7 sideline observed in the metaphase karyotype.,916.0,,7.7,6.13,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.Q61H; MAF 45%,,,,,,,,,,,,,,,,,,,,,,,,,1.4861314073618968,High
16-00519,2713,Male,Male,White,1,n,47.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,47.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,Bone Marrow Transplant,"Cyclophosphamide, Fludarabine, TBI",Allogeneic - Sibling,-1.0,Alive,381.0,Alive,False,False,,0,0.0,,72.9,0.0,0.0,20.3,3.4,3.4,6.9,49,21.0,3.5,1.08,,42.6,15.0,"46,XY[20]",353.0,86.8,Normal,34.0,"CD7, CD13, CD33, CD34, CD38, CD58, CD117, dim CD123 HLA-DR and MPO+ ,",7.4,8.98,False,False,,negative,negative,,,,,,,,,,,,,,p.R35fs*125; MAF 50%,,,p.P505L; VAF 45%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.7984703381539374,Low
16-00525,2715,Female,Female,Asian,1,n,26.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,26.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",4,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Cyclophosphamide, Fludarabine, TBI",Allogeneic - Mismatched Unrelated Donor,-1.0,Alive,352.0,Alive,False,False,,0,0.0,95,40.2,0.0,0.0,45.5,9.8,4.5,0.2,32,58.0,3.1,0.69,,22.3,7.4,"46,XX,r(2)(p23q31),der(4)t(4;16)(q21;q12-13)del(16)(q22q22),der(16)t(4;16)(q21;q12-13),add(18)(p11.2),del(20)(q13.2)[16]/46,XX[4]",,97.8,"CBFB: 88% of cells were missing a signal for CBFB, consistent withdeletion associated with the unbalanced t(4;16) seen on chromosome analysis. No evidence for disruption. This probe will be useful in following this abnormal clone.",154.0,"CD13, partial CD15, CD34, CD38, partial CD56, CD58, partial CD117 and CD123+",5.8,9.27,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.D61G; MAF 15%,,,,,,,,,,,,,p.S1039L; MAF 50%,,,,,,1.6188008484892056,High
16-00538,2694,Male,Male,Black,6,n,50.0,False,False,False,RUNX1-RUNX1T1,False,False,n,,y,n,n,n,n,n,n,n,RUNX1-RUNX1T1,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,50.0,21,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Unknown,Standard Chemotherapy,20.0,Standard Chemotherapy,HiDAC,Consolidation,182.0,Alive,424.0,Alive,True,True,16-00474,-22,,8,0,0.0,,12.0,29.0,54.0,,19,9.0,2.3,0.51,,22.8,7.5,"46,XY,t(8;21)(q22;q22)[20]",,88.7,RUNX1/RUNX1T1 fusion positive in 6.5% of cells,224.0,,5.1,6.8,True,True,16-00474,negative,negative,,"p.P581R, MAF 46%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p.D111N, MAF 52%",,,,,,,,,,"ASXL1, PDGFRB, SMC1A",,,,,,,,,,,,,0.26191633974224127,High
16-00540,2721,Female,Female,White,3,n,66.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",66.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,UNKNOWN,Standard Chemotherapy,6.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6.0,Unknown,,,False,False,,0,,,16,,,,,,,,,,,,,,"47,XX,+8[18]",,,Normal,,"Large population of CD117 pos myeloblasts, representing 80% of leukocytes, consistent w/ AML.",,129.5,False,False,,positive,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.Val379fs; MAF 13%,p.Arg415Trp; MAF 48.9%,0.8283479024988568,High
16-00547,2723,Male,Male,HispNative,1,n,29.0,False,False,False,MLLT3-KMT2A,False,False,y,Non-Hodgkins Lymphoma,y,n,n,n,n,n,n,n,MLL-MLLT3,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,29.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,19.0,Standard Chemotherapy,HiDAC,Re-induction,4.0,Dead,65.0,Dead-Unknown,False,False,,0,0.9,82,20,0.0,2.6,26.3,33.4,7.9,3.6,40,19.0,3.1,0.84,,27.3,9.1,"46,XY,t(9;11)(p22;q23)[20]",324.0,89.5,"94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, consistent with MLL rearrangement and the 9;11 translocation observed in the metaphase karyotype.",52.0,"CD11b, varibleCD13, CD14, brightCD33, CD64, and HLA-DR positive",6.7,3.88,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.16920385515613706,Low
16-00548,2119,Male,Male,White,1,n,76.0,True,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77.0,417,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor),2,Consolidation|Induction,Complete Response,Standard Chemotherapy,35.0,Standard Chemotherapy,Incyte trial (azacitidine and JAK 1 inhibitor),Induction,77.0,Dead,520.0,Dead-Unknown,True,False,16-00557,6,0.0,,,0.9,,60.3,38.5,0.3,,19,19.0,3.2,1.0,,24.2,8.6,"47,XY,+8[cp14]/47,sl,der(21)t(1;21)(q11;p11.1)[2]/46~47,sl,der(22)t(1;22)(q11;p11.2)[cp2]/46,XY[1]",261.0,102.5,"Eighteen of twenty-one cells examined were trisomy 8, previously observed.Two of these cells also had an extra 1q attached to a chromosome 21 short arm, and two other cells had an extra 1q attached to a chromosome 22 short arm. These are new clonal changes. One cell appeared normal male.",7.0,,7.2,3.4,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.7997490595541437,High
16-00566,2741,Male,Male,White,5,n,39.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,40.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,"GCLAC (GCSF, Clofarabine & Cytarabine)",1,Re-induction,,,,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Re-induction,-1.0,Unknown,,,True,False,16-00565,0,0.0,41,14,0.0,,5.0,5.0,76.0,,12,17.0,3.6,0.83,,29.4,10.2,"46,XY[15]",,,Negative,24.0,Positive,5.9,3.6,True,False,16-00565,positive,positive,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.45086364777924903,High
16-00627,2785,Male,Male,White,7,n,67.0,False,False,False,Unknown,True,False,n,,y,n,n,n,n,n,y,y,,MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,Adverse,Not Enough Information,MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,66.0,0,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,Cytarabine|Decitabine,2,Induction|Supportive/Palliative Care,UNKNOWN,Standard Chemotherapy,-1.0,Standard Chemotherapy,Cytarabine,Induction,-1.0,Unknown,,,False,False,,0,,17,7,,,,,,,,,,,,,,,,,Trisomy 8,,,,,False,False,,negative,negative,,positive,,,,,,,,,,,,,,,,,,,,,,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,positive,,,positive,,,,,,positive,,,,,,,,,,-0.43236049304711505,Low
16-00699,3975,Male,Male,HispNative,2,n,46.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",46.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,6.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6.0,Dead,9.0,Dead-Treatment,False,False,,0,,92,75,,,5.0,19.0,1.0,,,,2.8,1.13,,18.4,6.2,"46,XY[20]",,113.6,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",31.0,"CD2(+), surface CD3(-),  cytoplasmic CD3(dim +), CD4(-), CD7(partial +), CD11b(partial +),  CD13(variably +), CD14(few +), CD15(-), CD16(-),  CD33(-), CD34(partial +), CD36(-), CD38(bright +), CD45(dim  +), CD56(small subset +), CD64(-), CD117(+), HLA-DR(partial +), MPO(partial +), TdT(partial dim+)",,151.6,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.5927998827643058,Low
16-00702,3976,Male,Male,White,7,n,77.0,False,False,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,79.0,0,Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,Decitabine,Induction,-1.0,Unknown,,,False,False,,0,,,,,,,,,,,,,,,,,,,,Translocation between the long arm of chromosome 3 and short arm of chromosome 12.,,,,,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.5688393481217895,Low
16-00705,3978,Male,Male,White,5,n,59.0,True,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64.0,0,Relapse,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, TBI ",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Dead,1824.0,Dead-Disease,False,False,,0,0.0,59.5,12,0.0,,55.0,3.0,29.0,,37,22.0,4.1,,,25.2,8.3,"47,XY,+13[2]/94,slx2[2]/46,XY[19]",,,"5p15.2/5q31(EGR1), 7 centromere/7q31, 8 centromere/20q12, 12 centromere/13q14 D13S319/13q34 (13qter)",46.0,Negative,6.4,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.4427654686303731,Low
16-00708,3979,Male,Male,HispNative,2,n,70.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71.0,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,Azacitidine|Decitabine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,98.0,Unknown,,,False,False,,0,0.0,44,31,2.0,,46.0,0.0,14.0,,41,18.0,3.7,0.91,,21.6,7.1,"47,XY,+21[19]/46,XY[1]",91.0,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],",35.0,"CD2(-), CD4(dim +), CD7(-), CD10(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD22(-), CD19(partial +), CD33(partial +), CD34(+), CD36(-), CD38(bright and variably +), CD45(+), CD56(-), CD64(-), CD79a(-), CD117(+), HLA-DR(predominantly + and variable), TdT(partial +), and MPO(-)",7.7,5.05,False,False,,positive,negative,,,,,Foundation; R1480*; MAFs: 88%,Foundation; P304fs*117; MAFs: 72%,,,,,,,,,,,,,,,Foundation; R882H; MAFs: 44%,,,,,negative,,,negative,negative,,,,,,,,,,,,,,Foundation; I679fs*21; MAFs: 5%,,,,,Foundation; R225*; MAFs: 87%,,,Foundation; A72T; MAFs: 8%,,,Foundation; I366fs*114+; MAFs: 57%,,,,,,,,,,Foundation; Q742*; MAFs: 41%,,,,,,0.24630459328539375,High
16-00710,2694,Male,Male,Black,6,n,50.0,False,False,False,RUNX1-RUNX1T1,False,False,n,,y,n,n,n,n,n,n,n,RUNX1-RUNX1T1,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,50.0,73,Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Unknown,Standard Chemotherapy,20.0,Standard Chemotherapy,HiDAC,Consolidation,182.0,Alive,424.0,Alive,False,False,,0,,0,,,,,0.0,,,,,,,,,,"46,XY[20]",,,RUNX1/RUNX1T1 fusion negative,126.0,No morphological evidence of acute leukemia,,7.7,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.11164261172405078,Low
16-00724,3986,Female,Female,White,2,n,62.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62.0,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"Vidaza|7+3 (Cytarabine, Idarubicin)|Lenalidomide|Hydroxyurea",3,Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,7.0,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1.0,Dead,198.0,Dead-Disease,False,False,,0,0.8,34,3.3,1.6,,14.9,5.0,68.6,,13,11.0,2.6,0.5,,32.4,10.7,"46~47,XX,del(5)(q15q35),i(8)(q10),add(11)(q23),add(17)(p11.2),add(21)(q22),+2~3mar[cp3]/47~49,idem,add(7)(q11.2),-add(11),+11,+14,-20[cp4]/45~49,idem,del(7)(q22q36),-add(11),+11,+14,-20[cp2]/45~48,idem,der(7)del(7)(q22q31)dic(7;20)(q36;q11.2),-add(11),+11,+14[",304.0,,"nuc ish(D5S2064x2,D5S630x2,EGR1x1)[184/200],(D7Z1x2,D7S522x1)[115/200],(D8Z2x2,D20S108x1)[142/200],(RUNX1T1x3,RUNX1x2)[180/200],(5'MLL amp,3'MLL amp)(5'MLL con 3'MLL amp)[66/200],(PML,RARA)x2[197],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",36.0,"CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+),CD56(+), CD64(-), CD117(partial +), HLA-DR(partial +).",5.3,8.35,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,negative,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,R213fs; MAF 34%,,,,,0.8982921632850456,High
16-00731,3990,Female,Female,White,1,n,69.0,False,False,False,None,False,False,y,Breast Cancer,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",69.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,7,"7+3 (Cytarabine, Idarubicin)|Azacitidine, Midostaurin|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924",4,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,6.0,Targeted Therapy - Other,ALRN-6924,Salvage,-1.0,Alive,442.0,Alive,False,False,,0,1.8,40,42.1,0.9,8.8,10.5,9.6,26.3,2.8,27,22.0,3.4,0.64,,23.5,7.1,"46,XX[20]",399.0,103.5,normal,12.0,"CD13, CD34, CD58, CD117, partial MPO and HLA-DR +",6.5,61.22,False,False,,positive,negative,,,,,,,,,,,,,,,,,p.S893L; MAF 41%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.A187T; MAF 42%,,p.K700E; MAF 51%,,,,,,,,p.K751fs*61; MAF 44%,,,,,,0.8938371474139729,High
16-00733,2119,Male,Male,White,1,n,76.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77.0,472,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor),2,Consolidation|Induction,Complete Response,Standard Chemotherapy,35.0,Standard Chemotherapy,Incyte trial (azacitidine and JAK 1 inhibitor),Induction,77.0,Dead,520.0,Dead-Unknown,True,False,16-00732,0,0.0,54,13,6.9,,51.6,39.6,1.9,,20,23.0,3.2,1.0,,25.4,8.6,"47,XY,+8[cp15]/47,sl,der(22)t(1;22)(q11;p11.2)[2]/46,XY,dup(1)(q21q42)[cp2]",,92.0,"Seventeen of twenty cells examined were trisomy 8, previously observed.Two of the trisomy 8 cells had additional non-clonal abnormalities and two cells had an extra 1q attached to a chromosome 22 short arm, also previously observed.",22.0,"The myeloid blasts are CD13, CD34, CD38, CD117, and HLA-DR positive. Atypical monocytic cells comprise approximately 41% of analyzed events and are CD11b, CD13, CD14, CD64, and dim HLA-DR positive. T cells show a CD4:CD8 ratio of 6.9:1 without  aberrant antigen expression.",7.2,4.5,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.6137007261930177,High
16-00755,4001,Female,Female,White,1,n,58.0,False,False,True,GATA2-MECOM,False,False,n,,y,n,y,n,n,n,n,n,EVI1_F,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,58.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,2,"SWOG S0919 (Ida/Ara+Pravastatin) |Busulfan, Cyclophosphamide",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,70.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,0.0,Alive,157.0,Alive,True,False,16-00751,0,0.0,21,0,0.0,2.3,41.7,25.9,30.1,0.1,,,,,,35.1,11.0,"46,XX,t(3;3)(q21;q26)[20]",,107.0,Abnormal,360.0,"variable CD11b, CD13, dim CD33, CD34, CD58, CD117, CD123",,13.83,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.G12D; MAF 47%,,,,,,,,,,,p.K666N; MAF 47%,,,,,,,,,,,,,,0.054370897467515805,High
16-00766,4006,Male,Male,White,2,n,81.0,False,False,True,None,False,False,n,,n,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,81.0,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,2,Vidaza|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,3.0,Dead,97.0,Dead-Disease,False,False,,-32,,33,8,4.0,,28.0,24.0,44.0,,22,20.0,4.1,1.07,,27.5,9.5,"45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]",333.0,,"nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5’CBFB con 3’CBFB dimx1,5’CBFB con 3’CBFBx1)[200]",28.0,"CD4(+), CD5(partial +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(predominantly -), CD16(-), CD33(+), CD34(+), CD36(-),CD38(variably +), CD45(variably +), CD56(predominantly -), CD64(partial +), CD117(+), HLA-DR(predominantly + and variable),MPO(-), TdT(-).",6.6,2.2,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,Foundation; EP300-ZNF205 fusion; MAFs: N/A,,,,negative,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Foundation; L206fs*41; MAFs: 31%,,,,,0.20576925424307033,High
16-00770,4007,Female,Female,White,6,n,50.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,51.0,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|5+2 (Cytarabine, Idarubicin)|HiDAC|7+3 (Cytarabine, Idarubicin, Bortezomib",3,Unknown|Induction|Re-induction,Unknown,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Fludarabine",Unknown,-1.0,Alive,555.0,Alive,False,False,,0,,12,,,,,17.0,,,,,,,,,,"46,XX[20]",,,,16.0,"FLT3 (ITD) Not detected. Not detected for the FLT3 TKD Mutation. Pathogenic alterations are detected in the BCOR, IDH2 and WT1 genes. Positive for CD34, HLADR, CD117, CD13, CD33 and CD43 and negative for CD11B, CD14, CD64, TDT and MPO.",,1.5,False,False,,negative,negative,,,,,"p.E1348Ifs, MAF 32%",,,,,,,,,,,,,,,,,,,,,negative,,,,"p.R172K, MAF 41%",,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p.T171Cfs*116, MAF 39%",,-0.9864847808769166,Low
16-00771,4008,Female,Female,HispNative,6,n,34.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,34.0,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Intrathecal,3,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Etoposide, Mitoxantrone",3,Unknown|Induction|Re-induction,Refractory,Standard Chemotherapy,35.0,Intrathecal,Cytarabine,Unknown,6.0,Dead,157.0,Dead-Unknown,False,False,,0,,15,,,,,12.0,,,,,,,,,,"46,XX[20]",,,,426.0,,,26.4,False,False,,negative,negative,,,,,,,,,,,,,,,,,,"p.A470V, MAF 51%",,,"p.R882C, MAF 51%",,,,,negative,,,,,,,,,,,negative,,,,,,,,,"p.G13R, MAF 48%",,,,,,,,,,,,,,,,,,,,"p.R282Q, MAF 51%",,,,,0.02488114186972341,High
16-00810,4028,Female,Female,White,1,n,61.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1.0,Alive,189.0,Alive,False,False,,0,0.0,83,11.5,1.8,1.8,13.3,63.7,7.9,0.1,69,35.0,3.0,0.87,M5,34.7,11.6,"46,XX[20]",337.0,95.6,Normal,146.0,Positive,6.1,44.83,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.R132H; MAF 37%,,,,,,,,,,,,,,,,,p.G13D; MAF 38%,,,,,,,,,,,,,,,,,,,,,,,,,-1.0553109692064768,Low
16-00815,4030,Female,Female,White,1,n,60.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea",4,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Complete Response,Standard Chemotherapy,18.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1.0,Alive,197.0,Alive,False,False,,-1,0.0,75,44,0.0,0.9,28.7,46.1,24.3,0.0,18,13.0,2.9,1.19,M5,26.4,8.8,"46,XX[20]",222.0,96.4,Normal,175.0,Positive,6.9,34.6,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,p.T15_G16insP; MAF 48%,,,,,,,,,,,,,,,,,,,,,p.G12S; MAF 40%,,,,,,,,,,,,,,,,,,,p.H437fs*7; MAF 42%,,,,,,-1.312349326959462,Low
16-00818,4029,Female,Female,White,3,n,65.0,False,False,True,GATA2-MECOM,False,False,n,,n,n,n,n,n,n,y,y,EVI1_F,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,65.0,3,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,,True,False,16-00813,-3,,,,,,,,,,,,,,,,,"47,XX,+X,inv(3)(q21q26.2),-7,+22[2]/48,sl,+21[18]",,,evidence of monosomy 7 in 191/200 (95.5 percent) cells scored,,,,,True,False,16-00813,negative,negative,,,,,,,,,p.Leu367fs; MAF 24%,p.? ; MAF 16.5%,,,,,,,,,,,p.Ala571Pro; MAF 51.5%,,,p.Pro636Ala; MAF 94.7%,,p.Val579Ala; MAF 2.3 %,,,,,,,,,,,,,,,,,,,,,,,,,,p.Gly60Ser; MAF 49.1%,,,p.Asp198Gly; MAF 63.7%,,,,,,,,,,,,,,,,1.5499363973468605,High
16-00820,4032,Male,Male,White,1,n,67.0,False,False,True,None,False,False,n,,y,n,n,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,67.0,0,Residual Disease,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Fludarabine, Melphalan|Azacitidine|Hydroxyurea|Idarubicin and Cytarabine",3,Allogeneic - Sibling|Induction|Re-induction,Refractory,Standard Chemotherapy,1932.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1.0,Alive,179.0,Alive,False,False,,0,2.6,42.5,54,0.9,0.0,44.2,2.7,0.9,0.0,21,15.0,2.0,2.62,,23.1,7.9,"45,XY,+5,dic(5;8)(q11.2;p12)x2,del(7)(q22q32),-18,del(20)(p11.2)[cp20]",,91.7,"5p/5q: 88/100 (88%) cells had one signal for EGR1 (5q31) and three signals for 5p, consistent with the metaphase karyotype; 5 cells (5%) had one EGR1 signal and four 5p signals, consistent with a previous sideline with three copies of the dicentric 5;8 chromosome.  ",22.0,Positive,5.3,1.27,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,p.G570E; MAF 44%,,,,,,,,,,,,p.V617F; MAF 3%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.K132R; MAF 45%,,,,,1.7498090548542422,High
16-00822,2747,Male,Male,White,6,n,62.0,False,False,True,None,False,False,n,,y,n,n,n,y,n,n,n,,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,62.0,81,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Azacitidine|Fludarabine, Melphalan, ATG",2,Unknown|Allogeneic - Matched Unrelated Donor,,,,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Allogeneic - Matched Unrelated Donor,-1.0,Alive,256.0,Alive,True,False,16-00578,0,,9,,,,,7.0,,,,,,,,,,"46,XY[12]",,,The abnormalities normally seen in MDS are not detected.,,A very dim/negative CD45 population was also detected by the flow analysis. This population is negative for all the myeloid and lymphoid markers including CD34. This is mentioned here for documentation purposes but we believe that they do not represent blasts.,,,True,True,16-00701,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.260576382943828,High
16-00831,4038,Male,Male,Black,2,n,73.0,False,False,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",77.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Supportive/Palliative Care|Targeted Therapy - Other,6,Vidaza|AG-221|Bortezomib|Cytarabine|Lenalidomide|Decitabine,3,Hypomethylating/Low Dose Cytarabine|Experimental|Supportive/Palliative Care,,,,Targeted Therapy - Other,AG-221,Experimental,267.0,Dead,1490.0,Dead-Disease,False,False,,0,,95,48,1.0,,42.0,6.0,2.0,,14,14.0,3.5,1.1,,27.3,9.4,"88<4n>,XXYY,+del(1)(p22p36),i(2)(p10),-5,-7,-7,-21,-21[12]",453.0,,"nuc ish(RUNX1T1x4,RUNX1x2)[200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[200],(PML,RARA)x4[200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[174/200]",23.0,"92% population of variably-sized cells with the following immunophenotype: CD2(-), CD4(-), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(+), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(variably +), HLA-DR(partial +).",6.5,3.0,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,"R140Q (c.419G>A, p.Arg140Gln)",,,,,,,,,,,,,,,,,,,,,,E76Q,,,loss,,,,,,,,,,,,,,,,0.1339013901660888,High
16-00836,4039,Male,Male,White,1,n,73.0,False,False,True,None,False,False,n,,y,n,n,n,y,y,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|Hydroxyurea",1,Induction,Refractory,Standard Chemotherapy,167.0,Standard Chemotherapy,"S0919 Trial (Pravastatin, Idarubicin, Cytarabine)",Induction,21.0,Dead,28.0,Dead-Disease,False,False,,0,0.0,88,38,0.0,1.7,20.9,60.9,1.7,0.1,27,40.0,3.0,1.2,,33.0,11.2,"46,XY[20]",,105.8,normal,55.0,Positive,7.5,58.97,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,p.R882H; MAF 42%,p.N674D; MAF 50%,,,,,,,,,,,,,,,,p.M3398V; MAF 51%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.5148425351441196,Low
16-00846,4043,Male,Male,White,6,n,25.0,True,False,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",26.0,0,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,3,"Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Unknown|Induction,Complete Response,Standard Chemotherapy,79.0,Standard Chemotherapy,Bu/Cy/ATG,Unknown,22.0,Alive,444.0,Alive,False,False,,0,,,14,8.0,,17.0,2.0,54.0,,39,49.0,3.2,0.79,,19.3,6.5,,,101.0,,33.0,,4.9,1.6,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.45735577429904006,High
16-00867,4042,Female,Female,White,1,n,61.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61.0,3,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Hydroxyurea,1,Induction,Unknown,Standard Chemotherapy,8.0,Standard Chemotherapy,Hydroxyurea,Induction,8.0,Dead,8.0,Dead-Unknown,False,False,,-5,0.0,93,85,0.8,0.0,16.5,0.8,1.6,0.2,19,21.0,2.7,0.78,,21.1,7.1,"46,XX[20]",360.0,84.4,Normal,43.0,"partial CD13, CD33, dim/partial CD56, CD58, dim CD117, CD123 and MPO",5.7,30.54,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.R140Q; MAF ~50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.09283101081925883,Low
16-00875,4052,Female,Female,Black,6,n,45.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",46.0,0,Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|CLAG (Cladribine, Cytarabine, Filgrastim)",4,Consolidation|Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,25.0,Standard Chemotherapy,"CLAG (Cladribine, Cytarabine, Filgrastim)",Salvage,23.0,Alive,465.0,Alive,False,False,,0,,3,,,,,4.0,,,,,,,,,,"45,XX,-7[4]/46,sl,+mar[2]/46,XX[14]",,,,69.0,MLL-PTD is not detected. FLT3-ITD not detected. FLT3-TKD mutation not detected. Pathogenic alterations are detected in the DNMT3A and IDH1 genes. Genomic alteration of uncertain significance is detected in the DNMT3A gene.,,1.3,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.3121192220697626,Low
16-00882,4006,Male,Male,White,2,n,81.0,False,False,True,None,False,False,n,,n,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,81.0,41,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Supportive/Palliative Care,2,Vidaza|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,3.0,Dead,97.0,Dead-Disease,True,True,16-00766,-73,0.0,,70,0.0,,3.0,1.0,36.0,,25,33.0,4.1,1.26,,24.1,8.1,"45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]",853.0,98.0,"nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5’CBFB con 3’CBFB dimx1,5’CBFB con 3’CBFBx1)[200]",74.0,negative,,39.12,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.3208201426276971,High
16-00951,4075,Male,Male,White,3,n,42.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,42.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)",4,Allogeneic - Sibling|Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1.0,Alive,223.0,Alive,False,False,,-3,,,,,,,,,,,,,,,,,"45,XY,t(3;17)([21;q11.2),add(4)(q21),add(5)(p15),ins(10;11)(p12;q23q13),der(12;18)(q10;q10)[19]/46,XY[1]",,,11q23 rearrangement involving the  KMT2A (MLL) locus in 184/200 (92.0 percent) cells scored,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.29705696253013175,Low
16-01004,4195,Male,Male,White,2,n,70.0,False,False,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,70.0,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Vidaza|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,Vidaza,Hypomethylating/Low Dose Cytarabine,4.0,Alive,95.0,Alive,False,False,,0,0.0,85,77.8,0.0,,7.4,0.0,11.1,,12,32.0,2.8,0.62,,21.8,7.0,,1195.0,,,103.0,,5.2,25.85,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.8531248299654617,Low
16-01005,4196,Female,Female,White,5,n,55.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,55.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin) plus Enasidenib|Busulfan, Cyclophosphamide",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1.0,Alive,153.0,Alive,False,False,,0,1.0,30,0,0.0,,31.0,4.0,6.8,,10,11.0,4.3,,,32.4,9.9,"46,XX,del(5)(q22q35)[2]/46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.2)[14]/46,XX[3]",,,Probe: 8 centromere/20q12,83.0,Negative,7.2,10.6,False,False,,negative,negative,,c.190 0_1922 delAGAGAGGCGGCCACCACTGCCAT; p.R634Rfs; MAF 33%,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,c.419G>A; P.R140Q; MAF 46%,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,0.10639027306522439,High
16-01010,4197,Female,Female,White,1,n,45.0,False,False,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,46.0,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32.0,Standard Chemotherapy,Sunitinib,Consolidation,2.0,Dead,634.0,Dead-Disease,True,False,16-01104,0,0.0,,,0.0,0.0,20.4,0.0,66.7,1.0,58,44.0,3.3,1.04,,23.8,8.1,,401.0,88.5,Positive,14.0,,7.3,6.18,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.6270622890529223,High
16-01017,4043,Male,Male,AdmixedHispNative,6,n,25.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",26.0,28,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Unknown|Induction,Complete Response,Standard Chemotherapy,79.0,Standard Chemotherapy,Bu/Cy/ATG,Unknown,22.0,Alive,444.0,Alive,False,False,,0,,70,8,,,,4.0,,,,,,,,,,"46,XY,-3,del(5)(q31q35),der(7)t(7;?)(p11.2;?),+der(11)(q23),-12,+mar[20]",,,,10.0,"MONOBLASTS, 61%. These are dim45positive and also express CD13, CD33, CD11b, CD14, CD64  but lack CD16, CD34, CD117, HLADR ",,30.2,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.S2496C; MAF 45%,,p.Q61K; MAF45%,,,,,,,,,,,,,,,,,,,,,,,,,0.00239791650138768,High
16-01047,4205,Female,Female,White,6,n,67.0,True,False,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,69.0,0,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,2,Cytarabine|Idarubicin and Cytarabine,2,Consolidation|Induction,Complete Response,Standard Chemotherapy,9.0,Standard Chemotherapy,Cytarabine,Consolidation,40.0,Alive,927.0,Alive,False,False,,0,,,94,0.0,,3.0,0.0,1.0,,18,52.0,3.2,1.03,,24.6,8.6,,,93.5,,28.0,,5.7,108.9,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p.R132S, MAF 46%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.5767169792425871,Low
16-01049,4207,Male,Male,Asian,2,n,78.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",78.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Decitabine|7+3 (Cytarabine, Idarubicin) plus Azacitidine|IDAC|Etoposide, Cytarabine",4,Induction|Re-induction|Maintenance|Supportive/Palliative Care,Refractory,Supportive/Palliative Care,-1.0,Standard Chemotherapy,"Etoposide, Cytarabine",Supportive/Palliative Care,-1.0,Dead,372.0,Dead-Disease,False,False,,0,0.0,20,3.8,7.8,,40.0,5.2,40.0,,9,49.0,3.1,1.41,,25.7,8.5,"46,XY[20]",675.0,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",30.0,"CD2(-), CD3(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(small subset+), CD16(-), CD19(-), CD20(-), CD33(+), CD34(+),CD36(-), CD38(dim+), CD45(dim +), CD56(-), CD64(variably+), CD117(+), HLA-DR(dim +), MPO(partial +), and TdT(-).",6.9,4.9,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.475895211139451,Low
16-01061,4197,Female,Female,White,1,n,45.0,False,False,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47.0,14,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32.0,Standard Chemotherapy,Sunitinib,Consolidation,2.0,Dead,634.0,Dead-Disease,True,False,16-01104,0,,,,,,,,,,,,,,,,,,,,Positive,,,,,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.343890543212313,High
16-01080,4225,Female,Female,White,1,n,69.0,False,True,False,PML-RARA,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,69.0,1,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,"ATRA, Idarubicin",1,Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"ATRA, Idarubicin",Induction,-1.0,Unknown,,,False,False,,-1,1.7,90,59.5,1.7,0.8,13.5,5.0,6.7,0.9,45,41.0,3.4,1.09,M3,24.1,8.6,"46,XX,t(15;17)(q24;q21)[20]",,92.7,PML/RARA fusion,39.0,"dim CD2, CD13, dim CD15, CD33, CD38, CD58, CD64, CD117, CD123, variable HLA-DR and bright MPO positive",6.5,34.36,False,False,,positive,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,p.P2438L ; MAF 47%,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-1.8907616655276511,Low
16-01082,4226,Male,Male,White,1,n,68.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,68.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,-1.0,Unknown,,,False,False,,0,0.0,,10,0.9,0.0,81.8,4.6,10.9,0.0,27,26.0,4.1,1.0,,33.6,11.9,"46,XY,del(7)(q22),inv(16)(p13.1q22)[18]/46,XY[2]",330.0,106.7,"CBFB, D7S486/ CEP 7",106.0,"CD5, CD19, dim CD20, dim CD22, CD23 and light chain negative",6.9,2.16,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.5091138890637338,Low
16-01093,4229,Male,Male,White,2,n,61.0,False,True,False,None,False,False,n,,n,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",61.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,,False,False,,0,0.0,48,6,0.0,,31.0,14.0,47.0,,27,27.0,4.2,0.86,,36.9,12.6,"47,XY,t(8;19)(q24.1;q13.1),+10[17]/46,XY[3]",294.0,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",175.0,,7.0,2.43,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.5442090516247478,Low
16-01094,2254,Female,Female,White,2,n,52.0,True,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",53.0,462,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,7.0,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,-1.0,Dead,633.0,Dead-Disease,True,True,15-00653,-463,,76,1,,,,,,,,,,,,,,"46,XX[20]",,,"nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.5235463211720811,Low
16-01097,2116,Female,Female,White,1,n,10.0,True,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,12.0,568,Post-Chemotherapy|Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,33.0,Standard Chemotherapy,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Re-induction,-1.0,Alive,569.0,Alive,False,False,,0,0.0,46,,0.0,0.0,81.3,8.3,10.4,18.1,31,27.0,3.8,0.53,,30.5,10.2,"47,XX,+10[19]/46,XX[1]",,96.8,Normal,11.0,"variable CD7,  dim CD13, CD33, CD34 bright CD38,CD56, CD58, CD117, HLA-DR positive",7.0,1.93,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.3544247449062654,Low
16-01100,4231,Male,Male,White,2,n,65.0,False,True,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Cytarabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Cytarabine,Supportive/Palliative Care,-1.0,Dead,2.0,Dead-Unknown,False,False,,0,,,,,,,,,,,,,,,,,,,,"nuc ish (PML,RARA)x2[199]",,,,,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.6271048538131423,Low
16-01102,4232,Female,Female,White,2,n,72.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1.0,Alive,358.0,Alive,False,False,,0,,30,5,,,,,,,37,93.0,,,,,,"45,XX,der(5)inv(5)(p13q15)del(5)(q15q33),-16,-17,der(17)t(17;17)(p13;q11.2),der(18;22)(q10;q10),+22,+r[cp20] .ish r(MLL+)[2]",,,"nuc ish(D4Z1,D10Z1)x2[200],(D5S2064x2,D5S630x2,EGR1x1)[196/200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[197],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3) [142/200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[200]",16.0,,,44.63,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.8602252749285351,High
16-01103,4197,Female,Female,White,1,n,45.0,False,False,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47.0,23,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32.0,Standard Chemotherapy,Sunitinib,Consolidation,2.0,Dead,634.0,Dead-Disease,True,False,16-01104,0,0.0,90,90,0.0,0.0,5.0,0.0,0.0,0.0,27,43.0,1.6,0.93,,22.5,7.9,,,82.1,Positive,43.0,"variable CD7, CD13, dim CD33, partial CD34, CD38,dim CD58, partial and variable CD117 and CD123 positive",5.1,18.38,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.9358521737008285,High
16-01109,4235,Male,Male,Black,5,n,33.0,False,True,False,CBFB-MYH11,False,False,n,,y,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,33.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,HiDAC,Consolidation,-1.0,Alive,116.0,Alive,True,False,16-01108,0,0.0,72,95,0.0,,3.0,0.0,1.0,,29,24.0,3.4,,,19.8,6.5,"46,XY,inv(16)(p13.1q22)[20]",,,Positive for CBFB rearrangment for 91% of cells,31.0,Positive,6.6,93.2,True,False,16-01108,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,,,,,,negative,,,,,,,,,,,,,,,,,,,c.652G>A; p.V218M; MAF 50%,negative,,,,,-0.5135697851476442,Low
16-01121,4239,Male,Male,White,3,n,61.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|IDAC plus Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Sorafenib",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Matched Unrelated Donor,-1.0,Alive,184.0,Alive,False,False,,0,,86,89,,,,,,,,,,,,,,"46,XY[20]",,,Normal,57.0,,,115.15,False,False,,positive,positive,,,,,,,,,,,,,,,,,,,,,p.Arg326Cys; MAF 44.5%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p.Ala911fs; MAF 40.6%,,,,,,0.47639744836070363,High
16-01127,2538,Male,Male,White,1,n,67.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68.0,261,Post-Chemotherapy,Leukapheresis,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,4,"AG-120|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC",4,Consolidation|Salvage|Induction|Experimental,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,-1.0,Alive,528.0,Alive,True,True,16-00157,-52,,,,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,,,,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.8093309132214811,Low
16-01138,2315,Male,Male,White,1,n,62.0,True,False,True,None,False,False,n,,y,n,y,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63.0,412,Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,Decitabine|Hydroxyurea,2,Induction|Re-induction,Complete Response i,Standard Chemotherapy,-1.0,Standard Chemotherapy,Hydroxyurea,Re-induction,-1.0,Dead,424.0,Dead-Disease,True,True,15-00778,-412,0.9,,,0.0,0.0,7.8,1.7,4.3,0.1,18,21.0,2.8,1.43,,25.0,8.2,"46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]",564.0,102.5,EGR1 (73.5%) ;  TP53: (85.5%),139.0,,6.6,46.79,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.4795150640568409,High
16-01151,4248,Male,Male,White,1,n,81.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,81.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Vidaza, BI836858 (anti-CD33)",1,Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"Vidaza, BI836858 (anti-CD33)",Induction,-1.0,Alive,355.0,Alive,True,False,16-01150,0,0.0,,80,0.0,7.0,7.8,0.0,6.9,0.5,31,42.0,3.2,1.3,,25.1,8.8,"46,XY[19]",665.0,85.1,Normal,16.0,"dim CD13, CD33, CD38, CD58, dim CD64, CD71, dim CD117 and CD123-positive",7.2,33.81,True,False,16-01150,negative,positive,,,,,,,,,,,,,,negative,,,, p.T640N; MAF: 14%,,,negative,,,p.G709D; MAF: 17%,,negative,,,negative,p.R140Q; MAF: 46%,,,negative,,Splice site-Intron 5 3' end mutation; MAF:3%,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-0.4727847388456075,Low
16-01185,4252,Male,Male,White,5,n,50.0,False,False,False,None,False,False,y,Not specified,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,50.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, Thiotepa, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Dead,201.0,Dead-Unknown,False,False,,0,0.0,75,82,2.0,,4.0,0.0,8.0,,39,45.0,3.7,,,20.1,6.5,"46,XY,add(1)(p11),del(5)(q15q33),del(7)(q22q36),der(11)t(1;11)(p31;p12-14)[20] ",,,Loss of 5q31 sequences for 99% of total cells,12.0,"Positive: CD38, CD56, CD13, CD34, CD45, CD117, HLA-DR",6.3,119.6,False,False,,positive,negative,,,,,C.3067T>C; p.F1023L,,,,,,,,,negative,,,,,,,negative,,,,,,,,negative,negative,,,negative,,,negative,,,negative,,,,,,c.7625G>A; p.S2542N,negative,,,,,,,,,,,,,,,,,,,,negative,,,,,1.388580693868461,High
16-01191,4256,Female,Female,White,3,n,65.0,False,False,True,None,False,False,n,,y,n,y,y,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,65.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Vidaza|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)",3,Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1.0,Alive,246.0,Alive,True,False,16-01190,0,,,,,,,,,,,,,,,,,"45,XX,-7[20]",,,"7cen (D7Z1), 7q31 (D7S486): monosomy present ",,,,,True,False,16-01190,negative,negative,,,,,,,,,,,,,,,,,,,,,p.Gln231fs; MAF 33.2%,,,,,,,,,p.Arg140Gln; MAF 44.2%,,,,,,,,,,,,,,,,p.Gln61Glu; MAF 47.8%,,,,,,,,,,,,,,,,,,,,,,,,,-0.40055432291545545,Low
16-01192,4201,Female,Female,White,1,n,52.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,52.0,34,Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"MiDAC|FLAG-IDA plus Midostaurin|7+3 (Cytarabine, Idarubicin) plus Dasatinib ",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,FLAG-IDA plus Midostaurin,Salvage,-1.0,Alive,414.0,Alive,True,True,16-01143;16-01022,-6,1.4,,,0.2,,9.2,24.3,64.9,,119,151.0,3.2,0.76,,28.4,9.2,"46,XX[20] ",380.0,93.4,Normal,395.0,,6.6,6.5,True,False,16-01143;16-01146,negative,negative,,,,,,,,,,,,,,negative,,,,,,,p.R882C; MAF 14%,,,,,negative,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-0.33791515123971794,Low
16-01201,4260,Male,Male,White,1,n,53.0,False,False,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",54.0,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,7,"AG-120|7+3 (Cytarabine, Idarubicin)|Azacitidine|MGD006 (CD123 x CD3) |MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)",5,Salvage|Induction|Experimental|Re-induction|Maintenance,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,Incyte trial (azacitidine and JAK 1 inhibitor),Salvage,-1.0,Dead,543.0,Dead-Disease,False,False,,0,0.0,75,90,0.0,0.0,22.1,6.2,1.8,0.0,19,33.0,1.8,0.84,,25.5,8.1,"46,XY,t(4;12)(q12;p13)[10]/46,XY[10] ",706.0,91.4,"42/100 (42%) interphase cells scored were positive for  ETV6 rearrangement.  Metaphase FISH showed part of the ETV6 signal (red) on  the long arm of chromosome 4.  Based on the breakpoint, ETV6/CHIC2 fusion  is predicted, consistent with AML",25.0,"partial CD7, CD13, CD33, CD38, CD34, CD58, CD117, CD123,  HLA-DR positive ",6.6,118.0,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,p.R882H; MAF 49%,,,,,negative,,,p.R132S; MAF 48%,negative,,,negative,,,,,,negative,,negative,,,,,negative,,,,,,,,,p.R166*; MAF 50%,,,,,p.P95H; MAF 50%,,,,,,negative,,,negative,,1.1758644282507413,High
16-01210,4263,Male,Male,White,3,n,63.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC",3,Consolidation|Induction|Allogeneic - Child,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Child,-1.0,Alive,395.0,Alive,False,False,,-17,,26.3,12,,,,,,,,,,,,,,"46,XY[11] ",,,Normal,69.0,,,9.28,False,False,,negative,negative,,,,,p.Tyr354*; MAF 72.2%,,,,,,,,,,,,,,,,p.Thr835Met; MAF 47%,,,,,,,,p.Arg132Cys; MAF 2.9%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.4385922627309215,High
16-01216,4263,Male,Male,White,3,n,63.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63.0,1,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC",3,Consolidation|Induction|Allogeneic - Child,Complete Response,Standard Chemotherapy,-1.0,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Child,-1.0,Alive,395.0,Alive,True,True,16-01210,-18,,,,,,,,,,,,,,,,,"46,XY[11] ",,,Normal,,,,,True,True,16-01210,negative,negative,,,,,p.Tyr354*; MAF 72.2%,,,,,,,,,,,,,,,,p.Thr835Met; MAF 47%,,,,,,,,p.Arg132Cys; MAF 2.9%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0115616372487573,High
16-01219,4271,Male,Male,White,1,y,47.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,47.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,7.0,Standard Chemotherapy,HiDAC,Consolidation,-1.0,Alive,317.0,Alive,False,False,,0,0.0,83,82,3.4,0.0,23.1,3.4,0.0,1.6,23,11.0,3.5,0.95,,31.1,10.2,"46,XY[20]",290.0,88.9,,24.0,"CD7, CD13, CD33, CD34, CD38, partial CD56,  CD58, dim CD64, CD117, CD123, HLA-DR, and cMPO ",6.5,18.71,False,False,,negative,negative,,,,,,,,,,,,,,p.I68fs; MAF 50%,,,,,,,negative,,,p.S519P; MAF 51%,,negative,,,negative,negative,,,negative,,,negative,,,,,negative,,,,,"p.G13D, MAF 3%",,,,,,,,,negative,,,,,,,,,,,negative,,,p.R458*; MAF 23%,,-1.3740214152499144,Low
16-01223,4273,Male,Male,White,2,n,73.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",73.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1.0,Dead,31.0,Dead-Unknown,False,False,,0,,83,59,,,,,,,21,23.0,,,,,,"46,XY[20]",,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[195],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",22.0,,,24.23,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.4470805779127696,High
16-01225,4274,Female,Female,White,1,n,61.0,False,False,True,None,False,False,n,,n,n,n,n,n,n,y,y,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61.0,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Hydroxyurea,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1.0,Dead,316.0,Dead-Disease,False,False,,-2,,,,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,,,,False,False,,positive,positive,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,0.031162229063256327,High
16-01227,4275,Female,Female,HispNative,6,n,39.0,True,False,False,Unknown,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,40.0,0,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,39.0,Standard Chemotherapy,HiDAC,Consolidation,-1.0,Alive,399.0,Alive,False,False,,0,,,91,,,9.0,,,,21,34.0,3.8,0.49,,29.3,9.9,,,93.6,,66.0,,5.8,73.0,False,False,,negative,positive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.42383603354538135,High
16-01237,4291,Female,Female,HispNative,6,n,73.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,73.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1.0,Alive,122.0,Alive,True,False,16-01238,0,,71,3,1.0,,68.0,8.0,11.0,,11,23.0,2.9,0.51,,24.9,7.8,"46,XX,del(1)(p22),der(15)t(15;?)(q15;?),-17,+mar[19]/46,XX[1]",,110.7,Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.,95.0,"blasts 55% of all events; they are positive for cd34, hla-dr, cd117, cd13, cd33, and  negative for cd11b, cd14, cd64, tdt and mpo.",4.8,63.4,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,negative,,,,,,,,,,,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.1105987037274094,High
16-01254,4299,Female,Female,White,1,n,38.0,False,True,False,None,False,False,n,,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,38.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,Standard Chemotherapy,HiDAC,Consolidation,-1.0,Alive,303.0,Alive,False,False,,0,,47,21.7,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,"CD117, dimCD4,  heterogeneous CD13, CD33, dimCD64 and  MPO positive ",,46.27,False,False,,negative,positive,,,,,,,,,,,,,,negative,,,,,,,p.R882H; MAF 46%,,,,,negative,,,p.R132H; MAF 25%,negative,,,negative,,,negative,,,p.Q61L; MAF 10%,,negative,,,,,p.G13D; MAF 24%,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-1.1711331894679573,Low
16-01262,4303,Female,Female,White,1,n,59.0,False,True,False,PML-RARA,False,False,n,,y,n,n,n,n,n,n,n,PML-RARA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,59.0,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide, Idarubicin",1,Induction,Complete Response,Standard Chemotherapy,-1.0,Standard Chemotherapy,"ATRA, Arsenic Trioxide, Idarubicin",Induction,-1.0,Alive,28.0,Alive,False,False,,0,0.9,90,90,1.7,44.0,8.6,0.0,6.0,1.5,110,255.0,2.4,0.86,M3,19.8,6.7,"46,XX,t(15;17)(q22;q21)[20]",,88.4,86/100 cells (86%) had the 1r/1g/2f dual fusion signal pattern consistent  with PML/RARA fusion and with t(15;17) as seen on metaphase analysis. ,30.0,"CD13, CD33, CD58, CD64, CD117, CD123, MPO",5.4,47.35,False,False,,negative,negative,,,,,,,,,,,,,,negative,,,,,,,negative,,,,,,,,negative,negative,,,negative,,,negative,,,negative,,negative,,,,,negative,,,,,,,,,negative,,,,,,,,,,,negative,,,negative,,-1.2745811163557466,Low
16-01270,4317,Female,Female,White,1,n,72.0,True,False,False,Unknown,False,False,n,,n,n,n,n,n,n,n,n,CBFB-MYH11,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,74.0,0,Relapse,Peripheral Blood,y,y,y,y,y,y,1,Targeted Therapy - Kinase Inhibitor(s),1,Dasatinib,1,Experimental,,,,Targeted Therapy - Kinase Inhibitor(s),Dasatinib,Experimental,16.0,Unknown,,,False,False,,0,,,,,,,,,,,,,,,,,,,,,,,,,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.29655249221217533,Low
16-01272,4310,Male,Male,White,6,n,64.0,False,False,False,None,False,False,y,Not specified,y,n,n,n,n,n,n,n,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64.0,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,6.0,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6.0,Dead,80.0,Dead-Unknown,False,False,,0,,17,,,,,5.0,,,,,,,,,,"42,XY,-3,-7,der(12)t(12;?)(q24.3;?)-17,der(17)t(17;?)(p13;?),-21,der(22)t(22;?)(p11.2:?)[10]/46,XY[10] ",,,,43.0,"NOT DETECTED for the MLL partial tandem duplication (PTD). NOT DETECTED for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR). NOT DETECTED for the FLT3 TKD Mutation. Pathogenic alterations are DETECTED in the DNMT3A, NF1 and TP53 genes. ",,2.2,False,False,,negative,negative,,,,,,,,,,,,,,,,,,,,,"c.2635_2651delAACATGAGCCGCTTGGC; p.N879Efs*36         c.2656C>T; pQ886*    MAF 43%, 36% ",,,,,negative,,,,,,,,,,,negative,,,,,,,c.2192_2199delTCTTGCCC; p.L731Qfs*3  MAF 38%,,,,,,,,,,,,,,,,,,,,,,c.610G>T;p.E204*    MAF 51%,,,,,0.5247368713965136,High
